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Harnessing the immune system to recognize and destroy tumor cells has been 
the central goal of anti-cancer immunotherapy. Adoptive cell therapy (ACT) is a 
treatment that uses a cancer patient's own T lymphocytes with anti-tumor activity, 
expanded in-vitro and re-infused into the patient. The ability to genetically engineer 
human lymphocytes and use them to mediate cancer regression in patients, which has 
recently been demonstrated, has opened possibilities for the extension of ACT 
immunotherapy to patients with a wide variety of cancer types and is a promising new 
approach to cancer treatment. Clinical monitoring of ACT utilizes serial blood 
analyses to discern T cell activity. While useful, these data are 1-dimensional and lack 
spatiotemporal information related to treatment efficacy or toxicity.  In this 
dissertation, I have utilized a human genetic reporter, somatostatin receptor 2 
(SSTR2), and PET, to quantitatively and longitudinally visualize whole-body T cell 
distribution and antitumor dynamics using a clinically approved radiotracer. Initial 
evaluations determined that SSTR2-expressing T cells were detectable at low densities 
with high sensitivity and specificity.  
While keeping a close eye on the status of immunotherapy is shown in the 
early part of this thesis, later topics address the ideal antigens to target tumors, more 
specifically targeting solid tumors. We turned to targeting inflammation, specifically 
intercellular adhesion molecule-1 (ICAM-1), as an ideal marker for solid tumors. 
ICAM-1, which has been implicated to play a critical role in tumor progression in various 
   ii 
types of cancer, has also been linked to cancer metastases, where this molecule facilitates 
the spread of metastatic cancer cells to secondary sites. The unique expression profile of 
ICAM-1 throughout solid tumor microenvironment makes ICAM-1 an intriguing 
molecular target, as evidence suggests that approximately 25% of all human cancer 
worldwide is associated with chronic inflammation. 
Utilizing ICAM1 as a target, I share the success of using an ICAM1 specific 
chimeric antigen receptor (CAR) T cells to eliminate anaplastic thyroid cancer tumors, 
in a solid tumor mouse model. The first attempt was using the single-chain fragment-
variable of R6.5, an ICAM-1 specific antibody. Followed by the utilization of the 
active domain (I-domain) of the natural ligand to ICAM-1, lymphocyte function 
associated antigen-1 (LFA-1). For I-domain CAR, many engineered affinity variants 
were studies, to help determine the ideal antigen to affinity, to maintain CAR T cell 
persistence without any systemic toxicities sometimes observed with ACTs.
   iii 
BIOGRAPHICAL SKETCH 
 
Yogindra Vedvyas is the second child born to an Indian family between Anil 
Vedvyas and Vandhana Vedvyas in New Delhi, India. He grew up with the nickname 
Yogi, constantly being hazed as a child, due to a popular TV show at the time, “Mr. 
Yogi”. He immigrated to the US in 1999, with his family. He attended middle school and 
high school in Queens, New York, where he grew up with a diverse group of friends. With 
the nickname Yogi, the hazing never stopped, “Mr. Yogi” turned to Yogi-Bear, turned to 
Yugioo. He learned to find the humor in it, as he knew there are many variation still to 
come.  
While he always enjoyed building things, taking things apart and try to put them 
back together, he never considered choosing a career in science. Through out high school 
and undergraduate studies, he was more interested in business and finance. It was a 
molecular biology requirement as an Undergraduate at Baruch College, which encouraged 
him to enroll in more science classes. This led to more and more course work in biology 
as an elective that led him to enroll at Hunter College to pursue a BA/MA in Molecular 
biology. From there he started working in the lab of Dr. Lesek Kotula at New York Blood 
Center. Eventually deciding to pursue graduate studies at Cornell, initially enrolling in the 
Masters of Engineering program. While doing an M.Eng project in the lab of Dr. 
Moonsoo Jin and Dr. David Putnam, it was evident that he enjoyed various protein 
engineering projects and drug/gene delivery systems.  
With the support of Dr. Jin, he was able to enroll into the PhD program in 
Biomedical Engineering. It was a non-traditional route into science. His goal for a PhD 
was never just the degree; the primary goal was to successfully translate work from the 
bench into clinic. With the Jin Lab moving from Ithaca campus to New York, he was able 
to work on more clinically translatable projects. His PhD years have been productive with 
   iv 
many collaborations and publications, and the goal to translate work into the clinic is 
likely to come true. His most recent projects in CAR T cell are being validated in the 
Good Lab Practice (GLP) run, and an Investigational New Drug (IND) application with 
the FDA is being submitted. After a successful defense, he plans to carry this over the 
threshold.   
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CHAPTER 1 
INTRODUCTION 
Adoptive T Cell therapy: A variety of options to translate to the clinic.  
The application of Adoptive T cell (ATC) therapy has re-energized the field of 
cancer immunotherapy. These therapies are sub-classified into two main technologies 
of tumor immunotherapy: Chimeric Antigen Receptor Engineered T Cell (CAR-T) 
and Gene Modified T cell receptors (TCR). (Figure 1.1)[1]. Both these strategies have 
the common goal of improving the ability of T cell receptors to recognize and attack 
specific target cell antigens by means of genetic modification. Both platforms were 
introduced with the initial intention of using adaptive immunity, rather than more 
traditional therapies such as radiotherapy, chemotherapy, and surgery to treat cancer. 
Adaptive immunity has numerous beneficial properties that provides amenable 
treatment for cancer: 1) T cell responses are specific and thus can potentially 
distinguish between healthy and cancerous tissue. 2) T cell responses are robust, 
undergoing up to 1,000-fold clonal expansion after activation. 3) T cell response can 
be directed to the site of the antigen, suggesting a mechanism for eradication of distant 
metastases. 4) T cell responses have memory, allowing for the therapeutic effect to be 
maintained for years after initial treatment.  
 
The evolution of TCR therapy 
TCR therapy evolved from the understanding that T cells are able to recognize 
and target specific antigens, presented to the major histocompatibility complex (MHC) 
proteins, that are present on the tumor and are not present or are poorly expressed on 
healthy tissue. Tumor-associated antigens (TAAs), neo-antigens or over expressed 
antigens, were identified by seminal studies in the 1990s [2], which conclusively 
demonstrated that immune cells could distinguish cancerous cells from healthy cells 
2 
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3 
 3 
 Figure 1.1 Molecular design of engineered TCR and CAR-T. 
T cells physiologically recognize their target by the T cell receptor (TCR) complex 
that is composed of the TCR ! and " chain for recognition and the CD3 chains for 
signaling. The variable regions of each TCR chain (! and ") together bind to the MHC 
presented antigen. T cells can be genetically engineered with defined specificity by 
expression of recombinant TCR !" chains of known specificity. In contrast to the 
TCR, the chimeric antigen receptor (CAR) is a polypeptide chain composed of a 
single chain fragment of variable region (scFv) antibody for antigen recognition, the 
extracellular spacer domain, a trans-membrane domain and the intracellular CD3# 
("first generation" CAR), CD28-CD3# ("second generation" CAR) or the CD28-
OX40-CD3# ("third generation" CAR) signaling chain. (Figure from Carl H. June 
(2018)) [3] 
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It was these tumor-infiltrating lymphocytes (TILs), which were able to recognized 
TAAs, that became the starting point for TCR therapy. In its earliest form it was 
demonstrated that TILs isolated from cancer samples and cultured with cytokines such 
as IL-2, exhibited cytotoxic activity against cancer cells in vitro[2]. Much more 
reliable therapeutic success was observed after advents of lymphodepletion (total body 
irradiation and chemotherapy), and selection of tumor-specific T cell clones generated 
from repeated antigen-specific stimulation of patient-derived (autologous) or donor-
derived (allogeneic) T cells in vitro[4]. 
To further refine the therapy, tumor-reactive TCR must first be identified in T 
cells isolated from patients with naturally occurring anti-tumor activity, and can be 
engineered to increased affinity specificity by changing the complementarity-
determining regions[5]. Alternatively, antigen-specific TCR can be derived from mice, 
that are engineered to express human antigens, expanding a subset of tumor reactive T 
cells. This enriched tumor reactive TCR repertoire cDNA is transferred, via viral 
transduction, back into the patient T cells[6]. A key theoretical concern with this 
approach is that engineered T cells contain both endogenous and engineered TCR (and 
thus possess dual specificity), which may lead to cross-reactivity after activation. The 
TCR chains from native and engineered TCR could also pair with each other to create 
novel TCR with new specificities. Despite this concern, side effects of genetically 
engineered T cell therapy have primarily been due to on-target off-tumor effects of 
TAAs expressed on healthy tissue. To put it in other words, the TAA was being 
expressed on healthy tissue, usually at a lower level of expression. 
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The success rate of these engineered TCR T cells has not been as successful as 
a mixture of TILs[7]. Despite the comparatively weak responses and safety concerns, 
there is a high interest in TILs ability to treat a wider variety of cancers and the 
potential to improve results by additional genetic modifications. Moreover, TCR 
engineered T cells are capable of penetrating the blood-brain barrier and inducing 
regression of brain metastases[8], with hope that patients with metastases at otherwise 
incurable sites may benefit from ATC. There was great success in melanoma targeting 
TCR, with specificity for gp100, cloned from melanoma reactive TILs, and transferred 
by retroviral means. This was then expanded to a few more melanoma specific targets 
such as MAGE-A3/4, MART-1, and NY-ESO-1/2.  
There have been drawbacks noted for TCR therapies. Tumor cells may become 
invisible to TCR modified T cells due to repression of the MHC complex[9], 
mutations in "2 microglobulin [10], and compromising  of antigen processing 
machinery[9, 11]. All of these changes may hinder antigen presentation and reduce 
TCR-mediated T cell activation. Engineering T cells with a recombinant TCR may 
produce additional safety hazards. Since the transgenic !" TCR is being expressed 
with endogenous TCR, the transgenic and endogenous TCR may form miss-paired 
hetero-dimers. These misspairing of TCR chains can induce severe auto-reactivity due 
to gaining of an unpredictable specificity[12, 13]. The situation can theoretically be 
solved by switching the constant moieties of the transgenic TCR from human to non-
human mammalian and by inserting additional cysteine bridges to facilitate 
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preferential pairing of the recombinant TCR !" chains in the presence of the 
physiologic !" TCR [14, 15]. 
While gene-modified T cells can be generated against many tumor antigens, 
TCR is still human leukocyte antigen (HLA)-restricted, meaning that new specificities 
must be described for each tumor antigen and HLA allele. The development of CARs 
provided a more universal approach to targeting tumor antigens that are expressed on 
the membrane of cancer cells.  
CAR-T therapy: An alternative to TCR therapy 
CAR-T therapy was introduced in the early 1990’s, when Dr. Zelig Eshhar and 
his group showed how they could stably transduce, a new hybrid surface molecule on 
a T cells by using a lentivirus or retrovirus. This recombinant molecule, also named 
immunoreceptor, linked the antigen recognition with the downstream signaling 
machinery of the TCR. This 1st generation CARs were equipped with the extracellular 
domain with a tumor-binding moiety, typically a single-chain variable fragment 
(scFv), followed by a hinge/spacer of varying length and flexibility, a transmembrane 
(TM) region, and one or more signaling domains associated with the T-cell signaling 
(the stimulatory domain of the CD3# endodomain) to initiate T cell activation.[1] 
(Figure 1.1) These engineered T cells recognize their new target by CAR binding and 
become activated to secrete pro-inflammatory cytokines, amplify and lyse the cognate 
target cells. Since the binding is independent of MHC, independent of individual HLA 
subtype, CAR-T cells are not affected by MHC repression and loss of HLA molecules 
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on target cells.  This also opened the door to non-typical T cell targets like 
carbohydrates and gangliosides.[16, 17] 
However, full and lasting T cell activation requires two complementary 
signals: one provided by the TCR/CD3 and the other by co-stimulation domains, like 
CD28 or 41BB. Furthermore, prolonged T cell activation requires co-stimulation by 
autocrine factors, such as IL-2, which is only secreted upon TCR signaling activation 
and simultaneous CD28 signaling.  This led to what is now classified as 2nd 
generation CAR. The most commonly used, 3rd generation CAR, an additional 
transducer domain (CD27, 41-BB or OX40) is added to the CD28 and #-chain to 
maximize strength, potency, and duration of the delivered signals[18-20]. (Figure 1.1) 
In the past few years, there have been groups claiming a 4th generation CAR-T, 
where they fuse IL-12 to the base of the 2nd generation constructs. This is known as T 
cell redirected for universal cytokine-mediated killing (TRUCKs). TRUCKs augment 
T-cell activation and attract innate immune cells to eliminate antigen-negative cancer 
cells in the targeted lesion. This strategy allows to target additional non-susceptible 
cells in the tumor micro-environment by the inducible release of transgenic immune 
modifiers. Such TRUCK T cells can also treat viral infections, metabolic disorders, 
and auto-immune diseases[21]. Additional groups have taken this a step further and 
integrated the secretion of molecules such as IL-12, CD40L, 4-1BBL, or even 
additional scfv’s to change the tumor microenvirnment or bypass immune checkpoint 
inhibition (PD1/PD-L1)[22]. 
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Inflammation as a target for Cancer: Up-regulation of ICAM-1 on tumors. 
Inflammation is the bodies’ necessary response to harmful insult, in which a 
careful interplay between the immune system and damaged tissues mediate the healing 
process. The restoration is characterized by heat, pain, redness, and swelling, which is 
instigated by increased blood flow, accumulation of fluid, and release of chemicals, 
such as histamine and bradykinin [23]. This intricate process requires tight control 
over the various components of the immune system for achieving desired immune 
responses to eliminate the stimulus and heal in a timely manner[24]. Acute 
inflammation is a self-limiting transient response that usually results in controlled 
wound healing. Chronic inflammation, on the other hand, is a prolonged response 
prompted by dysregulated immunomodulation [25].  
The link between inflammation and cancer was first postulated by Virchow in 
the 19th century, when he discovered the presence of leukocytes in tumors. Since then, 
many studies have strengthened this hypothesis, and recently, clear evidence that 
inflammation plays a role in tumor progression has been demonstrated [26]. Now, it is 
generally accepted that an inflamed milieu is a critical component of tumor initiation 
and progression, dubbing cancer as “wounds that do not heal.”[27] In many cases, 
some form of chronic inflammation precedes tumor development. While initial 
inflammatory responses are a part of normal host defense, tumorigenic pathogens can 
sabotage host’s immune response and establish chronic inflammation, facilitating 
cancer development. For example, persistent Helicobacter pylori infection is 
associated with gastric cancer and mucosa-associated lymphoid tissue lymphoma [28], 
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while infections with hepatitis B or C viruses can increase the risk of hepatocellular 
carcinoma [29].  
Conversely, by mirroring wounds, tumors can also initiate inflammation. Once 
established, solid malignancies trigger an intrinsic inflammatory response that 
launches a pro-tumor microenvironment [30]. Tumors begin remodeling the 
neighboring stroma through secretion of chemokines/cytokines, recruitment of 
leukocytes, and initiation of angiogenesis [31, 32]. As a result of the transformation, 
tumor microenvironment is composed of innate and adaptive immune cells that co-
exist with tumor cells as well as stromal cells, including mesenchymal cells, 
endothelial cells, and fibroblasts [33]. During this development, malignancies demand 
increasingly higher blood supply. When the tumor’s metabolic needs are no longer 
met, the cells receiving insufficient levels of nutrients die, forming a necrotic core and 
releasing pro-inflammatory cytokines, such as IL-1 [34]. The augmented inflammation 
promotes further angiogenesis and the resultant wave of immune cells provides the 
tumor with necessary cytokines and growth factors [35]. Much attention has been 
given to the molecular and cellular pathways linking inflammation with cancer and the 
local tumor environment to identify new target molecules that could lead to improved 
diagnosis and treatment [30, 36]. Among the many molecular players involved in the 
complex response, key point in induction of inflammation is the transcription factor 
known as nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB). 
Malignant epithelial cells manipulate NFkB, which controls various genes involved in 
inflammation, to be constitutively active. For example, in tumor-associated 
macrophages, activated NF-kB causes polarization of the cells into a phenotype that 
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suppresses cytotoxic T lymphocyte response, increases angiogenesis, and promotes 
tumor development [37]. One of the genes induced by the activation of NF-kB is 
intercellular adhesion molecule (ICAM)-1, known for its highly sensitive and 
localized expression in response to inflammatory signals. 
ICAM-1 is a transmembrane glycoprotein belonging to the immunoglobulin 
superfamily of adhesion molecules and is composed of five extracellular 
Immunoglobulin G-like domains. ICAM-1 is continuously expressed at low levels on 
various cell types including fibroblasts, endothelial cells, and some leukocytes, but is 
profoundly inducible in inflammation [38, 39]. More specifically, inflammatory 
mediators, including lipopolysaccharide, IFN-!, IL-1, and TNF" have been shown to 
cause strong induction of ICAM-1 in a wide variety of tissues and greatly increase 
binding of leukocytes, facilitating the infiltration of damaged tissues [40].  
In line with the increasing reports on the importance of inflammation in tumor 
progression, ICAM-1 has also been implicated to play a critical role in tumor 
progression in various types of cancer [41-44], where its over-expression has been 
correlated to poor prognosis [44-46]. In addition, the expression level of ICAM-1 has 
also been linked to cancer metastases, where ICAM-1 facilitates the spread of 
metastatic cancer cells to secondary sites [44-46]. Not only is ICAM-1 over-expressed 
on many carcinomas, but it is also induced in the inflamed milieu in the vicinity of 
tumors[36, 47]. This unique expression profile of ICAM-1 throughout solid tumor 
microenvironment makes ICAM-1 an intriguing molecular target, which holds great 
potential as an important diagnostic tool for assessing the progression and prognosis of 
tumors. In therapy, using drug-delivery or immunotherapy methods targeted against 
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ICAM-1 would bypass the efforts often required in identifying proper tumor antigens 
for each type of cancer. 
Integrin are members of a versatile family of noncovalently associated !/" 
heterodimeric cell surface receptors that stabilize cell-cell and cell-extracellular matrix 
adhesion during immune responses [47]. A type of leukocyte Integrin, !L"2 or 
lymphocyte function associated antigen (LFA)-1, is constitutively expressed on all 
leukocytes and is the natural ligand for ICAM-1. Although originally identified using 
antibodies that inhibit T cell-mediated killing, LFA-1 is also critically important for 
other leukocyte functions, including adherence to endothelial cells, fibroblasts, and 
epithelial cells[38]. In resting lymphocytes, the integrin remains in a low affinity state 
but it is rapidly synchronized to undergo dynamic conformational changes during 
lymphocyte activation, which greatly increases its binding affinity to ICAM-1. In 
addition to the affinity modification, avidity alteration through clustering in the 
membrane plays an important role in regulating adhesiveness of LFA-1 to ICAM-1 
[47]. Therefore, regulation of LFA-1 activation is pivotal for controlling leukocyte 
trafficking and immune responses in health and diseases. 
 
Difficulty with CAR-T cell against solid cancer, and strategies to overcome this 
hurdles 
Looking at recent clinical trials the most successful ones have been CARs, but 
those are only limited to leukemia/lymphoma and mostly non-solid tumors. TCR is 
mainly against melanoma due to the need for a TCR to have a homologous MHC on 
the Target cells. To date, CAR-T cells have demonstrated tremendous success in 
eradicating hematologic malignancies (e.g., CD19 CARs in leukemias). Two 
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autologous CAR-T cell therapies (Kymriah TM and Yescarta TM) were recently 
approved by the FDA. Kymriah TM is for the treatment of pediatric patients and young 
adults with refractory or relapse (R/R) B cell precursor acute lymphoblastic leukemia, 
while Yescarta TM is for the treatment of adult patients with R/R large B cell 
lymphoma. In common, both are CD19-specific CAR-T cell therapies lysing CD19-
positive targets. Many media reports have highlighted their dramatic efficacy in the 
short term [48]. 
However, this success has yet to be extrapolated to solid tumors. CAR-T cells 
have to surmount a lot of challenges in the solid tumor microenvironment. The two 
most favorable trials of ErbB2-CAR treating sarcoma, where 4 out of 17 patients 
showed stable disease, and GD2-CAR treating neuroblastoma, where 3 of 11 patients 
showed complete remissions [49]. The reason for CAR-T cells under-performing in 
solid tumor models is thought to be multifactorial. First, CAR-T cells must efficiently 
gather at the tumor site despite potential incompatibility between chemokine receptors 
present on T cell surface and chemokines secreted by tumors [50]. Second, CAR-T 
cells must infiltrate physical barriers posed by tumor stroma and interact with tumor 
cells in spite of possible antigen loss or heterogeneity. Third, CAR-T cells must 
overcome lack of nutrients, hypoxia, oxidative stress, acidosis, and immune-
suppression [51, 52]. The exciting success of CAR-Therapy in hematologic 
malignancies is fueling the application of CARs in solid tumors. However, a more 
complete grasp over the major hurdles seen in solid tumors will be necessary to 
optimize CAR engineering.  
As with most cancer therapies, there is an emerging set of toxicities associated 
with CAR-T cell therapies. In the case of CD19 CAR-T cells, these toxicities include 
B cell aplasia, tumor lysis syndrome (TLS), and cytokine release syndrome (CRS). 
Intravenous immunoglobulin can be used to replace quantitative antibody deficiency. 
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TLS has been managed successfully by standard supportive therapy, including 
hydration, alkalinization, allopurinol, and rasburicase [53]. In patients with B cell 
malignancies, CRS occurs at the time of peak levels of CAR-T cells in blood and bone 
marrow. Corticosteroids and cytokine blockade are currently being evaluated for 
patients with Chronic lymphocytic leukemia (CLL) and Acute lymphocytic leukemia 
(ALL). The tumor microenvironment contains multiple inhibitory factors to 
potentially suppress CAR-T cells. In order to prevent tumor cells from developing 
mechanisms to avoid the eradication by CAR-T cells, CAR-T biodistribution will help 
to analyze immune modulating cells (Tregs), Myeliod-derived suppressor cell 
(MDSCs), Immune checkpoints (e.g. PD-L1) and T cell suppressive cytokine. 
For ACT, the T cell subset matters, adoptively transferred CD8+ T cell clones 
poorly persist[54] and need help of CD4+ T cell. Prolonged T cell anti-tumor 
response also requires resistance to repression in the tumor tissue. A number of efforts 
are currently undertaken to counteract tumor associated T cell repression, in particular 
mediated by Treg cells and checkpoint mediators. In animal models, CD28 co-
stimulation without induction of IL-2 secretion protects a CAR redirected T cell 
response from Treg cell repression[55]. On the other hand, repetitive T cell 
stimulation upregulates CTLA-4, which acts as negative regulator to return the T cell 
to a resting stage. Administration of a CTLA-4 blocker, e.g., ipilimumab antibody, 
may prolong the anti-tumor activation of transferred T cells, although it is not locally 
restricted and will likewise affect all T cells[56, 57]. Expression profiling of TCR-
engineered T cells demonstrates overexpression of multiple inhibitory receptors in 
persisting lymphocytes, including PD-1 and CD160. The latter is associated with 
decreased reactivity of TCR T cells in a ligand independent manner[58]. Essentially 
the same was observed for CAR-T cells[59].  
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Disparities in imaging T Cell bio-distribution.  
The enthusiasm in CAR-T cell therapy, however, was dampened by reports on 
serious adverse events and fatalities after CAR-T cell administration[60-62]. In a 
clinical trial targeting ErbB2, healthy cells expressing low levels of the antigen in the 
lungs caused respiratory failure, leading to death. These rouge T cells were sufficient 
to trigger "on-target-off-organ" T cell activation[63]. In addition, CAR-T cell therapy 
can cause several alarming side effects, such as cytokine storms causing cytokine 
release syndrome (CRS), encephalopathy, and B cell hypoplasia. The trickiest of these 
be CRS, where the patients will have a fever, tachycardia, hypotension, capillary leak 
syndrome, and respiratory difficulty. Patients with encephalopathy will become 
confused and convulsive while patients with B cell dysplasia will have repeated 
infections due to poor immunity in vivo. These factors and other serious adverse 
events emphasize a careful evaluation of potential targets and the necessity for T cell 
dose escalation studies to balance anti-tumor efficacy and auto-immunity[64, 65]. 
Conventional methods used to monitor the immune system can be limited and biased. 
T cell responses are monitored most often through peripheral blood analysis and 
biopsy when appropriate. Blood measurements are the easiest and most robust method, 
providing information on cytokines, cell subsets, total cell quantity, and an easy 
method to track T cells in the periphery. However, blood sampling is limited by an 
inability to assess the T cell composition in alternative organs and tissues. These 
adverse events highlight the need to monitor ACT in patients.  Furthermore, the 
inability to monitor these cells in-vivo makes it difficult to predict success or failure 
from the onset of therapy, and doesn’t allow us to implement timely intervention in 
case there is toxicity. Specifically, a quantitative imaging modality such as Positron 
Emission Tomography (PET) is an essential tool that can be integrated into all ACTs.  
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PET is a powerful noninvasive imaging technique able to measure distinct 
biological processes in vivo by administration of a radiolabeled probe.  Whole-body 
PET measurements track the probe accumulation providing a means to measure 
biological changes such as metabolism, cell location, or tumor burden. PET scanners 
detect the location of positron-emitting probes in vivo and produce a three-
dimensional (3D) image. As the probe decays, positrons from the radionuclide 
annihilate with an electron in nearby tissue and emit two antiparallel 511 keV high-
energy photons[66]. For immunotherapies (in particular understanding T cell 
responses), PET can be utilized for spatial and longitudinal tracking of T lymphocytes. 
Preclinical microPET scanners typically have spatial resolutions of 1–2 mm, whereas 
clinical scanners have a resolution of approximately 1 cm, which is sufficient to detect 
lymph nodes in both instances.[67] 
Although PET has been utilized clinically for over 30 years, the recent 
development of additional PET radiotracers have dramatically expanded the use of 
PET to detect endogenous or adoptively transferred T cells in vivo. We have to be 
considerate to the criteria for selecting the ideal PET tracer for this work, particularly 
looking at aspects such as Specificity, Specific activity, and a favorable time window 
of PET. Specific activity is the ratio of the radiotracer molecule that is active, or in this 
case radiolabeled. It is ideal to have a very high specific activity, where a majority of 
the molecules injected in the patient is radiolabeled, as it would provide good counting 
statistics during the PET. However, it is also important to not violate the criterion of 
minimal mass effect due to the tracer, where the labeled ligands should not occupy 
more than 1 to 5% of the target receptor sites[68]. Time window of PET refers to 
turnover time of the tracer in tissue and must be within the time window of the PET 
technique and the radioactivity decay time of the labeling isotope. The commonly used 
positron emitters have rather short half-lives (ie. 68Ga, 68min; 18F, 108min, etc.). 
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Considering the radiation dose to the subject, the half-life should not be longer than is 
required for high-quality measurements. 
When addressing the specificity, we are considering what target the PET is 
imaging. When it comes to successful imaging of T cells, there are 3 strategies that 
work: 1) pre-labeling T cells with radionuclides, 2) immuno-PET, and 3) genetically 
modified T cells to express a reporter gene. Each of these strategies has their 
advantages and disadvantages.  
 
The comparison of direct-labeling vs. immunoPET vs. genetically modified PET-
reporter. 
Pre-Labeling T cells is a process in which cells of interest are harvested, 
incubated with the radiotracer of choice for intracellular uptake and retention, and then 
infused back into the patient for subsequent noninvasive detection. Generally, the 
radiotracers are taken up by cells via passive diffusion due to the use of lipophilic 
chelators and are retained by binding to intracellular proteins. There are many aspects 
of ex-vivo cell labeling that need to be optimized/determined to establish a 
reproducible radiolabeling procedure that does not cause toxicity for the cells of 
interest prior to imaging experiments, such as incubation time, radioactivity 
concentration per cell, retention of radioactivity over time, viability, radio toxicity, 
DNA damage, and altered phenotype or activation state. The significant drawbacks of 
this approach are the restricted longitudinal imaging due to radiotracer half-life, 
radiotracer dilution due to cell proliferation or cell death, and the small amount of 
radioactivity that can accumulate in each cell. In the context of radiolabeled T cells, 
strict attention needs to be made on cellular activation and cell death due to 
established radio-sensitivity of T lymphocytes. Although this is a relatively routine 
procedure in nuclear medicine, it is nonetheless a labor-intensive process. This 
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methodology has been used to detect sites of inflammation or infection using gamma-
emitting radionuclides, such as 99mTc-hexamethylpropyleneamine oxime (99mTc -
HMPAO), to detect sites of inflammation or infection[69] Similarly, other radio-
isotopes have been used like 18F, 64Cu, 89Zr or 111In, allowing to image T cell bio-
distribution from 90 min to up to 7 days[68-70].  While the imaging strategy is 
specific to the re-infused T cells, this might not be the best option to image ACT’s. 
Ex-vivo radiolabeling will not provide information about the presence of adoptively 
transferred cells, weeks post-reinfusion due to the limitation of radionuclide half-life. 
Consistent T cell handling, incubation times, radiolabeling efficiency, viability, and 
phenotype of T cells must be established for routine clinical use. 
The immuno-PET strategies use radiolabeled proteins targeting extracellular 
epitopes of T cells, by utilizing high specificity of antibodies to T cell subset, such as 
CD8+ or CD4+ on T cells, or activation specific, such as the checkpoint inhibitors like 
CTLA-4 or PD-1 expressed on tumor-infiltrating cytotoxic T lymphocytes. The long 
circulation half-lives of intact antibodies that range from days to weeks requires the 
use of long-lived PET radionuclides, such as 124I (4.2 days), 89Zr (3.2 days), and 64Cu 
(12.7 hr.)[71-73]. Since intact antibodies have a circulation half-life of week’s in-vivo, 
long-lived isotopes conjugated to full-antibodies result in increased radiation dose for 
the patient. To reduce radiation exposure, enhance the target-to-background at early 
times, and make use of short-lived radionuclides, antibody engineering has allowed for 
the construction of antibody fragments for immuno-PET, including diabodies/bivalent 
diabody (scFv dimer; ~55 kDa; half-life ~2–5 hr in mice) and minibodies (scFv-CH3 
dimer; ~80 kDa; half-life ~5–10 hr)[74-76]. These engineered minibodies do not 
deplete CD8+ T cells in vivo, as they lack the full Fc domain used by effector cells 
such as Natural Killer (NK) cells.  
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While immuno-PET using intact antibodies and antibody fragments, is a useful 
tool, the targets developed so far target the entire T cell population in-vivo, not 
necessarily modified T cells such as TIL or CAR-T. In addition, antibodies also 
function indirectly by eliciting immune responses utilizing the antibody Fc domain 
engaging Fc$ receptors on immune cells (antibody-dependent cellular cytotoxicity) or 
complement (complement-dependent cytotoxicity). 
The third strategy of genetically modified PET-reporter is perhaps the best 
option for tracking ACT bio-distribution. Cells are stably transduced to express a 
surface protein or enzyme, such as a PET reporter and are then monitored for location, 
quantity, and bio-distribution by the corresponding PET probe. The major limitations 
in reporter imaging are the need to genetically manipulate cells ex-vivo and the risk 
of immunogenicity from ectopic expression of a foreign protein. Pre-clinically a few 
PET-reporters have been adapted for ACTs: human Norepinephrine transporter 
(hNET), Sodium Iodine Symporter (NIS), human Somatostatin Receptor 2 (hSSTR2), 
and Herpes Simplex Virus Type 1 Thymidine Kinase (HSV-TK). So far, HSV-TK has 
been the only one attempted for T cell imaging in humans. 
Human Norepinephrine transporter (hNET) as a PET reporter gene is detected 
by [124I]-metaiodobenzylguanidine ([124I]-MIBG) [77]. hNET was first shown with 
Adoptive T cells reactive to Epstein–Barr virus (EBV). Initially, T cells were injected 
intra-tumorally, where they were able to detect as little as 104 cells per tumor in the 
microPET scan. Investigators then tracked the expansion/infiltration of these EBV 
reactive CD8+ T cells long-term, showing an increase in Tcell presence up to 28 days 
later.  
Sodium Iodine Symporter (NIS) is another PET-reporter that is a transporter 
expressed endogenously in the thyroid and stomach. Ectopic expression of NIS can 
allow reporter gene imaging by administration of iodine radionuclides (124I, 131I) for 
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PET [78] and even technetium-99m pertechnetate (99mTcO-)[79]. One advantage to 
NIS is the high specificity demonstrated in-vivo without needing to synthesize or 
radiolabel a reporter-specific probe. A major hindrance to using this reporter is the 
endogenous expression of NIS in salivary and lacrimal glands, stomach, choroid 
plexus, ciliary body of the eye, skin, placenta, lactating mammary gland, thymus, and, 
to a lesser extent, the prostate, ovary, adrenal gland, lung, and heart[80, 81]. Liver is 
regarded as the major organ for metabolism of radio-iodinated thyroglobulin released 
from functioning thyroid tissues[82]. This obscures any real possibility of using NIS 
as a T cell PET-reporter.  
Herpes Simplex Virus Type 1 Thymidine Kinase (HSV-TK) was initially used 
a suicide gene, showing cell elimination by compounds such as Ganciclovir 
(GCV)[83]. It was then adapted for PET using 124I and 18F [84, 85]. In each case, a 
radiolabeled acycloguanosine-like compound was able to visualize HSV-TK 
expression in mice. In 2002, Gambhir group explored a mutant form of HSV-TK with 
improved Vmax/Km for GCV (sr39TK)[86]. Initially, this mutant was used to monitor 
tumor burden in mice transplanted with sr39TK expressing leukemic cells [87]. This 
study was the first demonstration of the feasibility for PET reporter imaging of HSV-
TK as a tool to monitor the location of systemic immune cells not located as a 
subcutaneous graft. Infused cells could be monitored by PET imaging for up to 15 
days post-transplant. Most recent studies with HSV-TK have shifted away from the 
[124I]-FIAU probe and instead utilize a penciclovir analog, 9-(4-[18F]-fluoro-3-
hydroxymethylbutyl) guanine ([18F]-FHBG). These studies have successfully tracked 
the location and infiltration of tumor reactive T cells in mouse models of 
immunotherapy. The dual functionality and efficacy of sr39TK as a reporter and 
suicide gene were recently validated in a humanized mouse model [88, 89]. Human 
hematopoietic stem cells (HSCs) were transduced to express a TCR and sr39TK. 
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Engraftment and T cell development were tracked by [18F]-FHBG signal. To ablate the 
engineered cells, therapeutic doses of GCV were given. Efficacy was determined by 
follow-up [18F]-FHBG scans that displayed little to no signal in ablated animals [88]. 
However, when this as attempted in humans, expression of HSV-TK was 
immunogenic in patients with CD8+ T cells against the HSV-TK gene[90, 91]. 
The type 2 human somatostatin receptor (hSSTR2) was originally targeted as a 
highly expressed target on neuroendocrine tumors, with SPECT and PET agents 
developed for diagnosis and staging [92]. Outside of these tumors, expression of 
hSSTR2 is low throughout the body making this a suitable PET reporter gene. Several 
studies have demonstrated longitudinal reporter imaging with [68Ga]-DOTATOC in 
mouse models[93, 94]. It is the low background signal from this clinically approved 
tracer and reporter that led us to pick hSSTR2 as our PET-reporter of choice, 
expanded on chapters 2-5.  
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Dissertation outline  
Chapter 2 describes the development of intercellular adhesion molecule-1 
(ICAM-1) targeting CAR-T for the treatment of aggressive thyroid cancer, a solid 
tumor model. This third-generation CAR-T leverages adoptive T cell therapy as a new 
treatment modality against advanced thyroid cancer. ICAM-1 CAR-T cells 
demonstrated robust and specific killing of anaplastic thyroid cell lines in-vitro and in-
vivo. Even though these cells had heterogeneous levels of ICAM-1 expression, 
addition of cytotoxic CAR-T cells induced increased ICAM-1 expression such that all 
cell lines became targetable, mediating profound tumor killing that resulted in long 
term remission and significantly improved survival compared to that of untreated 
mice. Similar results were shown even with patient derived tumors. 
Chapter 3 documents the utility of human somatostatin receptor 2 (SSTR2), as 
a PET reporter. Specifically to be used with ATC to quantitatively and longitudinally 
visualize whole-body T cell distribution and antitumor dynamics using a clinically 
approved radiotracer, showing T cells were detectable at low densities with high 
sensitivity and specificity. SSTR2-based PET was applied to ICAM1-targeting CAR-T 
cells to show the treatment dynamics in-vivo with anaplastic thyroid tumors. 
Particularly, this approach highlights how timely CAR-T cell infusions resulted in 
survival of tumor-bearing mice, while later infusions led to uniform death. Real-time 
PET imaging revealed biphasic T cell expansion and contraction at tumor sites among 
survivors, with peak tumor burden preceding peak T cell burden by several days.  
Chapter 4 illustrates, utilizing the same PET reporter, to help establish safety 
criteria for CAR-T. Particularly evaluates the ideal affinity of the antigen recognition 
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moiety to use when developing a CAR-T therapy. A panel of affinity-variant CARs 
was constructed targeting ICAM-1, using its physiological ligand, LFA-1. Anti-tumor 
T cell potency in-vitro was directly proportional to CAR affinity and ICAM-1 density. 
Longitudinal T cell tracking by PET/CT and concurrent cytokine measurement 
revealed expansion and contraction kinetics of micromolar affinity CAR-T cells and 
inflammatory cytokines. Highlighting how utilizing a reduced affinity-targeting 
moiety, can significantly boost efficacy and safety. 
Chapter 5 is a compilation of multiple studies underway, where the utility of 
SSTR2 is evaluated beyond a simple PET reporter. Here, we see the possibility of 
using this report to activate and control ACT. Furthermore, there are additional studies 
to show the utility of SSTR2 PET with CD19-CAR, which was recently approved by 
the FDA.  
Chapter 6 includes concluding remarks and additional possibility that this work 
would translate to, and its potential for translation into clinic.  
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CHAPTER 2 
 
CAR-T THERAPY TARGETING ICAM-1 ELIMINATES ADVANCED HUMAN 
THYROID TUMORS 
Summary  
1Poorly differentiated thyroid cancer and anaplastic thyroid cancer (ATC) are 
rare yet lethal malignancies with limited treatment options. Many malignant tumors 
including papillary thyroid cancer (PTC) and ATC are associated with increased 
expression of intercellular adhesion molecule-1 (ICAM-1), providing a rationale for 
utilizing ICAM-1-targeting agents for the treatment of aggressive thyroid cancer. 
Therefore, we developed a third-generation chimeric antigen receptor (CAR) targeting 
ICAM-1 to leverage adoptive T cell therapy as a new treatment modality against 
advanced thyroid cancer. ICAM-1 CAR T cells demonstrated robust and specific 
killing of PTC and ATC cell lines in vitro. Interestingly, although certain ATC cell 
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lines showed heterogeneous levels of ICAM-1 expression, addition of cytotoxic CAR 
T cells induced increased ICAM-1 expression such that all cell lines became 
targetable. In mice with systemic ATC, a single administration of ICAM-1 CAR-T 
cells mediated profound tumor killing that resulted in long term remission and 
significantly improved survival compared to untreated controls. Patient-derived ATC 
cells overexpressed ICAM-1 and were largely eliminated by autologous ICAM-1 CAR 
T cells in vitro and in animal models. Our findings are the first demonstration of CAR 
T therapy for metastatic, advanced thyroid cancers that exhibit dramatic therapeutic 
efficacy and survival benefit in animal studies. 
 
Introduction 
Thyroid cancer is the most common malignancy of the endocrine system with an 
estimated 64,300 new cases being diagnosed in the US in 2016 [1]. This rate of 
diagnosis is increasing more rapidly than any other endocrine cancer in the US [2]. 
Most thyroid cancers are indolent and curable with standard treatments such as 
surgery, radioactive iodide (RAI) therapy, and thyroid stimulating hormone (TSH) 
suppression therapy for localized or regional disease. However, thyroid cancer patients 
can have widely different clinical outcomes depending on the pathological subtype. 
The follicular-derived thyroid cancers are divided into well-differentiated papillary 
thyroid cancer (PTC), follicular thyroid cancer (FTC), poorly differentiated thyroid 
carcinoma, and anaplastic thyroid carcinomas (ATC). The mortality rates of well-
differentiated PTC (WDPTC), poorly-differentiated PTC (PDPTC), and ATC are 
reported to be 3–10%, 38–57%, and close to 100%, respectively [3]. Moreover, distant 
metastases occur at higher frequencies in PDPTC and ATC patients (representing 
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approximately 5% of all thyroid cancer patients), reducing their 5-year survival to 
55.3% from 99.9% for localized, well-differentiated tumors [4]. The occurrence of 
ATC is fortunately rare estimated to be 2-5% of all thyroid cancers, but when it does 
occur it is rapidly lethal with a median survival of 5 months and 1-year survival rate 
estimated at 10-20% [5]. 
Research on targeted therapeutic interventions has focused on inhibiting 
aberrant pathways implicated in well-differentiated thyroid cancer, including RET-
PTC translocations and BRAF point mutations (V600E) in PTC, and RAS point 
mutations in follicular and poorly-differentiated thyroid carcinoma (4). Vascular 
endothelial growth factor and its receptors have also been extensively studied and 
targeted with multikinase inhibitor drugs like sorafenib, sunitinib, and lenvatinib. 
While these strategies hold promise for extension of progression-free survival, there is 
little evidence for improved overall survival of thyroid cancer patients treated with 
these drugs (1). Moreover, there are no systemic therapies (cytotoxic and/or targeted) 
that aid survival or quality of life in patients with metastatic ATC. Multikinase 
inhibitor drugs have shown very limited response in ATC patients except for a few 
reported anecdotal cases [6, 7], highlighting an urgent need for new treatment 
modalities. 
Recently, cancer immunotherapy and in particular, adoptive cell therapy 
(ACT) have made significant technological advancements leading to improvements in 
both efficacy and potential availability for the treatment of hematologic and solid 
tumors [8]. Successful application of ACT using unmodified cytotoxic T cells relies 
upon isolation and ex vivo expansion of patient T cells, typically tumor infiltrating T 
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cells (TILs), that recognize mutated or overexpressed tumor-associated antigens in an 
MHC-dependent manner. While successful in certain malignancies, most notably in 
melanoma [8], reliable extraction of TILs from a wider range of tumors is hampered 
by their low availability. Furthermore, tumors can down regulate MHC-I expression to 
render these T cell receptor (TCR)-based therapies less effective [9]. In order to enable 
effector T cells to target tumor antigens in a non-MHC-dependent manner, a CAR 
molecule that integrates antibody-derived antigen recognition via a single-chain 
fragment variable (scFv) and the zeta chain signaling domain from TCR complex was 
devised in the late 1980s [10]. Evolution of this design led to integration of additional 
signaling domains derived from co-stimulatory receptors such as CD28 and 4-1BB 
[11, 12] and these 2nd and 3rd generation CAR designs have shown remarkable success 
in hematologic cancers, particularly in B cell malignancies [13, 14]. Recently positive 
outcomes have also been observed in clinical trials treating solid tumors, including 
neuroblastoma, melanoma, and synovial cell carcinoma [8]. 
With the intention of developing a CAR T therapy applicable to recurrent, 
advanced thyroid cancer patients with no alternative treatment options, we first 
validated ICAM-1 as a suitable antigen for CAR-targeting by examining the 
correlation between ICAM-1 expression and malignant features in PTC and ATC. 
ICAM-1 is a member of the immunoglobulin superfamily, and is known to play a role 
in mediating cell-cell interactions such as leukocyte endothelial transmigration during 
inflammation [15]. Under non-inflammatory conditions, ICAM-1 expression is 
constitutively low and faintly detectable on endothelial cells. Increased ICAM-1 
expression levels have been observed in multiple myeloma [16] and across many 
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disparate carcinomas including breast [17], pancreas [18], and gastric [19] tumors, and 
are correlated with tumor progression and metastatic capability [20]. Moreover, 
clinical trials support the safety and tolerability of targeting ICAM-1 using 
monoclonal antibodies [21-25]. Previous studies have shown that ICAM-1 expression 
is highly correlated with the both the malignancy and metastatic status of thyroid 
tumors, as well as the V600E of BRAF (BRAFV600E) mutation [26, 27]. The stark 
correlation of ICAM-1 expression with adverse prognostic outcomes in thyroid cancer 
patients suggests that ICAM-1 may serve as a therapeutic target for advanced, 
recurrent thyroid tumors. 
Extending our prior study on ICAM-1-specific CAR T cells [28], here, we 
describe the development and preclinical application of ICAM-1 targeting third-
generation CAR T cells that showed marked eradication of ATC cell lines and patient-
derived primary ATC cells in an ICAM-1-specific manner. The surface expression 
levels of ICAM-1 on ATC cell lines and patient-derived primary ATC cells were 
sufficiently high to discriminate them from healthy primary tissue cells. Our CAR T 
cell-based immunological approach has potentially wide-ranging applications for the 
treatment of other solid cancers where there is a strong association between ICAM-1 
expression and adverse prognosis. 
 
Experimental Procedures 
Study Approval  
Patient sample collection procedures were approved by the Weill Cornell Medicine 
Institutional Review Board, and patients’ written consents were obtained prior to 
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inclusion in the study. All animal studies were approved by Weill Cornell Medicine’s 
Institutional Animal Care and Use Committee. 
 
Cell lines and Primary cell culture 
8505C and BCPAP cell lines were purchased from DSMZ, Germany. FRO and KHM-
5M cell lines were kindly provided by Dr. James A. Fagin (Memorial Sloan–Kettering 
Cancer Institute, New York, New York). HEK 293T, HMEC-1, and HeLa cells were 
purchased from ATCC. All cells except for HMEC-1 were maintained in RPMI 
medium supplemented with 10% FBS and 100 U/ml Pen/Strep. HMEC-1 cells were 
maintained in MCDB131 medium (ThermoFisher) supplemented with 10% FBS, 10 
ng/ml Epidermal Growth Factor (ThermoFisher), 1 !g/ml hydrocortisone (Sigma-
Aldrich), 10 mM glutamine, and antibiotics. Primary SAEC from healthy donors were 
purchased from Lonza and cultured in SABM media supplemented with SAGM bullet 
kit (Lonza). Primary kidney MVEC cells were purchased from Cell Systems and 
maintained in CSC complete media, which includes animal derived growth factors 
(CultureBoost) and 10 % serum (Cell Systems). Gene inactivation of ICAM-1 in 
8505C was carried out using CRISPR plasmids available from Santa Cruz 
Biotechnology (sc-400098 and sc-400098-HDR). For some studies, cell lines were 
transduced with a fLuc-F2A-GFP lentivirus (Biosettia). GFP+ and ICAM-1Hi cells 
were FACS sorted using the flow cytometry core facility at Weill Cornell Medicine. 
Peripheral blood mononuclear cells (PBMCs) were isolated over Ficoll-Paque PLUS 
(GE Healthcare) and cultured in Optimizer CTS T-cell Expansion SFM (Thermo 
Fisher) supplemented with 5% human AB serum (Sigma-Aldrich), 2 mM L-alanyl-L-
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glutamine dipeptide, 100 U/ml Pen/Strep and 30 IU/ml human IL-2 (Cell Sciences). 
Nonadherent PBMCs were recovered after 24 hours and magnetically enriched for T 
cells using Dynabeads Human T Expander CD3/CD28 (Thermo Fisher) at a 2:1 
bead/T cell ratio. Dynabead-bound T cells were subsequently cultured in IL-2–
containing media at a density of 1-2 " 106 cells/ml. Surgically resected fresh tumor 
tissues were cultured to establish patient-derived primary tumor cells with an 
endocrine pathologist (TS) reviewing each case to ensure correct diagnosis. Briefly, 
finely minced tumor tissues were digested with a mixture of collagenase and 
hyaluronidase (STEMCELL technologies) at 37°C on the shaker for 1 hour. After 
gently washing, tumor tissues were seeded on a 6-well plate in RPMI-1640 media 
supplemented with 10% FBS and 100 U/ml Pen/Strep. 
 
CAR T vector construction, Lentiviral production, and T cell transduction  
 
Engineering of R6.5 scFv into third generation pLenti plasmid has been described 
previously [28]. The sequence for rLuc was inserted into the vector using XbaI and 
SalI restriction sites. Production of lentivirus particles was described previously [28]. 
For transduction, human T cells were first activated for 24-48 hours by incubation 
with CD3/CD28 Dynabeads. At this point, cells were transduced by spinfection at 
1,000 g for 1 hour at 32°C. T cells were also transduced a second time, 24 hours after 
initial transduction. The viral titer was adjusted to obtain a transduction level of 
approximately 50% by flow cytometry. During and following transduction, T cell 
media containing IL-2 was replaced with media containing human IL-7 (10 ng/ml) and 
IL-15 (5 ng/ml) (Peprotech).  
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E:T assay and cytokine analysis 
Target cells (5x103) with fLuc expression were co-cultured with 1.25x104 ICAM-1 
CAR-transduced T cells in T cell media containing 150 !g/ml D-luciferin (Gold 
Biotechnology) with no addition of exogenous cytokines. Luminescence values were 
measured over time using a TECAN Infinite M1000 PRO plate reader and were 
normalized to control wells containing tumor and non-transduced parental T cell co-
cultures. Supernatants from ICAM-1 CAR T and target cell co-cultures were 
quantitatively analyzed for the presence of Human IFN-! and Human Granzyme B 
using the ELISA MAXTM Deluxe Kit and the LEGEND MAXTM Human Granzyme B 
ELISA Kit, respectively (both from BioLegend). Supernatant samples were spun for 3 
minutes at 300 x g to remove debris and stored at -80° C, avoiding freeze/thaw cycles. 
Exogenous IFN-! (Peprotech) was added to certain cells for analysis of ICAM-1 
induction. 
 
Flow cytometry analysis for protein expression and cell cycle 
Staining of cell lines and primary cells were performed on ice for 20 minutes in 1x 
Hank’s buffered saline solution (HBSS) staining solution containing 2% normal goat 
serum and 0.1% bovine serum albumin. ICAM-1 expression on cell lines and primary 
tumor cells was determined using mouse anti-human ICAM-1 R6.5 monoclonal 
antibody (5!g/ml) that was conjugated to Cy5.5 (Sulfo-Cyanine5.5 NHS ester, 
Lumiprobe) in laboratory or with secondary antibody against FITC-conjugated goat 
anti-mouse IgG (ThermoFisher) (R6.5 IgG was purified from hybridoma 
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(ATCC))[29]. Anti-human CD3-PECy5/CD4-PE/CD8-FITC cocktail, Alexa Fluor 647 
anti-human CD3 (HIT3a), PE-conjugated EPCAM, APC-conjugated ICAM-1 (HA58) 
antibodies were from BioLegend. FITC-conjugated anti-mouse F(ab’)2 antibody 
(ThermoFisher) was used to detect CAR expression in primary T cells. Live cell 
gating was determined by calcein blue (ThermoFisher) uptake. Organ tissues 
harvested from animals were macerated through a 70!m filter and after washing, 
tissue cell pellets were resuspended in red blood cell lysis buffer (BioLegend) on ice 
for 20 minutes. Mouse tissue cells were first blocked with mouse IgG (Sigma-Aldrich) 
at 2 !g/ml for 10 minutes, and then stained with primary antibodies. Dead cells and 
debris were excluded based on propidium iodide (PI, Sigma-Aldrich) staining at 
1!g/ml. For cell cycle analysis, 5x105 cells were seeded in 6-well plates overnight in 
RPMI media containing 10% FBS. Media was replaced with 2.5% FBS containing 
RPMI-1640 media in a subset of wells the following morning, and all cells were 
harvested and fixed 48 hours later using ice-cold PBS and 70% ice-cold ethanol, 
sequentially. After fixation at 4°C for 48 hours, cells were washed twice with PBS, 
treated with 100 ug/mL RNaseA for 30 minutes at 4°C, washed once with PBS, and 
stained with 50 ug/mL PI. For some experiments, cell cycle was determined by double 
staining of PI and FITC anti-BrdU antibody (BioLegend) after 30 min of incubation 
with 1 mM BrdU (Sigma-Aldrich) for 30 minutes. To determine Fas L- or TRAIL-
induced cell death, His-tagged recombinant human Fas Ligand (TSFSF6, R&D 
systems) or TRAIL (TNFSF10, R&D systems) protein was added to the cells in media 
along with 2 !g/ml of anti-His crosslinking antibody (R&D systems). Flow cytometry 
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data were acquired using Gallios flow cytometer and was analyzed using Kaluza 
software (Beckman Coulter). 
 
Cell Proliferation Assay 
The Vybrant MTT Cell Proliferation Assay Kit (ThermoFisher) was used to assess cell 
proliferation. 5x103 viable cells were seeded per well in a 96-well plate in a final 
volume of 200 !L of RPMI-1640 media supplemented with 10% FBS. After overnight 
incubation, vemurafenib (Selleck Chemicals) was added to each well at a final 
concentration of 0.2% in phenol red-free RPMI-1640 media containing 2.5% FBS. 
After 72 hours, cells were fixed in MTT stock solution, as per manufacturer’s 
instructions. Absorbance was read in an iMARK microplate reader (BioRad) at 
490nm. For colony formation assays, 2x103 cells per well were seeded in a 6-well 
plate. Treatment with vemurafenib was carried out as per the MTT assay. After 72 
hours, cells were incubated in regular media for 10 days, followed by methanol 
fixation and staining with 0.1% crystal violet solution (Sigma-Aldrich). 
 
Animals and Tumor growth analysis 
8-10-week-old female and male NOD-scidIL2Rgnull (NSG) mice (Jackson laboratory) 
were used for xenograft experiments with ATC cells. GFP and fLuc-expressing 8505C 
(0.75x106 cells per mouse) and patient-derived ATC cells (0.36x106 cells per mouse) 
were i.v. injected to establish systemic metastasis establishment [30]. Longitudinal 
measurements of 8505C tumor burdens were taken using a whole-body optical imager 
(In-Vivo Xtreme 4MP, Bruker) 15 minutes after intraperitoneal injection of 100 !l of 
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150 !g/ml D-luciferin (GoldBio). During imaging, mice were anesthetized under 3% 
isoflurane at 2 L/min O2. Image capture parameters were 4x4 binning collecting 
luminescence for 20 seconds. Total tumor burden was measured by generating full 
body region of interests (ROIs) and integrating total flux of luminescence using 
Bruker Analysis software. GFP-expressing livers, spleen, heart, and lungs were 
extracted from mice and imaged with a whole-body optical imager (In-vivo F-Pro, 
Bruker). Image capture parameters were no binning and 2 second exposure at 510 nm 
excitation and 530 nm emission. To track ICAM-1-CAR T cells expressing rLuc, mice 
were injected i.v. with 100 !l of RediJect Coelenterazine h (Perkin Elmer) and then 
immediately imaged using In-Vivo Xtreme 4MP (Bruker). Image capture parameters 
were 4x4 binning collecting luminescence for 60 seconds.  For tumor burden analysis 
of patient-derived ATC-xenografts, mice were scanned with a 7T preclinical MRI 
scanner (Bruker Biospec 70/30 USR). Animals were placed prone headfirst into the 
system, with a respiratory sensor on their bodies to implement respiratory gating 
within coil (inner diameter, 3 cm). MR data was acquired with a RARE, or Rapid 
Imaging with Relaxation Enhancement, sequence using the following parameters: 
echo time = 8.710 milliseconds, repetition time = 1144.512 milliseconds, RARE factor 
= 2, number of averages = 18, total scan time = 32 minutes, FOV = 30 mm x 30 mm, 
spatial resolution = 0.117 mm/pixel, matrix size = 256 x 256, slice thickness = 0.5 
mm, slices = 48. DICOM files were analyzed using open sourced software ITK-Snap. 
Tumor burden was calculated as a ratio of volume of tumor over volume of pulmonary 
cavity excluding heart. 
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Immunohistochemistry 
Human tumor specimens were collected from patients undergoing surgery at Weill 
Cornell Medical College/New York Presbyterian Hospital. Formalin-fixed, paraffin-
embedded human tissue blocks were cut at 5!m thick intervals and two consecutive 
slides were stained for ICAM-1 (G-5, Santa Cruz Biotechnology) and hematoxylin 
and eosin (H&E) at the Translational Research Lab at WCM Pathology and 
Laboratory Medicine [26]. Tumor xenografts were harvested, fixed in 4% 
paraformaldehyde in PBS, embedded in paraffin, and cut as 5!M sections. For lung 
tissues, 4% paraformaldehyde solution was perfused into the trachea to preserve the 
tissue morphology.  All five lobes were separated and paraffin fixed. Consecutive 
slides were stained for H&E, human CD3, and GFP (Histowiz, Brooklyn). An 
endocrine pathologist (TS) reviewed each case to ensure correct diagnosis and to 
determine the tumor extent, CD3, GFP, and ICAM-1 staining in patient-derived and 
cell line xenografted tumor blocks. 
 
TCGA data reanalysis 
Clinical parameters, genomics and computational methods are described in detail in 
[31]. The results here are in whole or part based upon data generated by the TCGA 
Research Network: http://cancergenome.nih.gov/. The level of ICAM-1 RNA 
expression was given as a Z-score, which is the relative expression of an individual 
gene within tumor to the gene's expression distribution in a reference population. The 
ERK activity score is derived from 52 gene-signatures that were responsive to a MEK 
inhibitor in BRAFV600E melanoma cell lines [32]. BRAFV600E-RAS score (BRS) 
 42 
determines whether PTC exhibited a transcriptional program that related closer to 
tumors with BRAFV600E or RAS activating mutations by computing expression of 71 
genes (details in [31]). Tumors with negative BRS were defined as BRAFV600E-like, 
while those with a positive BRS were defined as RAS-like. The thyroid differentiation 
score (TDS) was determined by the relative transcription of 16 different thyroid 
function genes. Tumors with a positive TDS retain thyroid functions, whereas those 
with a negative TDS indicates a loss of normal thyroid cell function. Disease-free 
survival curves and overall survival curves were graphed using the Kaplan-Meier 
Method and were compared using the log-rank test. We analyzed the 80% power using 
a two-sided, 0.05 alpha level test to estimate whether the total number of events were 
sufficient.  
 
Statistics 
Comparisons between categorical vs. continuous variables were performed using the 
Mann-Whitney U/Krusker-Wallis test as appropriate. The Spearman correlation test 
was used to compare continuous vs. non-continuous variables. To account for 
multiple-testing bias, the p-value was adjusted using the Bonferroni correction. 
Statistical analysis was performed using Stata 14 (College Station, TX) or GraphPad 
Prism (La Jolla, CA). Graph representations were performed using GraphPad Prism. 
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Results 
Widespread overexpression of ICAM-1 in aggressive thyroid cancers 
Previous reports have demonstrated a positive correlation between ICAM-1 RNA and 
protein expression levels and the aggressive potential of PTC [26, 27], constituting 
ICAM-1 as a biomarker and a potential target for therapeutic interventions in thyroid 
cancer. PTCs are most commonly driven by two mutually exclusive somatic 
mutations, BRAFV600E or mutated RAS [31]. The BRAFV600E mutation is an 
established marker associated with activation of MAPK and downstream ERK 
signaling, reduced iodine uptake [31], and advanced clinical staging in PTCs [33]. 
Therefore, we investigated the characteristics of BRAFV600E versus RAS-driven PTCs 
with coexistent ICAM-1-overexpression (390 PTC patients in the Cancer Genome 
Atlas (TCGA) research database [31]) to understand the underlying signaling and 
differentiation properties. Expression of ICAM-1 mRNA in PTC positively correlated 
with an ERK activity metric (Spearman: 0.693, p<0.0001) (Figure 2.1A). ICAM-1 
mRNA levels also associated better with tumors driven by BRAFV600E compared to 
RAS mutations (BRAFV600E and RAS-like tumors have negative and positive values in 
BRAFV600E-RAS score (BRS), respectively; details in Methods section) (Figure 2.1B). 
Moreover, ICAM-1 mRNA expression in PTC patients was higher in those with the 
BRAFV600E mutation compared to WT BRAF (Figure 2.2A). These data suggest that 
ICAM-1 transcriptional control is linked to the activation of BRAF- 
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Figure 2.1 ICAM-1 overexpression is associated with recurrent, advanced 
thyroid cancer cells. (A,B,C) Spearman’s correlation analysis between ICAM-1 
mRNA expression and ERK activity (A), BRAFV600E-RAS score (BRS) (B), and 
thyroid differentiation score (C) were calculated using 390 PTC patient’s genomics 
and clinical data available from TCGA analysis [31]. Algorithms for these scores have 
been described previously [31]. (D, E) Box plots compare tumor ICAM-1 mRNA 
levels via the absence (N0) or presence (N1) of tumors metastases to nearby lymph 
nodes (D) and cancer associated with extrathyroidal extension (E, None, no extension; 
T3, minimal extension; T4, moderate/advanced/highly advanced extension; n=226 and 
232 for N0 and N1, respectively; n=338, 133, and 18 for None, T3, and T4 groups 
respectively). The solid, horizontal middle line in each boxplot indicates the median 
value; the upper and lower edges of each boxplot are the 75th and 25th percentiles 
respectively, and the top and bottom short horizontal bars denote the 90th percentile 
and 10th percentiles respectively. Filled circles indicate outliers. Mann-Whiney (D) 
and Krusker-Wallis (E) tests were used for determining statistical significance 
between groups. (F) Kaplan-Meier plot indicating a significant difference between 
recurrence-free survival rate of 490 PTC patients with unaltered or overexpressed (Z 
score > 1.5) ICAM-1 expression levels. (G) Representative ICAM-1-specific IHC 
images of ATC patient-derived tissue. Well-differentiated PTC (WDPTC) or normal 
thyroid tissue images on the same slide are shown for comparison on the right. H&E 
images of the corresponding tissues are provided in Figure 2.4. 20X magnification. 
Inset images are 40x magnification. (H) Representative ICAM-1 IHC results are 
shown for distant thyroid tumor metastases at 20X magnification. 
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MAPK-ERK signaling pathway in PTC. Overexpression of ICAM-1 in PTCs was  
associated with downregulation of thyroid-specific genes (Figure 2.1C), increases in  
lymph node metastases (Figure 2.1D), and extrathyroidal extensions (Figure 2.1E). 
PTC patients with high ICAM-1 expression are more likely to suffer from recurrence 
(Figure 2.1F) and to become refractory to treatments with conventional therapies such 
as RAI and TSH therapies (Figure 2.1C). 
 Next, we obtained tissue sections from patients with ATC, the most lethal form 
of thyroid cancer, and examined ICAM-1 protein expression by histology. All ten 
ATC tumor specimens displayed high grade (3+) ICAM-1 staining with both 
cytoplasmic and membranous staining apparent in tumor cells (Figure 2.1G; 
hematoxylin and eosin (H & E) images of corresponding tumor blocks are provided in 
Figure 2.2). The fraction of tumor cells expressing ICAM-1 was also high, with seven 
out of ten samples staining diffusely positive, thus defining them as category 3 (>60% 
of total tumor cells stain ICAM-1 positive). The remaining three samples were 
grouped between categories 1 and 2 (1 = 1-29%, 2 = 30-59% positive cells among 
entire tumor). The ICAM-1 intensity score (defined as multiplying the 
immunoreactivity score and staining score) for our ATC patient samples was 7.8 ± 2.1 
standard deviation (SD)), which is similar to that previously reported for RAI-
refractory PTC and PDPTC [26]. The prevalence of ICAM-1 staining in ATC bears 
striking contrast to neighboring tissues in the same tissue slice, which display 
structurally limited ICAM-1 immunoreactivity at the apical membrane of WDPTC and  
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Figure 2.2 PTCs with BRAFV600E mutations are associated with ICAM-1 
overexpression. 
(A) ICAM-1 mRNA expression levels are compared between PTC patients with the 
BRAFV600E mutation or BRAFWT using the TCGA database [31]. (B) ICAM-1 mRNA 
expression level in patient ATCs is significantly higher than normal thyroid follicles 
[34]. (C) Comparison of ICAM-1 mRNA levels between PDPTC and ATC patients 
[35]. Statistical analysis was performed by Mann-Whitney test (***, p<0.0001; *, 
p<0.05). 
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Figure 2.3. Tumor tissue morphology in ATC patients.  
ATC tissue blocks used for ICAM-1 IHC as shown in Fig. 1G were also stained using 
hematoxylin and eosin. 20X magnification.  
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no ICAM-1 staining of normal thyroid follicles (Figure 2.3G, right). The 
demonstration of increased ICAM-1 protein expression in ATC agrees with previously 
reported ICAM-1 gene expression analyses that indicated significant differences in 
ICAM-1 expression between normal thyroid and PDPTCs (Figure 2.2 B & C) [34, 35]. 
We further analyzed ICAM-1 IHC within eight distant metastases originating from 
thyroid cancers (Figure 2.1H). Seven distant metastasis sites had category 3 ICAM-1 
staining and four tissues displayed level 3+, demonstrating an overall ICAM-1 
intensity score of 6.9 ± 2.5 (SD). Interestingly, metastatic thyroid cancers across each 
pathological subtype retained a similar ICAM-1 localization pattern. Distant 
metastases originating from WDPTC and follicular thyroid cancer displayed apical 
ICAM-1 staining, whereas poorly-differentiated follicular carcinoma and ATC 
exhibited broad ICAM-1 distribution with circumferential membranous staining 
(Figure 2.1H). Together, these findings demonstrate that ICAM-1 overexpression is a 
reliable molecular feature associated with PDPTC and ATC, and that circumferential 
membranous distribution of ICAM-1 is found in more advanced, metastatic thyroid 
cancers. 
  
ICAM-1 overexpression is associated with highly aggressive ATC cells 
We set out to investigate whether the level of ICAM-1 expression was linked to 
tumorigenic potency in established thyroid tumor cell lines. Several PTC and ATC 
lines were tested for the frequencies and levels of ICAM-1 expression by flow 
cytometry using the R6.5 monoclonal antibody [36]. The majority of thyroid cancer 
cell lines were ICAM-1 positive regardless of BRAF’s mutational status (Figure  
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Figure 2.4. ICAM-1+ is a biomarker for ATC. 
(A) Representative flow cytometry plots showing ICAM-1 expression in PTC 
(BCPAP, TPC1) and ATC (8505C, FRO, KHM-5M) cell lines. All cell lines except 
TPC1 harbor the BRAFV600E mutation. Boxes indicate cells that were determined to be 
ICAM-1 positive (shown as red dots) based on isotype controls. (B) ICAM-1 
histogram plots of parental (par) (orange lines) and FACS sorted (ICAM-1Hi) (blue 
lines) 8505C (left) and FRO cells (right). Gray histograms indicate isotype control 
stained par cells. (C) MTT analysis showing the percentage of live cells remaining 
after 72 hours of vemurafenib treatment in par and ICAM-1Hi cells isolated from 
8505C (left) and FRO (right). IC50 values for ICAM-1Hi cells relative to par were 
increased 4.6-fold and 17.7-fold in 8505C and FRO cells, respectively (n=3, 6). (D) 
Representative images of cell colonies formed after treatment with vehicle DMSO, 
low (1.5 and 2.5!M for 8505C and FRO, respectively) and high (2.5 and 10!M for 
8505C and FRO, respectively) doses of vemurafenib (left). Quantification of the total 
number of colonies and colonies of large size (> 2mm diameter) is shown on the right 
(*, p<0.05 by Mann-Whitney test, n=4). (E) Summary of cell cycle distribution 
between G0/G1 and proliferative phases of par and ICAM-1Hi-enriched 8505C (left) 
and FRO (right) cells (*, p<0.05; **, p<0.01 by Mann-Whitney test) (n=6, 8 for 
8505C and n=4 for FRO). 
 52 
2.4A). Two ATC lines 8505C and FRO, displayed heterogeneous expression of 
ICAM-1 with ~60% of both populations staining positive for ICAM-1 (Figure 2.4A). 
Next, 8505C and FRO cells were stratified by sorting according to ICAM-1 expression 
to determine if ICAM-1 levels were associated with tumorigenic potential. 8505C and 
FRO cells that were >85% ICAM-1-positive (designated as ICAM-1Hi) maintained 
their pattern of ICAM-1 expression across extended passaging to at least 10 passages 
(Figure 2.4B). 8505C-ICAM-1Hi and FRO-ICAM-1Hi cells were found to be more 
refractory to treatment with the BRAF inhibitor, vemurafenib, by 4.6 and 17.7-fold 
respectively, compared to their parental (par) counterparts (Figure 2.4C). Elevated 
vemurafenib resistance was also observed via colony formation assays, which 
demonstrated higher and larger colony-forming units in ICAM-1Hi populations (Figure 
2.4D). Cell cycle analysis showed that both 8505C-ICAM-1Hi and FRO-ICAM-1Hi 
cells had a higher percentage of cells at the proliferating stage (S-G2/M and S) relative 
to parental cells (Figure 2.4E & Figure 2.5). Taken together, ICAM-1-postive 8505C 
and FRO cells are distinguished by an increased resistance to vemurafenib and an 
elevated rate of proliferation, suggesting that ICAM-1 can serve as a biomarker for the 
aggressive nature of ATC cells. 
 
ICAM-1 targeting CAR T shows specific killing of malignant thyroid cells 
As the aggressive and vemurafenib-resistant features of ATC correlate with ICAM-1 
overexpression, we developed an immunotherapeutic strategy specifically targeting 
ICAM-1 as a novel treatment for refractory ATC. To molecularly target ICAM-1, we 
inserted a scFv derived from the ICAM-1-specific R6.5 monoclonal antibody into a  
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Figure 2.5 ICAM-1-overexpressing ATC cell lines are more proliferative. 
(A) Representative flow cytometry histogram plots for cell cycle distribution as 
measured by propidium iodide (PI) staining of parental (par) 8505C and 8505C cells 
sorted for ICAM-1 expression (ICAM-1Hi). (B) BrdU and PI staining shows an 
increased fraction of FRO-ICAM-1Hi cells at S and G2/M phase relative to FRO-par 
cells.
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third-generation CAR construct comprised of intracellular CD3", CD28, and 4-1BB 
(CD137) signal transduction domains (Figure 2.6A) [12, 28]. An additional renilla 
luciferase (rLuc) reporter gene was also inserted downstream of the CAR via a P2A 
ribosomal skipping sequence for CAR T cell tracking in vivo. Lentiviral transduction 
of this ICAM-1 targeting CAR construct (hereafter referred to as ICAM-1 CAR) into 
CD3+ T cells yielded between 20 and 60% CAR expression, which could be increased 
to approximately 100% after CAR-based sorting using an anti-mouse F(ab’)2 antibody 
(Figure 2.6B). ICAM-1 CAR expression on primary T cells did not alter the CD4:CD8 
ratio or T cell proliferation (Figure 2.7), suggesting a lack of self-directed cytotoxicity 
despite endogenous ICAM-1 expression on primary T cells.  
We tested the ability of ICAM-1 CAR T cells to eliminate PTC, ATC, and 
control cells with and without ICAM-1 expression using varying ratios of T cells 
(effector) to target cells (E:T) (Figure 2.6C). For this assay, we first established target 
cell lines with stable expression of GFP and firefly luciferase (fLuc) via transduction 
with a fLuc-F2A-GFP lentivirus and flow cytometry-based sorting for GFP+ cells. 
PTC BCPAP cells, which are mostly ICAM-1+, were eliminated fastest by ICAM-1 
CAR T cells relative to 8505C and FRO cells which have lower ICAM-1 expression 
(Figure 2.6C). HEK 293T cells, with diminutive ICAM-1 expression, were largely 
protected from ICAM-1 CAR T cells, displaying slow, gradual cell death from non-
specific T cell activity. Compiled data from E:T assays at the 2.5:1 E:T ratio 
demonstrated that ICAM-1 CAR T lysed BCPAP, HeLa, and FRO cells with similar 
kinetics followed by 8505C cells at a reduced rate (Figure 2.6D). Mock-transduced T 
cells exhibited minimal effects on all tested cells except for BCPAP (Figure 2.6D). At  
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Figure 2.6 ICAM-1-targeting CAR T activity is specific to the ICAM-1 expressing 
target cells. 
(A) Schematic demonstrating the ICAM-1 CAR T construct (B) Histogram plots 
demonstrate CAR expression in ICAM-1 CAR T cells was detected using a F(ab’)2 
antibody before (left) and after (right) sorting via F(ab’)2. (C) (top) The percentages of 
live target cells remaining after exposure to ICAM-1 CAR T plotted over time. Values 
were normalized to target cells with no T cell addition. The E:T ratio was incremented 
by a factor of 2 from 1.25:1 to 10:1. (bottom) Flow cytometry plots indicating the 
level of ICAM-1 expression in target and control cells after staining with the R6.5 
anti-ICAM-1 antibody.  Gates for ICAM-1+cells were determined based on staining 
with isotype control (grey filled histogram). (D) Compilation of the percentages of live 
target cells remaining after exposure to ICAM-1 CAR T and mock transduced T cells 
plotted over time (normalized against no T cell addition group, n=4-7 per target cell 
line). (E) ICAM-1 CAR T cytotoxicity against parental 8505C cells and 8505C cells 
with high (ICAM-1Hi) or minimal (ICAM-1KO) ICAM-1 expression. The plotted 
percentages of live cells were normalized against corresponding target cells incubated 
with non-transduced T cells to minimize the T cell alloreactivity. A statistical 
difference was observed between the number of live 8505C-ICAM-1KO and 8505C-
ICAM-1Hi cells remaining at the 24 and 30 hr timepoint (*, p<0.05 by Dunn’s multiple 
comparison test). 8505C-ICAM-1KO cells were generated using CRISPR/Cas9, and 
ICAM-1 expression levels were analyzed by flow cytometry and Western blot analysis 
(right). (F) ICAM-1 CAR T cytotoxicity against normal primary cells (SAEC, HMEC-
1 and late passage (p12) MVEC) along with control target cells. Membrane-bound 
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ICAM-1 expression on normal primary cells was characterized by flow cytometry 
(right). For MVEC, passage 6 and 12 were compared for ICAM-1 expression. Dunn’s 
multiple comparison tests at 24 hr were used to reveal statistical differences between 
the SAEC, HMEC-1, and 293T cells relative to HeLa cells when targeted by ICAM-1 
CAR T. Statistical difference between 8505C and 293T cells were *, compared, 
p<0.05; **, p<0.01; ***, p<0.001 (n=3-6 per target cells). (G) Histograms of latex 
beads coated with a fixed number of R6.5 anti-ICAM-1 antibodies were analyzed by 
flow cytometry on the right. Histograms plots for various target cells with R6.5 
antibody on the left were used to estimate the number of ICAM-1 molecules. 
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Figure 2.7 ICAM-1 CAR T cell phenotype characterization. 
(A) Representative flow cytometry plots showing the composition of CD4+ vs. CD8+ 
T cells prior to and after ICAM-1 CAR expression in primary T cells. (B) The 
proliferative capacity of T cells after ICAM-1 CAR lentiviral transduction were not 
statistically different from non-transduced T cells (n=4-5). 
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the 20-hr time point, approximately 40% of 8505C cells remained viable after 
exposure to ICAM-1 CAR T cells, a percentage that equates with the level of ICAM-1 
expression on 8505C cells (Figures 3C & 2.4A). The extent of ICAM-1 CAR T 
targeting of 8505C cells was dependent upon the level of ICAM-1 expression, as 
evidenced by the faster killing of 8505C-ICAM-1Hi cells compared to their lower 
ICAM-1-expressing parental counterparts (Figure 2.6E). Genetic disruption of ICAM-
1 via CRISPR/Cas9 in 8505C cells (referred to as 8505C-ICAM-1KO), abolished 
ICAM-1 CAR T mediated killing of 8505C cells thus demonstrating the targeting 
specificity of this treatment strategy in vitro (Figure 2.6E).  Abolished ICAM-1 
expression in 8505C-ICAM-1KO cells was confirmed by flow cytometry and western 
blot analysis (Figure 2.6E, right).  
To address the potential for ‘on-target, off-tumor’ killing by ICAM-1 CAR T 
cells, we investigated whether ICAM-1 CAR T could target healthy human cells with 
normal ICAM-1 expression [37]. We chose glomerular microvascular endothelial cells 
(MVEC) and small airway epithelial cells (SAEC) that have the highest ICAM-1 
expression among normal tissues according to the Human Protein Atlas database [37]. 
In contrast, these tissues have also been reported to stain poorly for ICAM-1 by 
immunohistochemistry (IHC) [17, 38]. By immunostaining with mAb R6.5, we found 
that SAEC, early passage (passage 6) MVEC, and late passage (passage 12) MVEC, 
were approximately 19%, 3%, and 29% ICAM-1 positive, respectively (Figure 2.6F 
right). As an additional comparison, we also added HMEC-1, immortalized dermal 
microvascular endothelial cells, which were 20% ICAM-1 positive. The levels of 
ICAM-1 expression in primary healthy cells were 2~10-fold lower than the 8505C and 
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FRO ATC lines (Figure 2.6C & 3F). The level of ICAM-1 CAR T cell-mediated 
killing of the lung, kidney tissue cells, and HMEC-1 was significantly lower than that 
observed for 8505C and HeLa cells. Indeed, the cytotoxicity directed against healthy 
tissue was not significantly different from that of the ICAM-1 negative cells, 293T and 
8505C-ICAM-1KO (Figure 2.6F left). Therefore, the magnitude of ICAM-1 CAR T 
cytotoxicity was reflective of the frequency and the extent of ICAM-1 expression in 
target cells with non-malignant, ICAM-1 low cells exhibiting limited susceptibility.  
In order to define the threshold level of ICAM-1 expression that is required for 
effectual cytotoxicity of ICAM-1 CAR T cells, we estimated the number of ICAM-1 
molecules expressed on target cell surfaces by comparing R6.5 antibody binding to 
cells with 8 µm latex beads coated with known amounts of R6.5 antibodies (Figure 
2.6G). From this comparison, we estimated that the primary healthy tissue cells and 
ATC lines display approximately 104 and 105 ICAM-1 molecules on their cell 
surfaces, respectively, suggesting a requirement for expression of 105 ICAM-1 surface 
molecules per cell to enable efficient engagement and killing by ICAM-1 CAR T 
cells. Therefore, due to ICAM-1 CAR T’s ability to discriminate between target 
thyroid cancer cells and primary tissue cells, ICAM-1 CAR T should exhibit a 
sufficiently high therapeutic index for clinical use. 
 
Surface ICAM-1 expression in thyroid cancer cells is modulated by IFN-! , which 
affects the efficiency of ICAM-1 CAR T cytotoxicity 
8505C cells exhibited slower ICAM-1 CAR T-induced death compared to BCPAP and 
HeLa cells with approximately 40% of targets remaining alive at the 20-24 hr time 
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points when co-cultured at a 2.5:1 E:T ratio (Figures 3D & 4A). Interestingly, the 
viable 8505C cells that remained after incubation with ICAM-1 CAR T cells at 18 hr 
displayed an elevated level of ICAM-1 expression (7.5-fold increase in MFI) relative 
to non-exposed cells (Figure 2.8B). A similar elevation of ICAM-1 expression was 
measured in 8505C, BCPAP, and FRO cells after incubation in pre-conditioned media 
collected from 18 hr co-culture of 8505C cells with ICAM-1 CAR T cells suggesting 
that soluble factors released into the media by cytotoxic CAR T cells are responsible 
for ICAM-1 induction (Figure 2.8C). A hallmark of cytotoxic T cell activity is 
secretion of the TH1 cytokine IFN-! [12]. We therefore measured the concentration of 
secreted IFN-! during ICAM-1 CAR T co-culture with target cells during the E:T 
assays. Release of IFN-! by CAR T cells was highest when co-cultured with 8505C-
ICAM-1Hi and HeLa cells, and remained at background levels with 8505C-ICAM-1KO 
and 293T cells (Figure 2.8D). Furthermore, addition of exogenous IFN-! into thyroid 
cancer cell monocultures induced ICAM-1 expression in a dose-dependent fashion, 
thus identifying IFN-! as a critical soluble factor responsible for ICAM-1 induction in 
target cells (Figure 2.8E).   
Addition of IFN-! at a concentration of 1x104 pg/ml was sufficient to induce 
an approximate 10-fold increase in ICAM-1 expression (~106 molecules per cell) in all 
tested thyroid cancer cells (Figures 4E & 3G).  The levels of IFN-! secreted by ICAM-
1 CAR T cells upon exposure to target antigen were also within a range capable of 
elevating ICAM-1 to those observed by exogenous IFN-! addition. In contrast, ICAM-
1 expression in 293T cells was absent either by addition of supernatant from HeLa 
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cells targeted by ICAM-1 CAR T (Figure 2.8C) or by administration of exogenous 
IFN-! (Figure 2.8E). Addition of supraphysiological concentration of IFN-! to early 
passage MVEC cells induced approximately 2-3-fold increase in MFI (Figure 2.8E). 
These data suggest that thyroid cancer cells are hyperresponsive to IFN-! induced 
ICAM-1 elevation compared to nonmalignant, healthy cells. In addition, E:T assays 
with IFN-!-stimulated target cells verified that ICAM-1 CAR T cells had an increased 
potency to target IFN-!-stimulated 8505C cells (Figure 2.8F). By contrast, MVEC 
displayed no difference in cytolysis by non-transduced T or ICAM-1 CAR T cells 
after administration of IFN-! except for increased cell death relative to cells without 
IFN-! treatment. IFN-! induction of ICAM-1 expression, therefore, may increase the 
therapeutic potency of ICAM-1 CAR T cells against thyroid cancer cells but 
minimally affect on non-malignant, normal tissues. 
The direct cytotoxic effects mediated by CAR T cells derive from their release 
of soluble factors such as perforin and granzymes, in addition to tumor necrosis factor 
(TNF) death receptor signaling triggered by direct cell-to-cell contacts. The level of 
granzyme B secretion was found to mirror the rate of ICAM-1-dependent target cell 
killing, which was highest in 8505C-ICAM-1Hi followed by parental 8505C, and 
negligible in the 8505C-ICAM-1KO cells (Figure 2.8G). The dependence upon 
perforin/granzyme B-mediated target killing was also validated by the substantial 
inhibition of CAR-mediated cytotoxicity by addition of EGTA to E:T co-cultures 
(Figure 2.8H). In contrast, activation of the TNF death receptor pathway by exogenous 
addition of its ligand, TRAIL, had little effect on 8505C cell death, while gradual 
killing of FRO cells was observed with increasing concentrations of TRAIL (Figures  
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Figure 2.8 ICAM-1 expression on thyroid cancer cells is IFN-!  inducible by 
enhancing target susceptibility to ICAM-1 CAR T. 
(A) The percentages of remaining viable target cells remaining after co-
culturing with ICAM-1 CAR T cells were compared between 24 hr and 43 hr 
timepoints (n=6-9 per target cells). (B) After a 18 hr co-incubation with ICAM-1 CAR 
T cells, 8505C (blue line) and 8505C-ICAM-1KO (orange line) cells were collected and 
stained for ICAM-1 expression in live cells by flow cytometry (left). 8505C cells 
stained with isotype control are shown by gray filled histogram. Quantitation of the 
fold increase of ICAM-1 mean fluorescence intensity (MFI) is shown on the right 
relative to non-exposed cells (n=6 per target cells). (C) Representative flow cytometry 
plots show thyroid cancer cell ICAM-1 expression after 18 hr culture with in media 
spiked with supernatant derived from E:T experiments using ICAM-1 CAR T. 
Supernatants from the ICAM-1 CAR T: target cell assay were collected and added to 
the indicated target cells with no dilution (blue line), 50% dilution (orange line), or no 
addition (black line) to the culture media. (D) The IFN-! levels in supernatants 
collected from E:T assays involving ICAM-1 CAR T against indicated target cells 
were measured using ELISA (n=4-8). Non-transduced T cells cultured with the same 
target cells produced levels of IFN-! that were below the limit of detection. (E) Flow 
cytometry analysis demonstrating ICAM-1 expression changes in thyroid cancer and 
control cells upon direct administration of exogenous, serially diluted IFN-! (pg/ml). 
(F) The percentages of cell death observed in untreated and IFN-! (1 x 104 pg/ml) 
added target cells were compared after addition of non-transduced T and ICAM-1 
CAR T cells using flow cytometry analysis (n=3). (G) The concentration of secreted 
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granzyme B from an ICAM-1 CAR T: target cell assay (n=4-6) per condition.  (H) 4 
mM EGTA was added to E:T assay media to inhibit the perforin/granzyme cytotoxic 
pathway (n=4 per group). (I) Anaplastic thyroid cancer resistance to TRAIL-induced 
death (J) Anaplastic thyroid cancer resistance to FasL-induced death. The Jurkat T cell 
line served as a positive control for both treatments (n=3-4 per condition).
 66 
2.8I & 2.8J). We therefore confirmed that the degree of ICAM-1 CAR T cytotoxicity 
is commensurate with the levels of surface ICAM-1 expression in target cells. 
Furthermore, we identified IFN-! as a crucial cytokine that can augment CAR T 
cytotoxicity that preferentially acts upon thyroid cancer cells. 
 
CAR T cells targeting ICAM-1 achieve rapid and enduring tumor eradication in 
vivo 
In order to evaluate the anti-tumor efficacy of ICAM-1 CAR T in vivo, we utilized 
systemic xenografts of human ATC 8505C cells in immunodeficient NOD-
scidIL2Rgnull (NSG) mice [30]. To track and quantitate the growth of ATC in mice, 
we used parental 8505C cells transduced and FACS sorted to express GFP and firefly 
luciferase Lucwith approximately 100% purity. A total of 0.75 million 8505C cells 
were injected intravenously (i.v.) into each NSG mouse, with primary tumors 
localizing prominently in the lungs (Figure 2.9A). With unimpeded growth, tumors 
gradually metastasize to other organs including the bones and liver, resulting in death 
within one month (median survival is 28 days). Treatment occurred on day 14 post 
xenograft with mice receiving an i.v. infusion of either 3 x 106 T cells transduced with 
an ICAM-1 CAR lentivirus (unsorted with 30-40% transduction levels) or an equal 
infusion of 3 x 106 non-transduced T cells. A third group received no treatment. The 
specific cytotoxicity of administered ICAM-1 CAR T cells were validated in vitro and 
their CD4:CD8 ratios were additionally confirmed to be comparable with non-
transduced T cells (Figure 2.10). At day 5 post-treatment with ICAM-1 CAR T, mice 
showed signs of tumor signal decrease and recovery of body weight, culminating in 
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complete tumor eradication and weight rebound within 12 days of treatment (Figures 
5A-5C). The observed remission was durable such that ICAM-1 CAR treated mice 
exhibited a significant and substantial increase in survival (Figure 2.9D). Non-
transduced T cells demonstrated minimal tumor-killing in mice, except for the 
occasional instances of donor T cell alloreactivity. Ex vivo fluorescence images of 
harvested organs taken 1 month after ICAM-1 CAR T treatment demonstrated that 
tumor lesions were strikingly diminished in the lungs and livers in contrast to the 
untreated group (Figure 2.9E). The reduction of tumor burden by ICAM-1 CAR T 
cells in the lungs was also evidenced by their lower (normal) weight compared to the 
2.2-fold higher weight of the same organs from the untreated group (Figure 2.11). 
The macroscopic descriptions of tumor eradication by ICAM-1 CAR T cells 
were validated at the cellular level by flow cytometry and IHC analyses. ICAM-1 
CAR T treatment led to negligible levels of GFP+ tumor cells in whole lungs and liver 
of ATC xenografted mice, in striking contrast to untreated groups in which 
approximately 18% and 4% of live cells were identified as GFP+ in the lungs and liver, 
respectively (Figure 2.9F). IHC analysis revealed that #1% of the lung and liver 
tissues retained GFP+ tumor cells at 70-80 days after a single administration of ICAM-
1 CAR T cells (Figure 2.9G). Meanwhile, human CD3+ T cells were still detectable in 
various organs at day 72 (Figure 2.9F & Figure 2.12A), which agreed with the 
assessment of CAR T cell persistence evidenced by whole body imaging (Figure 
2.12B). These findings demonstrate the ability of ICAM-1 CAR T cells to mediate 
potent and enduring anti-tumor activities, leading to tumor eradication and significant 
improvements in long-term survival in ATC xenograft mouse models.  
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Figure 2.9 ICAM-1 CAR T cells show robust and enduring tumor eradication in 
ATC xenograft models. (A) Representative total body bioluminescence images of 
fLuc+ 8505C xenografted NSG mice following ICAM-1 CAR T cell administration. 
Control groups include untreated and non-transduced T cell-administered mice. (B) 
Quantitation of total body bioluminescence units in individual mice from (A) (no T 
cell group=open circle, non-transduced T cells=solid square, ICAM-1 CAR T=red 
triangle; p=0.05, n=8-10 per group). (C) Summary of body weight changes in mice left 
untreated or after treatment with non-transduced T cells or ICAM-1 CAR T cells. (D) 
Survival curves of 8505C xenografted mice comparing no treatment, treatment with 
non-transduced T cells, and treatment with ICAM-1 CAR T cells until 80 days post-
xenograft.  Statistical differences between different treatments were analyzed by 
Kaplan-Meier (n=8-10 per group). (E) (left) Gross inspection of 8505C xenograft 
primary (lung) and metastatic (liver) organs taken 20 days after ICAM-1 CAR T 
treatment compared with untreated mouse organs. (right) Ex vivo GFP fluorescence 
images of the organs merged with bright field images.  Scale bar is shown on the right 
(Units are P/s/mm2). (F) (left) Flow cytometry plots showing analysis of percentages 
of GFP+ 8505C (y-axis) and human CD3+ T cells in indicated organs extracted from 
untreated and ICAM-1 CAR T treated 8505C xenografted mice (20 and 72 days after 
T cell administration). (bottom) Compilation of the frequency of live, GFP+ 8505C 
cells observed in the lung and liver with and without ICAM-1 CAR T treatment. (G, 
H) Representative IHC images showing H & E staining of low (left) and high (middle) 
magnifications of lung (G) and liver (H) tissues isolated from xenografted mice 
receiving no T cell (top) or ICAM-1 CAR T (bottom) treatment. The adjacent sections 
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were stained for GFP to identify tumor cells (right). Scale bar = 2 mm (left), 300 !m 
(middle, right) 
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Figure 2.10 Validation of ICAM-1 CAR T cells used in vivo experiments. 
(A) Transduction rate of ICAM-1 CAR construct in PBMC-derived T cells. (B) E:T 
assay of ICAM-1 CAR T cells against target cells. (C) Immunophenotype of non-
transduced and ICAM-1 CAR T cells. The ratio of CD4:CD8 T cells were similar 
prior to and after ICAM-1 CAR expression in primary T cells. 
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Figure 2.11 Organ weight changes in ATC xenografted mice after ICAM-1 CAR 
T treatment. 
The weights (g) of lung and heart were significantly reduced in 8505C xenografts 
treated with ICAM-1 CAR T when compared with non-transduced T cell treatment 
group and were similar to the weights of healthy organs from NSG mice (no 
Tumor/No T group) (n=4-6 per group). 
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Figure 2.12 CAR T cells in ICAM-1 CAR T treated and ATC xenografts. 
(A) Representative IHC images of CD3+ T cells in 8505C xenograft tissues treated 
with ICAM-1 CAR T cells compared to untreated or non-transduced T cell treatment. 
(B) Bioluminescence of RLuc activity is detectable in spleens and other organs of 
ICAM-1 CAR T-treated mice at X86T72. No detectable RLuc activity is measured in 
NSG xenografts without treatment or treatment with non-transduced T cells. Spleen is 
demarcated with a white line. 
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Autologous ICAM-1 CAR T eliminates thyroid cancer patients’ tumor cells in 
vitro and in vivo 
Acknowledging the modeling deficiencies of using donor-derived T cells to treat 
allogeneic, cell line-derived tumor cells, we wanted to test the therapeutic efficacy of 
ICAM-1 CAR T cells in a more realistic setting using patient-derived tumors and 
autologous T cells. We therefore initiated primary cultures of fresh tumor specimens 
derived from PDPTC and ATC thyroid cancer patients. Surgically removed tumor 
blocks were IHC stained for ICAM-1, which exhibited ICAM-1 expression at the 3+ 
level of intensity (Figure 2.13A & 6B). After 2-5 days of primary culture, the majority 
of PDPTC and ATC cells were dual positive by flow cytometry for surface expression 
of ICAM-1 and epithelial cell adhesion molecule (EPCAM), a marker for follicular 
epithelial cells (Figure 2.13A & B). While PDPTC tissues indicated sparse (~10%) 
ICAM-1 expression by IHC, expression after sub-culturing was over 90%. Several 
factors may account for such a discrepancy in ICAM-1 expression including 
unintended induction of ICAM-1 due to culturing conditions and selective growth of 
ICAM-1+ cells in culture. 
 Next, we tested cytotoxic activity of autologous ICAM-1 CAR T cells against 
patient-derived tumor cells. ICAM-1 CAR T cells obtained from a PDPTC patient 
eliminated autologous thyroid tumor cells with similar kinetics to HeLa cells with no 
reactivity toward 293T cells (Figure 2.13A). Similarly, ICAM-1 CAR T cells derived 
from an ATC patient lysed autologous primary tumor cells, HeLa, and 8505C cells at 
comparable rates, achieving near 100% killing by 48 h. The rate of killing was 
somewhat slower in the autologous setting compared to the previously observed  
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Figure 2.13 Autologous ICAM-1 CAR T cells are effective in reducing tumor 
burden in thyroid cancer patient-derived tumor cells in vitro and in vivo. 
(A-B) Tumors from PDPTC (A) and ATC (B) patients are analyzed by ICAM-1-
specific IHC (10x magnification) (left) and flow cytometry for EPCAM and ICAM-1 
expression (middle). E:T assays using autologous ICAM-1 CAR T cells against 
primary tumors along with control 293T and HeLa cells are shown on the right. (C) 
Single cell-resuspensions were isolated from subcutaneous xenografts of ATC 
patient’s primary cells (Supplemental Figure 8) were i.v. injected into NSG mice for 
secondary transplantation. After 11 days, autologous ICAM-1 CAR T and non-
transduced T cells were infused i.v. to assess therapeutic efficacy in vivo. T1 MRI 
analysis was carried out in no T cell and ICAM-1 CAR T groups at 67-72 days post-
xenograft to estimate tumor burden in the lung. Tumor outline is demarcated with 
white dotted lines. Quantification of the percentages of lung tumor burden were 
summarized and compared between no treatment and ICAM-1 CAR T-treatment 
groups (*, p<0.05; n=3 per group) D. H&E staining of lung lobes in untreated, non-
transduced T, and ICAM-1 CAR T administered animals. Numbers of lung tumor 
nodules were quantified and analyzed to assess significant differences between non-
transduced T and ICAM-1 CAR T-treated animals. (*, p<0.05; n=3 for no T and n=4 
for T cell groups, one untreated mouse showed diffuse lung metastasis and therefore 
not quantified) E. Survival curves of ATC patient-derived tumor xenografted mice 
comparing no treatment, treatment with non-transduced T cells, and treatment with 
ICAM-1 CAR T cells up to 80 days post-xenograft. Kaplan-Meier analysis was 
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performed to assess statistical difference between different treatment groups (n = 5, 7, 
10 for no T, non-transduced T, and ICAM-1 CAR T, respectively). 
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Figure 2.14 Establishment of ATC patient-derived xenografts. 
(A) Patient-derived ATC tumors were transduced with GFP and fLuc expressing 
lentivirus, and subcutaneous bilateral tumor growths in NSG mice were tracked via 
bioluminescence imaging. (B) H & E stained tumor cells with nuclear morphology 
characteristic of ATC (10X magnification). (C) GFP+ tumor cells from bulk tumor 
were analyzed for ICAM-1 and EPCAM1 expression by flow cytometry. 
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Figure 2.15 CAR T activity is detectable throughout the body. 
Bioluminescence of rLuc activity is detectable in spleens and other organs in ICAM-1 
CAR T-treated xenografts at X31T19. 
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Figure 2.16 Correlation between ICAM-1 overexpression in TCGA cancer 
patient tumors and overall survival. 
Kaplan-Meier plots demonstrate significant differences between the overall survival 
rates of patients with glioblastoma multiforme, kidney renal clear cell carcinoma, 
kidney renal papillary cell carcinoma, and liver hepatocellular carcinoma with 
unaltered and ICAM-1-overexpression (Z score>1.5). Clinical information and ICAM-
1 expression levels were derived from TCGA datasets [39]. Retrospectively, sample 
size was estimated to be able to detect differences in survival with 80% power using a 
two-sided, 0.05 alpha level. 
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response from healthy donor-derived ICAM-1 CAR cells, which showed faster killing 
of target cells with high ICAM-1 expression (Figure 2.6E-F).  
 To more closely examine and predict patient-specific efficacy of ICAM-1 
CAR T therapy, we further established ATC patient-derived xenograft models in NSG 
mice. The patient-derived ATC tumors carried a mutational profile (mutations in 
NRAS, p53, and PTEN) that differed from that of 8505C, which carries known 
mutations in BRAFV600E and p53 [40]. ATC patient-derived tumor cells were 
transduced with the fLuc-F2A-GFP lentivirus obtaining GFP expression of 15%. ATC 
cells were first injected subcutaneously into bilateral flanks, which, over a period of 
one month, grew to form uneven tumor masses (Figure 2.14A). Tumors harvested 
from xenografted mice displayed distinct pleiomorphism, hyperchromatism, increased 
nuclear to cytoplasmic ratio, and multiple mitoses, which are known features of 
undifferentiated thyroid cancer cells (Supplemental Fig 8B). At this stage, the 
percentages of GFP+ cells in the bulk tumor were reduced to approximately 5%, yet 
GFP+ tumor cells were found to retain the same EPCAM/ICAM-1 profile as the 
original primary patient cell cultures (Figure 2.14C). 
 Patient cells derived from subcutaneous tumors (as in Figure 2.14) were 
expanded in culture for additional 2 passages, and i.v. injected to produce metastatic 
tumor xenografts in NSG mice. Similar to the 8505C cell line xenografts, patient-
derived ATC cells grew predominantly in the lungs (Figure 2.13C & 6D). Because of 
the difficulty in obtaining tumor cells with sufficiently high GFP and fLuc expression 
for tracking tumor growth by luminescence, we used MRI to detect the tumors in 
lungs, and quantified the volume fractions of tumor to the pulmonary cavity in 
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untreated and ICAM-1 CAR T-treated mice (Figure 2.13C). Lung tumor burden at 67-
72 days after xenografts was significantly reduced in mice treated with a single 
infusion of autologous ICAM-1 CAR T (>1.5 million cells per mouse) compared to 
untreated (No T) controls. Lung tissues obtained from untreated mice showed tumor 
growth characteristics that were either diffuse, nodular, or both in the lung 
parenchyma and pleura (Figure 2.13D). In comparison, the alveolar space was almost 
tumor free in CAR T-treated lung tissues with small remnant tumors found in pleural 
and perivascular regions. The number of visible metastatic tumor nodules within the 
lung lobes of ICAM-1 CAR T-treated mice was significantly reduced compared to 
non-CAR controls as measured by IHC (Figure 2.13D). Finally, ICAM-1 CAR T 
treatment led to a significant improvement in the overall survival of ATC xenografted 
mice compared to non-treated controls that lasted approximately 70-80 days post-
treatment (Figure 2.13E). During this period, whole body luminescence imaging 
confirmed persistence of rLuc-positive CAR T cells prominently in the head and the 
spleen, and weakly in lungs and other organs (Figure 2.15). 
 
Discussion 
Encouraged by impressive clinical developments of CAR T therapy for treatments of 
hematologic malignancies, we sought to develop CAR T therapeutics for advanced 
thyroid cancers. Here, we demonstrated the therapeutic potential of CAR T cells 
recognizing ICAM-1 for the treatment of a metastatic, aggressive thyroid cancer such 
as ATC, which is known to have one of the shortest median survival times among all 
solid tumors. Remarkably, we also showed that ICAM-1 CAR T cells manufactured 
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from the peripheral blood of a patient already compromised by ATC led to a 
significant reduction of tumor burden and led to prolonged overall survival of animals 
xenografted with autologous ATC tumors. To our knowledge, our approach is the first 
report utilizing patient-derived CAR T cells for the treatment of patient-derived, 
autologous solid tumor xenografts. This novel modeling approach can be used to aid 
the optimization of clinical protocols regarding treatment doses, timing, and 
administration of additional adjuvants to maximize therapy efficacy and safety. 
Our rationale for developing therapeutics targeting ICAM-1 for treatment-
refractory thyroid cancer is based upon several observations. ICAM-1 is significantly 
elevated in ATC and other thyroid cancer subtypes that metastasize to distant organs, 
thus presenting ICAM-1 as a useful prognostic marker for metastatic, aggressive 
thyroid cancer subtypes. From the analyses of TCGA PTC genomics in combination 
with clinical data, the level of ICAM-1 expression was found to correlate with 
aggressive tumorigenic features. This correlation was also experimentally validated in 
our study across multiple thyroid cancer cell lines. Moreover, ICAM-1 targeting 
therapy has potential applications in the treatments of other malignancies, including 
pancreatic ductal adenocarcinoma [18], breast cancer [17], multiple myeloma [41], 
and gastric tumors [19], where ICAM-1 surface expression is also significantly 
elevated compared to normal tissues. Along with thyroid carcinoma, TCGA studies 
indicated that overall patient survival was shorter when levels of ICAM-1 mRNA 
were upregulated in glioblastoma multiforme, kidney renal clear cell carcinoma, 
kidney renal papillary cell carcinoma, and liver hepatocellular carcinoma (Figure 2.16) 
[39, 42].   
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To target tumor cells with surface ICAM-1 expression, we adopted a scFv from 
R6.5 [36], a murine monoclonal antibody against ICAM-1, and fused it with the 
transmembrane and intracellular signaling components of a third-generation CAR 
construct incorporating CD28 and 4-1BB co-stimulatory domains [43]. The R6.5 
antibody (enlimomab) binds to the junction between the first and second domain of 
ICAM-1 and prevents interaction with LFA-1 [44]. The R6.5 antibody has a proven 
safety and tolerability record with benefits for relieving inflammatory activity in 
patients with rheumatoid arthritis, burn injuries, and receiving transplants [21-24]. Its 
use for the treatment of stroke cases generated side effects due to a complement 
reaction attributable to the Fc portion of the mouse IgG2a [45]. The F(ab) of R6.5 has 
an estimated affinity of 10 nM [29], and the R6.5 scFv in the present ICAM-1 CAR T 
construct endowed T cells with ICAM-1 specific cytotoxicity that recognizes ICAM-
1-overexpressing target tumor cells while sparing normal tissue with basal ICAM-1 
expression. One possible concern with using a CAR specific to ICAM-1 is the CAR’s 
competition with LFA-1 and potential inhibition of ensuing downstream signaling 
from T cell-LFA-1 engagement with ICAM-1 on target cells. This engagement elicits 
cytoplasmic Ca2+ release in target cells and downstream perforin/gramzyme B 
dependent cytolytic T cell activity, and appears to affect TCR and CAR activities as 
well [46, 47]. Alternatively, competition between LFA-1 and R6.5 scFv in the CAR 
for ICAM-1 binding may aid CAR T cells to be selective to target cells overexpressing 
ICAM-1 and to avoid excessive avidity interactions involving CD3 and other co-
stimulatory molecules, which can cause T cells to undergo activation induced 
exhaustion. 
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In addition to ICAM-1’s function as a tumor antigen, ICAM-1 possesses additional 
characteristics that can augment the anti-tumor activity of targeted CAR T cells. 
ICAM-1 is a well-documented inflammatory marker, and chronic inflammation has 
long been known to shape local and systemic immunity to promote an 
immunosuppressive tumor microenvironment and aid tumor development [48]. 
Specifically, tumor-associated fibroblasts and tumor-associated macrophages are 
known to interact with tumor cells through ICAM-1 and promote cancer growth and 
metastasis [49, 50]. Selective targeting of ICAM-1 expressing tumor and stroma by 
ICAM-1 CAR T may therefore yield synergistic anti-tumor activities when treating 
thyroid cancer. 
The marked enhancement of ICAM-1 expression in thyroid cancer cells upon 
addition of exogenous IFN-! suggests that its expression in advanced thyroid cancer 
cells in vivo is likely to increase upon antigen recognition and subsequent IFN-$ 
release by infused ICAM-1 CAR T cells. In comparison, ICAM-1 expression is 
constitutively low in a variety of tissues, but its expression may be induced via pro-
inflammatory cytokines such as IFN-!, TNF-#, IL-1$ in endothelial and some other 
cell types [15, 36, 51, 52]. Given that the IFN-! secretion by CAR T cells is a key 
indicator of their anti-tumor activity [53], concerns will arise over the possibility that 
paracrine IFN-! signaling may induce ICAM-1 expression in healthy neighboring 
cells, thus exposing them to CAR T cell cytotoxicity. Antigen density-dependent T 
cell activation is a known property of native T cells, where a threshold density of 
peptide/MHC is necessary for activation of TCR [54]. One strategy to further increase 
the therapeutic index of CAR T cells is lowering the CAR’s antigen affinity to 
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increase T cell selectivity for targets with highly expressed antigens only and sparing 
normal cells with weaker expression. This hypothesis was tested and validated 
preclinically in prior studies using Her2 and EGFR-directed CAR T cells [55, 56]. 
Decreasing the R6.5 scFv affinity to that of typical TCR-pMHC interactions (1-100 
!M) may endow ICAM-1 CAR T cells with a similar ability to discriminate between 
ATC with high ICAM-1 overexpression and nonmalignant tissue cells with lower 
ICAM-1 expression. Dynamic ICAM-1 expression across various acute and chronic 
medical conditions including cytokine release syndrome [53, 57] warrant further 
investigation as certain comorbidities may amplify ICAM-1 expression resulting in an 
increased risk of on-target off-tumor toxicity. Optimizing strategies to increase the 
therapeutic index and to limit off target toxicity will be crucial in bringing ICAM-1 
CAR T into a clinical setting. 
A number of studies suggest that thyroid cancers can evade immunosurveillance 
by immune evasion [58] or by developing immunosuppressive mechanisms [59, 60]. 
Advanced thyroid cancers including ATC are associated with a more diffuse and 
intense expression of the checkpoint ligand PD-L1 [59, 61]. It is unclear as to whether 
this augmented expression is reflective of an active immune response at the tumor site 
or if it is a signature of tumor cells that escaped immune attack [62]. Notably, the IFN-
! signaling pathway plays a critical role in both PD-L1 expression [63] and also in 
ICAM-1 expression as demonstrated in previous as well as the current study [64]. 
Blockade of the PD1-PD-L1 signaling axis has led to durable responses in several 
solid tumor indications, and it will be important to assess whether its combination with 
ICAM-1 CAR T therapy could bring further benefits to patients with advanced thyroid 
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cancers. The combination of a BRAF inhibitor with an anti-PD-L1 antibody in an 
immunocompetent model of ATC demonstrated significant treatment benefits 
compared to monotherapy suggesting that immune therapy used in combination has 
the potential to benefit patients with ATC [65]. 
In conclusion, we report the first demonstration of robust and durable CAR T 
therapeutic effects in preclinical models of ATC using both cell lines and patient-
derived tumors. The substantial surface and diffuse ICAM-1 expression patterns 
across almost all examined ATC samples demonstrate its potential as a target for CAR 
T therapies. ATC tumors are characterized by their heterogeneity, complex mutational 
landscape, and poor expression of molecules that have previously been exploited as 
molecular and cellular targets [3, 35, 66]. The prolonged survival achieved upon 
treatment of ATC inoculated mice with ICAM-1 CAR T was particularly notable 
when compared with previous treatment strategies in preclinical metastatic models 
using the same ATC cell line [67-69]. The preclinical xenograft model used here is 
limited by the inability to monitor potential toxicity mediated by ICAM-1 CAR 
against non-tumor tissue. However, additional modifications with emerging 
technologies such as inducible CAR expression [70], CAR T cell elimination via 
suicide gene activation [71], combinatorial antigen targeting [72], and affinity-tuned 
[55, 56] CAR T are likely to enhance safety while preserving on-target efficacy, thus 
providing a framework for adaptation of CAR T cells targeting ICAM-1 as a new 
treatment modality for advanced thyroid cancers and other solid tumors with ICAM-1 
overexpression. 
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CHAPTER 3  
  
LONGITUDINAL AND QUANTITATIVE IMAGING OF THE EXPANSION AND  
CONTRACTION OF TUMOR-TARGETED ADOPTIVELY TRANSFERRED T  
CELLS  
   
Summary  
1 Clinical monitoring of adoptive T cell transfer (ACT) utilizes serial blood  
analyses to discern T cell activity. While useful, these data are 1-dimensional and lack  
spatiotemporal information related to treatment efficacy or toxicity. We utilized a  
human genetic reporter, somatostatin receptor 2 (SSTR2), and PET, to quantitatively  
and longitudinally visualize whole-body T cell distribution and antitumor dynamics  
using a clinically approved radiotracer. Initial evaluations determined that SSTR2-  
expressing T cells were detectable at low densities with high sensitivity and  
specificity. SSTR2-based PET was applied to ACT of chimeric antigen receptor  
(CAR) T cells targeting intercellular adhesion molecule-1, which is overexpressed in  
anaplastic thyroid tumors. Timely CAR T cell infusions resulted in survival of tumor-  
bearing mice, while later infusions led to uniform death. Real-time PET imaging  
revealed biphasic T cell expansion and contraction at tumor sites among survivors,  
with peak tumor burden preceding peak T cell burden by several days. In contrast,  
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non-survivors displayed unrelenting increases in tumor and T cell burden, indicating  
that tumor growth was outpacing T cell killing. Thus, longitudinal PET imaging of  
SSTR2-positive ACT dynamics enables prognostic, spatiotemporal monitoring with  
unprecedented clarity and detail to facilitate comprehensive therapy evaluation with  
potential for clinical translation.   
Introduction  
Adoptive T cell transfer (ACT) of cytotoxic T lymphocytes is being studied as  
a potent treatment strategy for cancers that are refractory to standard chemotherapy  
and radiation therapy. Clinical advances have been made in patients with metastatic  
melanoma using autologous tumor-infiltrating lymphocytes (TILs) and in several B  
cell malignancies using autologous chimeric antigen receptor–modified (CAR-  
modified) T cells [1]. Methods used to predict or monitor the activity of infused T  
cells in patients provide useful but limited data related to treatment efficacy. Current  
practices involve serum pro ling of cytokines associated with T cell activation, direct  
enumeration of tumor-specific T cell numbers in peripheral circulation, and tumor  
biopsies [2, 3]. Changes in serum cytokine levels, while useful, likely reflect a  
broader, systemic immune response, illustrating not only the activation of adoptively  
transferred T cells, but also their effects on neighboring immune cells and dying tumor  
cells [4]. Similarly, while the quantification of adoptively transferred cells in  
circulation provides useful information regarding their proliferation, researchers and  
clinicians are blind as to whether the dynamism in T cell numbers relates to expansion  
at the primary tumor site, metastatic foci, or at off-tumor sites [5]. The ability to map  
the physical distribution and expansion of adoptively transferred T cells throughout  
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the body in a longitudinal manner could therefore significantly improve real-time  
monitoring of T cell activity against tumors, potential toxicity from off-tumor-site  
targeting, and contribute to exploring adjuvant therapies to enhance adoptive T cell  
efficacy against solid cancers [5–7].   
The imaging modalities with the highest potential for whole-body visualization  
of cell trafficking in humans are magnetic resonance imaging (MRI), single-photon  
emission computed tomography (SPECT), positron emission tomography (PET)/CT,  
or PET/MRI techniques for detection of labeled cells and co-registration of anatomical  
information of the body [8–10]. PET is particularly amenable to clinical use as it  
enables noninvasive, highly sensitive, repetitive, and quantitative imaging of positron-  
emitting, target- specific probes. The introduction of microPET for small-animal  
imaging has similarly made PET amenable to preclinical studies [11]. Ongoing  
activity of ACT against both on- and off-tumor sites can therefore be monitored in  
vivo by quantitative, radiotracer-based imaging of T cell distribution and expansion  
upon interaction with target antigen–expressing cells [2, 10, 12]. However, previous  
attempts to systemically monitor ACT in patients have yet to be adopted [13]. Passive  
labeling of T cells with positron-emitting probes ex vivo has been used to monitor the  
early-stage migration of infused T cells but suffers from potential inaccuracies due to  
signals from dead or dying cells, probe dilution upon cell division, and a limited  
ability to track cells over extended periods of time owing to short probe half-life [10].  
Alternatively, the stable transduction of T cells with a specific reporter gene allows for  
extended longitudinal studies using serial infusions of reporter-specific probes.  
Additionally, as only live cells are capable of continually expressing the reporter gene,  
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observed signals are limited to these cells only. Current reporter genes used in  
preclinical and clinical studies are based on both intracellular enzymes, e.g., herpes  
simplex virus type-1 thymidine kinase (HSV1-tk) and human deoxycytidine kinase  
[14–16], and surface receptors, e.g., sodium iodide symporter [NIS] [17], prostate-  
specific membrane antigen (PSMA) [18], and SSTR2 (19]. However, previous  
imaging studies have failed to demonstrate quantitative monitoring of critical T cell  
efficacy parameters, namely, whole-body, longitudinal visualization of T cell  
dynamics spanning initial localization, expansion, and subsequent contraction at  
primary and/or metastatic tumor sites, and the relationship between these parameters  
and tumor killing [5, 13, 20–22]. More importantly, imaging studies have yet to fully  
de ne treatment response parameters or prognostic markers of ACT efficacy and  
toxicity, and how these affect clinical outcomes in patients.   
We have chosen human SSTR2 as a reporter marker in efforts to determine the  
detection limit of T cells infiltrating solid tumors, and to predict the temporal kinetics  
of T cell recruitment and expansion, directly related to T cell activity against tumors.  
SSTR2 belongs to a family of G protein–coupled receptors, with expression restricted  
to the cerebrum and kidneys, and at low levels in the gastrointestinal tract [23]. It is a  
potentially ideal reporter marker for monitoring ACT owing to its limited basal  
expression throughout the body and the availability of clinically approved radiotracers  
for SSTR2, for example, gallium-68–chelated octreotide analogues (68Ga-  
DOTATOC) for the detection of SSTR2-overexpressing neuroendocrine tumors [19,  
24–26]. To determine the detection limit of T cells within a solid tumor mass, we  
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introduced SSTR2 into Jurkat T cells and titrated these with wild-type Jurkats to  
produce subcutaneous Jurkat tumor xenografts, each with defined ratios of SSTR2-  
expressing cells ranging from 0% to 100%. With this model, it became possible to  
replicate the varying degrees of T cell localization, penetration, and expansion at or  
within the tumor site. Over the course of tumor growth, PET/CT imaging was  
performed using 68Ga-DOTATOC to quantify the detection limit of SSTR2-positive  
T cells within the tumor and to correlate radiotracer uptake with tumor size and  
percentages of SSTR2-expressing cells. To further demonstrate the utility of SSTR2  
for imaging T cell distribution and expansion in a more physiologically relevant  
setting, we designed a single lentivirus vector to engineer primary human T cells to  
express both SSTR2 and a CAR specific to intercellular adhesion molecule-1 (ICAM-  
1), which is overexpressed in a range of malignant cancers [27–32]. Longitudinal,  
whole-body imaging of SSTR2-expressing, ICAM-1–specific CAR T cells by PET/  
CT was then performed in mice with systemic growth of poorly differentiated,  
radioactive iodine–resistant, anaplastic thyroid tumors [33, 34]. The kinetics of 68Ga-  
DOTATOC uptake in survivors demonstrated a biphasic T cell expansion and  
contraction pattern, the timing of which largely matched tumor burden kinetics except  
for a consistent lag in T cell contraction after tumor destruction. In contrast, unabated  
increases in 68Ga-DOTATOC uptake and tumor burden combined with rapid weight  
loss were observed in non-survivors, providing evidence that the rate of tumor killing  
by T cells in these instances is outpaced by that of tumor growth.   
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Experimental procedures  
Mammalian cell culture.   
Parental HeLa (ATCC), HEK 293 (ATCC), and 8505C (DSMZ) cells were  
transduced with lentivirus encoding Fire y Luciferase-F2A-GFP (Biosettia) followed  
by fluorescence- activated cell sorting (FACS) to purify GFP-expressing cells. HeLa-  
FLuc+GFP+ and HEK 293-FLuc+GFP+ cells were cultured in Advanced Dulbecco’s  
Modified Eagle Medium containing 10% (v/v) FBS, 2 mM L-alanyl-L-glutamine  
dipeptide (Gibco), and 100 U/ml penicillin-streptomycin (Pen/Strep) (Gibco). 8505C-  
FLuc+GFP+ cells were cultured in RPMI-1640 supplemented with 10% (v/v) FBS, 2  
mM L-alanyl- L-glutamine dipeptide, and 100 U/ml Pen/Strep. Human peripheral  
blood was obtained from healthy volunteer donors by venipuncture. Peripheral blood  
mononuclear cells (PBMCs) were isolated over Ficoll- Paque PLUS (GE Healthcare)  
and cultured in Optimizer CTS T-cell Expansion SFM (Thermo Fisher) supplemented  
with 5% human AB serum (Sigma-Aldrich), 2 mM L-alanyl-L-glutamine dipeptide,  
100 U/ ml Pen/Strep and 30 IU/ml human IL-2 (Cell Sciences). Nonadherent cells  
were removed after 24 hours and magnetically enriched for T cells with Dynabeads  
CD3/CD28 T cell expander (Thermo Fisher) at a 2:1 bead/T cell ratio. Dynabead-  
bound T cells were subsequently cultured in IL-2–containing media at a density of 1 !  
106 to 2 ! 106 cells/ml. All cells were incubated at 37°C in a 5% CO2 humidified  
incubator.   
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Construction of ICAM-1 CAR and SSTR2 reporter genes.   
The CAR gene specific to ICAM-1 was derived from the scFv sequence of a  
murine monoclonal anti–human R6.5 antibody — itself derived from hybridoma  
(ATCC) [56, 57]. The R6.5-speci c scFv was then fused to the transmembrane and  
cytoplasmic domains of CD28, CD137, and CD3" of an independent third-generation  
pLenti plasmid (a gift from Carl June at the University of Pennsylvania, Philadelphia,  
Pennsylvania, USA) [35]. A lentivirus vector (derived from the CAR vector) encoding  
human SSTR2 (NM_001050) was constructed by synthesizing the SSTR2- coding  
sequence (IDT) and inserting it into the vector using Xba1 and Sal1 sites.   
Lentivirus production and transduction of T cells.   
Lentivirus particles were produced by transiently transfecting HEK 293 cells  
using calcium phosphate. Brie y, 10 µg transfer gene, 7.5 µg CMV-dR8.2 (Addgene)  
and 5 µg pCMV-VSVG (Addgene) were mixed and incubated with 2 M CaCl2  
followed by 2! Hanks’ balanced salt solution (HBSS). Resulting solutions were added  
dropwise to 10-cm cell culture dishes seeded with 3.2 ! 106 HEK 293 in 10 ml  
DMEM 24 hours previously. Transfection media was replaced after 6 hours. Media  
containing lentivirus was harvested at 48 and 72 hours after transfection, filtered  
through 0.45-µm filters, and concentrated by ultracentrifugation at 75,000 g for 2  
hours at 4°C. Lentivirus was then resuspended in serum-containing media at an  
approximate titer of 108/ml and frozen at –80°C. Human T cells were transduced 24–  
72 hours after activation with CD3/CD28 Dynabeads either by spinfection at 1,000 g  
 101 
for 1 hour at 32°C or by overnight incubation of lentivirus in the presence of  
Synperonic F108 (Sigma-Aldrich) [58]. T cells were also transduced a second time, 24  
hours after initial transduction. The viral titer was adjusted to obtain a transduction  
level of approximately 50%. During and following transduction, media containing IL-  
2 was replaced with media containing human IL-7 (10 ng/ml) and IL-15 (5 ng/ml)  
(Peprotech), which was found to augment T cell persistence in vivo [59, 60]. Jurkat T  
cells were transduced by a single incubation with lentivirus overnight in the presence  
of Synperonic F108.   
Conformation of SSTR2 functionality and measurement of site density.   
SSTR2-transduced Jurkat T cells were incubated with or without 1 µM  
octreotide (Sigma-Aldrich) for 30 minutes at 37 °C. Subsequent internalization of  
SSTR2 was measured by flow cytometry analysis of SSTR2 expression. The site  
density of SSTR2 expression on Jurkats was determined by incubating nontransduced  
and SSTR2-transduced Jurkat T cells with DOTATOC (8–250 nM) at either 37°C or  
4°C for 30 minutes in PBS/0.1% BSA. After incubation, cells were washed 3 times  
and DOTATOC uptake was measured using a gamma counter (Packard, Cobra II  
Auto-Gamma). Values obtained were used for Scatchard analysis to estimate affinity  
and site density.   
Subcutaneous Jurkat T cell xenograft.   
SSTR2-expressing Jurkats were spiked with increasing numbers of  
nontransduced Jurkats to derive distinct cultures containing defined percentages of  
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SSTR2 expression ranging from 100%–0%. For each subcutaneous xenograft, 5 ! 106  
total cells were resuspended in 100 µl Matrigel Basement Membrane Matrix (Corning)  
and injected bilaterally into nonobese diabetic (NOD)/ LtSz-PrkdcscidIl2rgtm1Wjl/J  
(NSG) mice (Jackson Laboratory). Measurements of tumor size were made using a  
digital caliper. Tumor volume was calculated by using the modified ellipsoid formula  
0.5 ! (length ! width2). Length was measured as the longer dimension. Each  
dimensional measurement was rounded to the nearest 0.5 mm.   
Labeling of 68Ga-DOTATOC.   
DOTATOC (1,4,7,10-tetraazacyclododecane-NI,NII,NIII,NIIII- tetraacetic  
acid (D)-Phe1-thy3-octreotide, GMP grade) was obtained as 1 mg lyophilized powder  
(ABX Pharmaceuticals). The DOTATOC vial content was diluted with 18 MOhm  
water to 2 ml (0.5 mg/ml solution) and stored at 4°C as a stock solution. 68Ga was  
obtained by eluting an ITG 68Ge/68Ga generator (ITM) with 4 ml 0.05 M HCl  
solution. To the eluted 68Ga3+, 50 µl of the DOTATOC stock solution (25 µg) was  
added, followed by 80 µl of a 3N NaOAc solution for buffering. The mixture was  
immediately placed in a Thermomixer (Eppendorf) at 95°C and incubated for 15  
minutes. Following incubation, the mixture was passed through a previously activated  
C-18 Sep-Pak Lite (Waters) to trap the labeled peptide. The labeling vial was washed  
with 5 ml 18 MOhm water and the resulting wash was also passed through the C-18  
Sep-Pak. Finally, the Sep-Pak was washed with an extra 5 ml of 18 MOhm water to  
eliminate any remaining free 68Ga. The trapped 68Ga-DOTATOC was then slowly  
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eluted from the C-18 Sep-Pak using 100 µl of ethanol followed by 900 µl of saline  
solution for injection, providing the final product in a 10% ethanol, isotonic, injectable  
solution. The purity of the final product was checked by reverse-phase HPLC.   
E:T assay.   
2 ! 105 HeLa-FLuc+GFP+, 8505c-FLuc+GFP+, or HEK 293-FLuc+GFP+  
cells were cocultured with either nontransduced or CAR-expressing T cells (SSTR2-  
R6.5 or R6.5) at varying E:T ratios as indicated. Cocultures were carried out in T cell  
media containing 150 µg/ml D-luciferin (Gold Biotechnology) with no cytokine  
supplementation. Luminescence was measured using a plate reader (TECAN in nite  
M1000 PRO) with readings in each E:T condition normalized to the nontransduced T  
cell/target co-culture controls.   
8505C mouse model, measurement of ex vivo organs and whole-body tumor growth.   
8505c-FLuc+GFP+ cells (1 ! 106) were injected into NSG mice via tail vein.  
Primary human T cells (2 ! 106 to 3 ! 106) were injected via tail vein 7–15 days after  
tumor cell injection. Luminescence imaging of tumor xenografts in live mice was  
performed using a whole-body optical imager (In-Vivo Extreme 4MP, Bruker). Mice  
were first anesthetized with 3% isoflurane at 2 l/min O2 and subsequent to this,  
maintained at 2% isofurane at 2 l/ min O2. Growth or reduction in tumor burden was  
estimated by integration of luminescence over the lungs or the entire mouse body. Ex  
vivo fluorescence imaging of mouse liver, lungs, spleen, and resected tumors was  
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performed using a whole-body optical imager (In-Vivo F Pro, Bruker).   
PET/CT imaging.   
Registered CT images were acquired using a micro-PET/CT scanner (Inveon,  
Siemens) 1–2 hours after DOTATOC injection. Projection data were acquired in a  
cone-beam geometry with approximately 1-second steps at 1° angular increments. At  
least 10 ! 106 coincidence events were acquired for PET per study using a 250- to  
750-keV energy window and a 6-nanosecond timing window. A reference was  
included using a tube containing 100 µl of 10 %ID/cm3 for quantification of  
DOTATOC uptake in vivo. To compute DOTATOC uptake by Jurkat tumors, the  
ellipsoidal ROIs (AMIDE software; http://amide.sourceforge.net/index.html) were  
placed to enclose subcutaneous tumors that closely match overall tumor size and  
shape. For systemic 8505C tumor models, ellipsoids were drawn separately on the left  
and right sides of lungs to enclose all 5 lobes of mouse lungs. The %ID/cm3 values,  
computed relative to the counts in a reference tube, can be approximated to a standard  
uptake value (SUV) [61] by dividing %ID/cm3 by 4, assuming an injection ef ciency  
of 100% and 25 g body weight. Visualization and analyses of PET/CT images were  
performed using AMIDE.   
Flow cytometry.   
Jurkat tumor xenografts or mouse organs (lungs and liver) were harvested from  
mice following completion of PET/CT imaging. Tissues were diced and flushed  
through an 80-µm cell strainer to yield single-cell suspensions. Red blood cells were  
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lysed by incubating the cell suspension with 1! Ammonium-Chloride-Potassium  
lysing buffer (Thermo Fisher), followed by washing and resuspension in 1! HBSS  
containing 2% normal goat serum. Prior to staining, cells were blocked with mouse  
IgG (Sigma-Aldrich, 15381) at 2 µg/ml for 10 minutes. This was followed by live  
staining with 1 µg/ml propidium iodide (PI, Invitrogen, P3566) in combination with 2  
µg/ml murine anti–human CD3-Alexa Fluor 647 (Biolegend, 300322) or 2 µg/ml PE-  
conjugated murine anti–human SSTR2 (R&D Systems, FAB4224P). Flow cytometry  
gates were rst determined by live-cell gating (PI negative) and subsequently by  
staining of respective antibodies. ICAM-1 expression on tumor cell lines was  
determined using a murine anti–human R6.5 monoclonal antibody (10 µg/ml) derived  
from hybridoma (ATCC) [57]. R6.5-CAR expression on T cells was detected using  
FITC-conjugated goat anti–mouse F(ab#)2 secondary antibody (Thermo Fisher,  
31543).   
Histology.   
Jurkat tumor xenografts were harvested, fixed in 4% paraformaldehyde in  
PBS, embedded in paraffin, and were cut to produce 5-µm sections (Microtome,  
Leica). Paraffin-embedded sections were stained with hematoxylin and eosin (H&E)  
or hematoxylin only for CD3 immunostaining (performed by HistoWiz, Inc.). After  
euthanasia, mouse lungs were perfused via the trachea with 4% paraformaldehyde, and  
each of 5 lobes was separated after fixation and embedded in paraffin. Liver tissue was  
harvested and processed identically for histology. Histological analysis was performed  
by an experienced pathologist.   
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Statistics.   
One-way ANOVA and unpaired, 2-tailed Student’s t test were performed using  
Prism 7 (GraphPad) on data indicated. A P value less than 0.05 was considered  
significant.   
Study approval.   
The protocol for blood draw from healthy volunteers is approved by the  
Institutional Review Board of Weill Cornell Medicine (permit number: 1302013613).  
All animal experiments were performed in strict accordance with the  
recommendations contained within the National Institute of Health’s Guide for the  
Care and Use of Laboratory Animals and animal handling protocols were approved by  
the Institutional Laboratory Animal Use and Care Committee of Weill Cornell  
Medicine (permit number: 2012-0063).   
  
Results  
Expression and characterization of SSTR2 in Jurkat T cells.   
We constructed a lentivirus vector for expression of SSTR2 by inserting the  
human SSTR2 gene downstream of the elongation factor-1$ promoter [35]. With  
increasing lentivirus titer, 100% of Jurkat T cells were transduced to express SSTR2  
as measured by antibody binding (Figure 3.1A). Consistent with agonist-induced  
internalization of SSTR2 [36], incubation of T cells with the synthetic SSTR2 agonist  
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octreotide reduced surface expression of SSTR2, as indicated by reduced antibody  
binding (Figure 3.1B). Labeling of SSTR2-transduced Jurkat T cells with 68Ga-  
DOTATOC (hereafter referred to as DOTATOC) at concentrations ranging from 8 nM  
to 250 nM followed a first-order Langmuir isotherm equation, giving a dissociation  
constant (Kd) of 38 nM (Figure 3.1C). In comparison, DOTATOC uptake by  
nontransduced T cells was approximately 10-fold lower. Similar to the Kd estimated  
by Langmuir isotherm, Scatchard analysis estimated the Kd of DOTATOC to be 32  
nM and the site density of SSTR2 to be approximately 3.2 ! 106 molecules per cell  
(Figure 3.1D). Actual site density is likely to be lower due to recycling of SSTR2 after  
internalization of DOTATOC and some level of nonspecific binding. Incubation of  
cells at 4°C to inhibit SSTR2 recycling resulted in an estimated site density of 1.8 !  
106 molecules per cell; however, the affinity of DOTATOC for SSTR2 was also  
determined to be substantially lower (Kd = 170 nM) at this temperature (Figure 3.1D).   
PET imaging of DOTATOC uptake in SSTR2+ T cell xenografts.   
To examine the utility of SSTR2 for the detection of sparsely distributed T  
cells in tumors, we produced subcutaneous Jurkat T cell xenografts in mice with a  
mixture of SSTR2-transduced (referred to as SSTR2+) and nontransduced (wild-type)  
cells. These were titrated against each other immediately prior to xenografting to vary  
the levels of SSTR2- expressing cells within tumors from 0% to approximately 100%.  
Xenografted Jurkat T cell tumors began to show palpable growth at ~30 days after  
xenograft and exhibited continuous growth for the next 25 days, reaching   
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Figure 3.1 Expression of human SSTR2 by lentivirus vector in T cells.   
(A) A schematic of the lentivirus vector encoding human SSTR2 is shown. LTR, long  
terminal repeat; SD, splice donor; SA, splice acceptor; EF1$, elongation factor 1$  
promoter; %+, encapsidation signal. Histograms show the level of SSTR2-speci c  
antibody binding to wild-type Jurkat T cells (0%, top) and Jurkat T cells transduced  
with increasing virus titers. Percentages of SSTR2- positive cells are indicated. (B)  
Level of SSTR2- specific antibody binding to SSTR2-transduced Jurkat T cells with  
and without preincubation with 1 µM octreotide (37°C, 30 minutes). The numbers  
denote mean fluorescence intensity. (C) DOTATOC uptake by SSTR2-transduced and  
wild-type Jurkat T cells versus input DOTATOC concentration is shown. A first-order  
Langmuir isotherm equation was used to t the data and to nd the equilibrium  
dissociation constant (Kd). Confidence interval of Kd is shown in parentheses. (D)  
DOTATOC uptake at 37°C and 4°C by SSTR2-transduced and wild-type Jurkat T  
cells is shown via Scatchard plot. Predicted Kd is shown. Data shown are from 3  
independent experiments. CPM, counts per minute.  
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Figure 3.2 Quantitative PET/CT measurement of DOTATOC uptake by Jurkat  
tumors and statistical analysis. (A) Tumor volume (mm3) plotted against number of  
days after xenograft. (B) Measured DOTATOC uptake is quantified as percentage  
injection dose per volume (%ID/cm3) for Jurkat tumors (100%–0% SSTR2+) over the  
course of tumor growth. (C) Representative PET/CT images of mice xenografted with  
Jurkat T cells at 0%, 0.1%, 1%, 10%, and 100% SSTR2 expression. Images are  
maximum intensity projections (MIPs) of the entire mouse body (~20-mm-thick  
plane). PET intensity is pseudocolored in the range of 0–10 %ID/cm3. (D and G)  
DOTATOC uptake (%ID/cm3) for Jurkat tumors less or greater than 65 mm3,  
respectively. (E and H) Simulated Gaussian distribution as a function of the measured  
mean and standard deviation of DOTATOC uptake for each percentage SSTR2+  
tumor when the volume is less or greater than 65 mm3, respectively. (F and I)  
Receiver operating characteristic (ROC) curves of percentage sensitivity and  
specificity are shown for tumors less than 65 mm3 (D) and greater than 65 mm3 (G).  
** P < 0.01 vs. 0%, ***P < 0.001 vs. 0%, by Student’s t test.   
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Figure 3.3 Growth in vivo of mosaic Jurkat tumors.   
(A) Comparison of tumor volume across multiple xenografted Jurkat tumors  
containing a range of SSTR2+ ratios. No significance (n.s.) by one-way ANOVA was  
found among SSTR2+ groups. (B) CD3- and SSTR2-specific antibody binding to  
SSTR2+ and wild-type Jurkat T cells in culture and to the same cells harvested from  
tumors is shown in histograms. Percentages of CD3 and SSTR2 positive cells are  
indicated. (C) Paraffin embedded, hematoxylin stained section of Jurkat tumor was  
stained with anti-human CD3 antibody to visualize distribution of Jurkat T cells and  
stroma cells. Shown on the right is a high magnification view of the dotted yellow box  
in left image. Stroma containing blood vessels are identified by yellow arrows. Scale  
bar = 400 µm on left image and 60 µm on right.  
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approximately 0.7 cm3 (Figure 3.2A). Longitudinal measurement of tumor size across  
different SSTR2+ tumors revealed that the level of SSTR2 expression had no  
significant effect on the growth of Jurkat T cell tumors (Figure 3.3A; supplemental  
material available online with this article; doi:10.1172/jci.insight.90064DS1). We  
tested our ability to detect SSTR2+ T cells within tumors when both their tumor  
density and absolute numbers ranged from low to high in both respects. Thus, to cover  
this range, we initiated PET/CT imaging 12 days after xenograft of 0% to 100%  
SSTR2+ tumors, that is, before we could detect palpable tumor growth, and continued  
imaging until 56 days after xenograft (Figure 3.2B). The level of DOTATOC uptake  
by tumors was quantified as percentage injection dose per volume (%ID/cm3) based  
on the region of interest (ROI) enclosing tumors. The ROIs were defined by tumor-  
size measurements and anatomical information from CT images. Over the course of  
tumor growth, DOTATOC uptake was higher in tumors comprising increasing  
percentages of SSTR2+ cells (Figure 3.2B). PET/CT images showed DOTATOC  
uptake by tumors and uniformly higher uptake by the kidneys and bladder —  
consistent with its known biodistribution and renal clearance (Figure 3.2C) [19].  
DOTATOC uptake values, as measured by %ID/cm3, agreed with visual assessments  
of PET/CT images over the course of tumor growth and correlated with increasing  
SSTR2+ percentages within the tumors (Figure 3.2, B and C, and Figure 3.4). We also  
noted a minor increase in DOTATOC uptake during growth of 0% SSTR2+ tumors,  
which we speculate to be caused by the increasing leaky vasculature and stagnant  
blood pooling within tumors (Figure 3.2B).   
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Defining detection limit, specificity, and sensitivity of SSTR2+ T cells.   
We next analyzed DOTATOC uptake values to determine the detection  
sensitivity and specificity of SSTR2-expressing T cell density within tumors.  
Regarding small, palpable tumors (below ~65 mm3), DOTATOC uptake was slightly  
higher in those containing 1% SSTR2+ cells (0.64 ± 0.4 %ID/cm3; P = 0.1 vs. 0%  
SSTR2+), but was significantly higher in tumors containing SSTR2+ T cell densities  
of 10% (0.83 ± 0.5 %ID/cm3) and 100% (3.4 ± 1.7 %ID/cm3), compared with uptake  
within 0% SSTR2+ tumors (0.44 ± 0.2 %ID/cm3) (Figure 3.2D). Assuming a normal  
distribution of DOTATOC uptake values (Figure 3.2E), a threshold of 0.6 %ID/cm3  
was the DOTATOC uptake cutoff in order to obtain 95% specificity (5% false positive  
rate) for tumors of this size. The detection sensitivity (% true positive rates) for 1%,  
10%, and 100% SSTR2+ tumors with the 0.6 %ID/cm3 threshold was calculated to be  
54%, 69%, and 95%, respectively. The detection limit for 10% SSTR2+ tumors below  
~65 mm3 was considered marginally acceptable with an area under the receiver  
operating characteristic (ROC) curve (AUC) [37] value of 0.75 (Figure 3.2F). In  
contrast, DOTATOC uptake for more discernible SSTR2+ tumors (larger than 65  
mm3) was significantly higher within 100%, 10%, and 1% SSTR2+ tumors (7.1 ± 2.3,  
2.8 ± 1.1, and 2.0 ± 0.77 %ID/cm3, respectively) when compared with background  
uptake by 0% SSTR2+ tumors (0.8 ± 0.35 %ID/cm3) (Figure 3.2G). Uptake was also  
detectable, although not significant, even within 0.1% SSTR2+ tumors (1.1 ± 0.51  
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%ID/cm3, P = 0.12). A DOTATOC uptake cutoff of 1.1 %ID/cm3 gave 95%  
specificity and 87% sensitivity for 1% SSTR2+ tumors within the Jurkat model  
(Figure 3.2H). With the same threshold, one achieves greater than 95% sensitivity for  
tumors in which the SSTR2+ T cell density is at or above 10%. The ROC curve of  
DOTATOC uptake by 1% SSTR2+ tumors gives 0.95 AUC, while 0.1% SSTR2+  
tumors gives 0.68 AUC (Figure 3.2I). SSTR2+ T cells in culture were ~100%  
SSTR2+ by antibody staining (Figure 3.3B). However, later resection of 100%  
SSTR2+ tumors followed by staining for SSTR2 by flow cytometry revealed that the  
level of SSTR2 expression was reduced to ~80%, with the 20% reduction reflecting  
the presence of mouse stromal cells within tumors (Figure 3.3, B and C). The  
reduction of SSTR2 expression was not caused by the loss of SSTR2 expression  
during tumor growth, as a similar level of reduction was seen by CD3 staining: 70%  
CD3+ in cells harvested from tumors, reduced from 80%–85% CD3+ from the same  
cells in culture.   
To express the observed SSTR2+ T cell tumor density as an absolute number  
per volume, we resected Jurkat tumors and determined the average total cell density to  
be 5.1 ± 1.3 ! 108/cm3 (n = 4). Accordingly, 1% SSTR2+ tumors (comprising  
approximately 4 ! 108/cm3 Jurkat T cells and 1 ! 108/cm3 stroma) would contain ~4  
! 106 SSTR2+ T cells per cm3. Based on the data obtained using the Jurkat model, we  
proceeded to utilize SSTR2-based PET imaging to estimate and longitudinally monitor  
the density of reporter- expressing CAR T cells infiltrating solid tumors.   
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Efficacy of ICAM-1–specific CAR T cells against thyroid tumor cells.   
Radioiodine-resistant, poorly differentiated thyroid cancers have been found to  
overexpress ICAM-1 at levels correlating with tumor malignancy and metastatic  
potential [30]. The anaplastic thyroid cancer cell line 8505C was also found to be  
ICAM-1 positive (Figure 3.5A), the level of which varied due to culture conditions  
and growth in vivo. The anti–ICAM-1 CAR is third generation and consists of an  
ICAM-1–specific single-chain variable fragment (scFv) from the R6.5 antibody [38],  
the transmembrane and cytoplasmic domains of CD28, followed by CD137 and CD3"  
[35]. A lentiviral vector encoding both SSTR2 and R6.5-CAR was constructed by  
linking SSTR2 to the R6.5-CAR with a ribosome-skipping porcine teschovirus-1 2A  
(P2A) sequence [39] (Figure 3.5B). Primary T cells were transduced to express  
SSTR2 and R6.5-CAR at approximately 50% (Figure 3.5B). Expression levels of both  
SSTR2 and R6.5-CAR obtained via the single SSTR2-R6.5-CAR (SR) vector were  
comparable to what could be attained by separate SSTR2 (SS) and R6.5-CAR (RR)  
vectors at similar virus titers (Figure 3.5, B and C). To test the selectivity of CAR T  
cell–mediated killing of 8505C cells, we also used the cervical cancer cell line, HeLa,  
exhibiting high basal levels of ICAM- 1, and the ICAM-1–negative cell line, HEK  
293, as positive and negative controls, respectively (Figure 3.5A). All target cells were  
lentivirally transduced to express GFP and re y luciferase in order to quantitatively  
monitor cell viability. Incubation of CAR T cells with ICAM-1–positive and –negative  
cell lines showed that CAR T cell killing of target was strictly dependent upon ICAM-  
1 expression. After 24 hours, 17% ± 11% of HeLa and 52% ± 15% of 8505C cells  
were viable at effector to target (E:T) ratios of 2.5:1, with no killing of HEK 293 cells   
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Figure 3.5 CAR T cell efficacy against thyroid tumor cells in vitro and in vivo.  
(A) Representative histograms showing the level of anti–ICAM-1 antibody binding to  
ICAM-1–negative HEK 293T, ICAM-1–positive HeLa, and 8505C cells. (B)  
Schematic of the lentivirus vector encoding SSTR2-R6.5-CAR. CD8$ SS (signal  
sequence); TM, transmembrane; Cyt, cytoplasmic domain. Representative dot plots  
showing anti-SSTR2 and anti-CAR antibody binding to nontransduced (left) and  
SSTR2-P2A-R6.5-CAR–transduced (right) primary human T cells. (C) Primary  
human T cells were transduced separately with individual vectors encoding either  
SSTR2 or R6.5-CAR. Representative histograms show anti-SSTR2 antibody binding  
to either R6.5-CAR– or SSTR2- transduced ( lled) and nontransduced (open) primary  
T cells. (D) E ector/target (E:T) assay measuring lysis of target expressing (HeLa and  
8505C) or control (HEK 293) cells by CAR T cells at a 2.5:1 E:T ratio. Percentages of  
live cells were measured by bioluminescence intensity normalized to the levels of  
target cells incubated with nontransduced T cells. Octreotide (1 µM) was added to SR  
T cells as indicated (SR+Oct). n = 3–6 from 3 different donor T cells. NT,  
nontransduced T cells; SS, SSTR2-transduced T cells; RR, R6.5-CAR–transduced T  
cells; SR, SSTR2-R6.5-CAR–transduced T cells.  
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observed (106% ± 8%) (Figure 3.5D). Additionally, no killing of 8505C cells (97% ±  
2%) was observed upon coincubation with SS T cells. The rate of kill- ing of 8505C  
cells by RR and SR T cells, and that of HeLa by SR T cells with or without the  
addition of octreotide (1 µM) was comparable. This confirmed that SSTR2 expression  
on T cells, as well as binding of its cognate ligand (DOTATOC), does not alter CAR T  
cell functionality.   
Longitudinal PET imaging of SSTR2+ CAR T cells in vivo.   
In order to test the ability of an SSTR2-based reporter system to acquire in  
vivo visual mapping of CAR T cell localization and antitumor dynamics, NSG mice  
were first xenografted by systemic injection of 1 ! 106 8505C-FLuc+GFP+ cells.  
Bioluminescence imaging demonstrated that primary 8505C tumors localized to the  
lungs, with metastases occurring within the liver and at more distant sites (Figure  
3.6A), consistent with previously reported observations of 8505C tumor growth  
characteristics in mice [40]. Using bioluminescence as a measure of tumor burden, it  
was observed that an initial infusion of 1 ! 106 tumor cells expanded 50- to 100-fold  
over 21 days (Figure 3.6A). Tumor growth was not hampered by treatment with SS T  
cells 10–13 days after tumor xenograft (SS1–5, as defined in Figure 3.7), confirming  
the absence of nonspecific killing by non-CAR T cells in vivo. Prior to conducting  
DOTATOC imaging of SR T cells, we first examined the circumstances that give rise  
to nonspecific DOTATOC uptake, which may include leaky tumor vessels within  
areas of high tumor burden causing blood pooling. First, CT images of mice with no  
tumors that were infused with SS T cells showed the heart and tumor-free alveolar air  
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space in the lungs (Figure 3.6B). The level of DOTATOC uptake in these mice (0.7  
%ID/cm3) was comparable to those in Jurkat tumors containing 0% SSTR2+ cells  
(0.6–0.8 %ID/cm3) and is thus indicative of the absence of CAR T cell expansion. In  
comparison, mice xenografted with 8505C tumors had alveolar air space replaced by  
the growth of tumor cells (accounting for as much as 22% of total live cells in lungs),  
which generated increased alveolar tissue density in transverse CT images of these  
mice (Figure 3.6C). We observed low yet gradually increasing nonspecific  
DOTATOC uptake in the thoracic cavity of mice with high tumor burden (1.3 ± 0.5  
%ID/cm3 for 23 to 27 days after tumor xenograft) that received either no T cells or SS  
T cells. This was found to be due to subjects’ poor health and slower heartbeat,  
causing a longer circulation time and a delay in DOTATOC clearance. Mice treated  
with RR T cells (RR1–3, Figure 3.7) were also found to show only background levels  
of DOTATOC uptake in the lungs (1.0 %ID/cm3) (Figure 3.6D). This was despite the  
fact that over the course of tumor killing, RR T cells had expanded such that they  
accounted for 36% of total live cells in lungs.   
After confirming the relative absence of lung-specific DOTATOC uptake  
related to tumor burden itself or SSTR2-negative T cell expansion, we then treated  
tumor-bearing mice with SR T cells at days 7, 10, 13, and 15 after xenograft. Mice  
were subjected to longitudinal bioluminescence and concurrent PET/CT imaging to  
visualize the relationship between tumor burden and the dynamism of infused SR T  
cells over the course of their localization, tumor engagement, and killing (Figure 3.7,  
and Figure 3.8, A and E). Progressive delays in T cell infusion after tumor xenograft  
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were used in order to observe potential differences in CAR T cell dynamics related to  
differences in tumor burden. Primary tumor burden in the lungs from mice treated  
with SR T cells 7 and 10 days after xenograft (SR1–4) began noticeably decreasing at  
approximately 16 days after tumor xenograft with little change in body weight (Figure  
3.8, A–C). Increasing tumor burden over time correlated with increasing DOTATOC  
uptake within the lungs, indicating that infused SR T cells had stably localized to the  
tumor site where they were actively proliferating in response to engagement with  
ICAM-1–positive tumor cells (Figure 3.8A). It was also found that peak DOTATOC  
uptake, and therefore peak CAR T cell expansion, lagged behind peak tumor  
bioluminescence by approximately 4 days. Peak DOTATOC uptake within the lungs  
was followed by gradual curtailment and contraction corresponding to diminishing T  
cell numbers, thus demonstrating a biphasic antitumor CAR T cell response,  
incorporating classical antigen-mediated T cell expansion followed by T cell  
contraction upon antigen withdrawal (Supplemental Video 1 and Figure 3.8A). In  
contrast with the swift tumor elimination, followed by CAR T cell contraction within  
the lungs of surviving mice, further delay of treatment with SR T cells to 13 to 15 days  
after tumor xenograft (SR5–9) failed to reduce tumor burden and restore health before  
euthanasia was invoked (deemed necessary after a 25%–30% loss in body weight)  
(Figure 3.8, E–G). This was despite increasing lung-specific DOTATOC uptake  
confirming SR T cell expansion in the lungs of these mice (Supplemental Video 2 and  
Figure 3.8E). Longitudinal transverse CT images revealed that while tissue density in  
lungs associated with tumor and CAR T cell burden persisted in nonsurvivors, it was   
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Figure 3.6 Whole-body imaging of tumor growth by luminescence and  
DOTATOC uptake by PET/CT. (A) Tumor burden from day of intravenous tumor  
xenograft via tail vein (X0) and 21 days after (X21) was visualized and quanti ed by  
bioluminescence. (B–D) Transverse CT-only, PET-only, and PET/ CT superimposed  
images are shown alongside a coronal view of the entire mouse body. PET images are  
drawn in indicated ranges. Ex vivo uorescence images of lungs and liver are shown  
together with ow cytometry analysis of the CD3+ (T cell) and GFP+ (tumor cell)  
populations of the same lungs are also shown (C and D). Each PET/CT image is  
representative of at least 3 independent experiments. SS, SSTR2- transduced T cells;  
RR, R6.5-CAR–transduced T cells; no T, no T cell treatment.  
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Figure 3.7 Schematic of the longitudinal CAR T cell imaging experiment. Mice  
are divided into four groups according to the day of T cell treatment post tumor  
xenograft. SR = SSTR2-R6.5-CAR T cells; SS = SSTR2, non-CAR T cells; and RR =  
non-SSTR2, R6.5- CAR T cells. Days of xenograft, T cell injection, imaging and post-  
mortem analysis are indicated.   
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Figure 3.8 Quantitative PET for detection of CAR T cells and luminescence of  
tumor burden in survivors vs. nonsurvivors. Representative longitudinal, PET/CT  
(coronal view of 20-mm-thick plane, maximum intensity projection [MIP]) and  
concurrent bioluminescence imaging of survivors (n = 4) (A) vs. nonsurvivors (n = 5)  
(E). Diaphragms are traced with dotted lines, drawn to visualize tumor burdens  
separately in lungs and liver. Trend-line graphs plot region of interest (ROI) values for  
DOTATOC uptake (percentage injection dose per volume [%ID/cm3]) against  
bioluminescence values (photons [P]/sec) in the lungs taken from the same mice on  
the same day. Luminescence images are drawn with the same upper bound (106  
P/mm2/sec) with gradually increasing lower bounds (X16, X20 for 2.5 ! 104  
P/mm2/sec and X23, X27 for 5 ! 104 P/mm2/sec) for clarity of delineating tumor  
burden. Longitudinal PET/ CT images of the upper body cropped at the kidney apex  
are drawn with a uniform range of DOTATOC concentrations (0.5–5.0 %ID/cm3),  
while whole-body PET/CT images are drawn in 0.5–5.0 %ID/cm3 for (A) and 1–10  
%ID/cm3 for (E). Quanti cation of luminescence and DOTATOC uptake by the lungs  
(B and F) and body weight change (C and G) is shown for survivors and  
nonsurvivors. Representative longitudinal, PET/CT (transverse view of 1-mm-thick  
plane, MIP) views of lungs are shown for survivors (D) and nonsurvivors (H). PET  
images are drawn in indicated ranges. X, number of days after tumor xenograft; SR,  
treated with SSTR2-R6.5-CAR–transduced T cells.  
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Confirmation of PET and bioluminescence imaging by ex vivo analysis.   
Assessment of CAR T cell–mediated tumor killing by ex vivo fluorescence  
imaging of the lungs and liver (performed on day 28 after tumor xenograft) confirmed  
that tumor elimination had indeed occurred in survivors treated with SR T cells on  
days 7–10 after tumor xenograft (Figure 3.9A). Flow cytometry analysis of lungs that  
were determined to have undergone CAR T cell contraction by DOTATOC uptake  
showed that CD3+ cell levels were reduced to less than 1% of total lung cells (Figure  
3.9A). It also confirmed continuing expansion of SR T cells and substantial reduction  
of tumor burden in nonsurviving mice treated on days 13–15 after tumor xenograft  
(2.5%), compared with mice that received no T cells (22%) (Figure 3.9B vs. Figure  
3.6C). Furthermore, plotting the percentage of human CD3+ cells in the lungs of SR-  
treated mice against DOTATOC uptake from same, demonstrated that CD3 staining  
by ow cytometry was largely proportional to DOTATOC signal obtained by PET  
(Figure 3.9C). The observation that DOTATOC uptake values greater than 3  
corresponded to greater than 10% CD3+ T cells was in quantitative agreement with  
the findings from the Jurkat tumor model (Figure 3.5.2, G and H).   
Histological analysis of lung tissues further corroborated the conclusions  
drawn from whole-body PET/bioluminescence imaging, flow cytometry, and ex vivo  
organ images. Lung tissues from untreated mice (X23/no T cells) revealed extensive  
infiltration and growth of tumor cells into the alveoli, bronchioles, pulmonary vessels,  
and pleural spaces compared with their healthy no-tumor counterparts (Figure 3.9D  
and Figure 3.10). Lung tissues harvested from survivors (SR1–4) were   
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Figure 3.9 Ex vivo analysis of CAR T cell and tumor density in lungs. Ex vivo,  
GFP+ tumor cell uorescence of representative lungs and liver, and ow cytometry of  
total, live-gated lung cells from (A) survivors (n = 4) and (B) nonsurvivors (n = 5).  
Organs were harvested, imaged, and analyzed by ow cytometry on day 28 after  
xenograft (X28). (C) DOTATOC uptake (percentage injection dose per volume  
[%ID/cm3]) by the lungs in SR1–SR9 mice are plotted against the percentages of T  
cells (CD3+) determined by ow cytometry. (D) Representative histological images are  
shown for para n-embedded H&E-stained sections of 1 entire lung lobe (top), and  
anti–human CD3 antibody with hematoxylin counterstain (middle). High-magni cation  
views (yellow boxed regions in middle sections) show tumor cells and CD3-stained T  
cells (bottom). Tumor cells are identi ed by dark hematoxylin-stained nuclei. Human  
CD3+ cells are stained brown. Scale bars: 2 mm (top and middle sections) and 200 µm  
(bottom sections). Lungs were harvested from healthy mice with no tumor, mice 23  
days after tumor xenograft and no T cell treatment (X23/no T cell), and X28 for T  
cell–treated survivors and nonsurvivors.  
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Figure 3.11 DOTATOC uptake and histology of the liver. Transverse CT-only,  
PET-only and PET/CT images of the liver (1 mm thick slice, maximum intensity  
projection) of survivor (A) vs. nonsurvivor (B). Paraffin embedded H&E stained  
section of the liver from the same mouse, and CD3 stained sections shown at higher  
magnification underneath (selected area is marked with a dotted box). Scale bar = 4  
mm (a&b, top) and 200 µm (a&b, bottom).   
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mostly devoid of tumor infiltrates and SR T cells, and appeared to have restored  
normal alveoli structure. Nonsurvivor lung tissues (SR5–9) revealed much higher  
burden of tumor, yet infiltrating T cells (CD3 staining) were found to colocalize with  
tumor lesions, confirming ongoing tumor elimination by CAR T cells (Figure 3.9D).   
In contrast with the more evenly distributed and synchronized growth of  
tumors in the lungs, metastatic lesions in the liver were distinctive, isolated, and  
smaller, measuring only millimeters in size (Figure 3.6, C and D, Figure 3.9, A and B,  
and Figure 3.11). In most cases, these liver metastases would be of insufficient size to  
generate CAR T cell expansion to requisite densities for visual detection by  
DOTATOC/PET — even during efficient CAR T cell responses. However, we were  
able to detect elevated DOTATOC levels in certain livers with tumor metastases as  
visualized by luminescence, particularly within nonsurvivors (Figure 3.9B and Figure  
3.11B). Such elevated DOTATOC accumulation was scarce in survivors where large  
tumor lesions in the liver were absent (Figure 3.9A and Figure 3.11A). Infiltration of  
CAR T cells into metastatic liver lesions irrespective of their size was also confirmed  
by histology (Figure 3.11). These data therefore confirmed that dynamic DOTATOC  
uptake by SSTR2-expressing, adoptively transferred T cells can be used to monitor the  
presence of T cell infiltrates at both primary tumor sites and metastatic lesions.   
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Discussion  
Recent clinical studies have strived to find both primary and secondary  
indicators to enable real-time monitoring of adoptively transferred T cell activity and  
to predict the likelihood of systemic toxicity [41]. However, as ACT has demonstrated  
both profound potency and at times, lethal toxicity, there is a clear need for tracking  
modalities that can provide additional spatiotemporal information to enable both  
baseline mapping of T cell localization and real-time visualization of multiple sites of  
T cell expansion. Quantitative PET imaging is increasingly used for diagnostic  
purposes and to gauge therapy response in a more accurate and objective manner [42].  
To our knowledge, this study is the first to utilize PET/CT to conduct high- quality,  
longitudinal whole-body mapping of ACT localization that illustrates how its  
dynamics affect the course of treatment and survival outcomes. Furthermore, this was  
achieved using clinically approved imaging tools to demonstrate critical events such as  
T cell migration, expansion, peak expansion, and contraction — correlated to tumor  
burden.   
SSTR2 was chosen as a genetic reporter for several reasons. One was to take  
advantage of the FDA- approved PET radiotracer specific to SSTR2, which is  
currently in use in clinics to probe for overexpressed SSTR2 in neuroendocrine tumors  
[43]. SPECT-based imaging is also available using 111In-DTPAOC (octreoscan) [44].  
SSTR2 displays restricted basal expression in tissues and all major organs except in  
the kidneys and cerebrum, making it ideal for detection of adoptively transferred T  
cells targeting a multitude of solid tumors. SSTR2 can potentially function as a dual  
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reporter-suicide gene by conjugation of the therapeutic high-energy radioisotopes  
177lutetium, 90yttrium, or 213bismuth to DOTATOC instead of 68gallium [25, 45],  
thus enabling elimination of SSTR2-expressing T cells in the case of CAR T cell  
toxicity. Compared with HSV1-tk, SSTR2 is surface expressed and therefore does not  
require prior radioligand internalization into the cell. It has previously been shown that  
SSTR2 facilitates rapid radiotracer uptake, and this combined with swift renal  
clearance of unbound DOTATOC means that high-quality, clinical- grade images can  
be obtained 1 hour after DOTATOC injection [46] compared with 2 to 3 hours using  
HSV1-tk–based systems [13, 47]. DOTATOC also has a short half-life of 68 minutes  
which, combined with its rapid clearance, delivers a low radiation dose to the patient.  
The fact that SSTR2 is of human origin should also limit its immunogenicity, which  
has plagued experiments using nonhuman genetic reporters [48, 49]. Another surface-  
expressed reporter gene, PSMA, is reportedly superior to more widely tested receptors  
such as HSV1-tk and NIS for imaging purposes [18]. Therefore, with the myriad of  
available genetic reporters, choosing the most suitable for imaging adoptively  
transferred T cells will depend foremost on the tumor being targeted. For example,  
SSTR2 would be unsuitable for imaging ACT targeting neuroendocrine tumors  
because of its inherent overexpression in this malignancy. Therefore, it is inevitable  
that were the adoption of human reporter genes to become widespread, a repertoire of  
multiple reporters would be required to circumvent potential on-target, off–T cell  
radiotracer uptake. Interestingly, the synchronous use of distinct genetic reporters may  
create novel opportunities for near-simultaneous live imaging of multiple infused cell  
populations [50]. For example, central memory and naive T cells were recently  
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reported to provide superior antitumor efficacy compared with effector memory cells  
or clinical products derived from unenriched T cells [51, 52]. However, these studies  
lack in vivo mechanistic data demonstrating the differences in T cell dynamics behind  
the observations. Coexpression of CAR or T cell receptor with separate population-  
specific reporter genes, for example SSTR2 and PSMA, followed by sequential, time-  
delayed injection of cognate PET radiotracers, could reveal underexplored dynamics  
of, and interactions between, these populations in both clinical and preclinical studies.   
Adoptively transferred T cells have been shown to penetrate and distribute  
throughout tumor tissue [12]. The utility of any imaging modality capable of  
monitoring ACT will therefore depend upon a limit- of-detection threshold sensitive  
enough to enable monitoring of meaningful T cell activity at low tissue densities.  
Moreover, evaluation of this detection limit in a physiologically relevant model must  
also account for the sensitivity and specificity of the infused imaging agent for the  
reporter in question, whose density at the tumor site will vary exponentially as its  
cognate T cells expand and contract in response to target elimination. Therefore, to  
approximate the DOTATOC-based detection limit of tumor-infiltrating SSTR2-  
transduced T cells, we utilized mosaic tumor xenografts of Jurkat T cells with  
increasing ratios of SSTR2 expression to create a standard by which quantitative PET  
signals can be related to T cells of known density within tumors. Using the lentivirus  
developed in this study, the surface expression of SSTR2 in transduced Jurkat T cells  
was in the range of several million per cell, a level significantly higher than previously  
published [19] and therefore likely to extend the lower limit of SSTR2+ T cell  
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detection. We observed that with a known threshold of radiotracer uptake, one can  
detect tumor-infiltrating T cells down to a minimum density of 0.8% or ~4 ! 106  
cells/cm3, with 95% specificity and 87% sensitivity. This compares favorably with a  
previous report using PET to detect tumor-infiltrating T cells that used flow  
cytometry– based detection in a separate, equally treated cohort of mice as a reference  
to purport a tumor-infiltrating T cell detection limit of 0.5% within tumors [53].   
To demonstrate the feasibility of SSTR2 reporter–based imaging to predict and  
monitor tumor-directed T cell activity, we chose ICAM-1–positive anaplastic thyroid  
cancer cells as a target model and engineered T cells to express both ICAM-1–specific  
CAR and SSTR2 using a single lentiviral vector. A potential drawback to the use of  
genetic reporters for imaging receptor-modified ACT is that the T cells in question  
require the stable expression of 2 separate genes, which can substantially reduce the  
percentage of cells coexpressing both genes. However, with the use of a self-cleaving  
P2A sequence [39], we demonstrated that both CAR and reporter genes can be  
successfully expressed on the same individual cell without compromising the level of  
expression otherwise achievable using 2 independent vectors.   
T cells expressing the SSTR2-R6.5 CAR efficiently and specifically lysed  
ICAM-1–expressing 8505C and HeLa tumor cell lines within 24 hours, as monitored  
by bioluminescence, while leaving ICAM-1– negative HEK293 cells largely  
untouched. Furthermore, efficient killing was also observed at lower E:T ratios, thus  
demonstrating both specificity and high activity of the SSTR2-R6.5 CAR for ICAM-  
1– expressing target cells. This targeting efficacy was replicated in vivo, as treatment  
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of 8505C tumor-bearing mice with SSTR2-R6.5-CAR T cells resulted in a significant  
reduction in tumor burden across all treated mice compared with those that received T  
cells expressing SSTR2 only. Tumor lysis occurred 1–2 weeks after treatment, with  
the time required for CAR T cell–mediated tumor reduction correlating with tumor  
burden at time of treatment. Expanding SSTR2-R6.5-CAR T cells at the tumor site  
were visualized via increasing DOTATOC signals. PET imaging of SSTR2-R6.5-  
CAR T cells was sensitive enough to visualize their perfusion throughout the lungs  
such that the lung footprint and outline became distinguishable by the presence of T  
cells alone. This was confirmed by histological analysis of tissue sections, which  
demonstrated the ubiquitous presence of human CD3+ T cells throughout the lungs of  
treated mice. Despite the small size (several mm) of metastatic nodules in the liver,  
localized DOTATOC accumulation was also recorded, which coincided with the  
emergence, followed by attenuation, of distinct liver tumor nodules as detected by  
bioluminescence imaging. Extrapolation of the image quality and sensitivity obtained  
in the current study to similar scenarios in humans would likely enable equal if not  
better monitoring of ACT tracking to primary, metastatic, and critically, to on-target,  
off-tumor sites. Visualization of ACT expansion may even draw attention to  
previously undetected metastatic sites such that sufficiently sensitive reporter imaging  
of ACT may provide additional theranostic capabilities.   
Because of reported dose-limiting toxicity, the number of modified T cells  
infused to patients is typically in the range of 1 ! 106 to 10 ! 106 T cells/kg [2, 3, 41,  
54], and target-mediated expansion and persistence of T cells is therefore a  
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prerequisite for substantive tumor destruction to occur. Indeed, it has been reported  
that higher peak expansion of infused T cells correlates with increased rates of disease  
remission [2, 54]. Tumor-bearing mice in the current study were treated with  
approximately 1.5 ! 106 SSTR2-CAR+ T cells at days 7–15 after xenograft.  
Subsequent longitudinal monitoring of both tumor growth and CAR T cell expansion  
at the tumor site enabled several observations to be made. Timely infusion of CAR T  
cells resulted in survival of all subjects without weight loss, while later treatments led  
to uniform death despite evidence of tumor killing by CAR T cells. Survivors  
exhibited a biphasic pattern of DOTATOC uptake within the lungs, with a similar  
luminescence pattern observed regarding primary lung tumors. A notable feature of  
this correlative pattern was that the peak DOTATOC signal, and therefore peak T cell  
expansion, lagged behind peak tumor burden by several days. This expansion of T  
cells past the onset of peak tumor burden in survivors may result from enduring  
cognate antigen–mediated signals, causing continued CAR T cell expansion before  
eventual exhaustion and contraction occurred [55]. Swift contraction of CAR T cells  
following peak expansion indicates that target antigen density has fallen to levels no  
longer capable of sustaining CAR T cell expansion and that tumor elimination was  
achieved without immediate relapse. The biphasic pattern of DOTATOC uptake in  
survivors stood in stark contrast to the unrelenting increases in both T cell and tumor  
burdens in nonsurvivors where tumor growth was evidently surpassing the rate of  
killing by T cells. It would be interesting to investigate whether a similar pattern is  
observed in additional tumor models and in clinical studies. Finally, DOTATOC  
uptake values obtained in the longitudinal study enabled comparisons with uptake  
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values derived from the SSTR2-titrated Jurkat model. This indicated that peak CAR T  
cell density in 8505C tumors ranged from below 1% at infusion to ~10% in survivors  
and to well over 10% in mice with high tumor burden.   
In conclusion, we have demonstrated a clinically adaptable, quantitative  
imaging system capable of specifically detecting adoptively transferred CAR T cells  
and monitoring their target-specific expansion and contraction at the tumor site with  
unprecedented detail. A simple method for estimating the density of solid tumor–  
infiltrating T cells has also been established. We anticipate that the SSTR2 system can  
be easily adapted to multiple ACT models and can facilitate efforts towards increasing  
our understanding of the parameters behind the success and failures of ACT with  
particular regard to monitoring systemic toxicities and the responses to solid tumors.   
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CHAPTER 4 
 
UTILIZING SSTR2 REPORTER TO STUDY THE DYNAMICS OF AFFINITY 
TUNING CAR-T THERAPY  
Summary  
 
1Adoptive transfer of high-affinity chimeric antigen receptor (CAR) T cells 
targeting hematological cancers has yielded impressive clinical results. However, 
safety concerns regarding target expression on healthy tissue and poor efficacy have 
hampered application to solid tumors. Here, a panel of affinity-variant CARs were 
constructed targeting overexpressed ICAM-1, a broad tumor biomarker, using its 
physiological ligand, LFA-1. Anti-tumor T cell potency in vitro was directly 
proportional to CAR affinity and ICAM-1 density. In a solid tumor mouse model 
allowing simultaneous monitoring of anti-tumor potency and systemic off-tumor 
toxicity, micromolar affinity CAR T cells demonstrated superior anti-tumor efficacy 
and safety compared to their nanomolar counterparts. Longitudinal T cell tracking by 
PET/CT and concurrent cytokine measurement revealed expansion and contraction 
kinetics of micromolar affinity CAR T cells and inflammatory cytokines. Therefore, 
we developed an ICAM-1-specific CAR with broad anti-tumor applicability that 
utilized a reduced affinity targeting strategy to significantly boost efficacy and safety. 
                                                
1This chapter was originally published in Scientific Reports (Park, S., Shevlin, E., 
Vedvyas, Y., Zaman, M., Park, S., Hsu, Y, Min,IM. And Jin, MM. SciEntific RePoRts 
| 7: 14366 | DOI:10.1038/s41598-017-14749-3 and is reprinted with permission. 
Vedvyas Y contributed CAR T vector construction, lentivirus production, Radiotracer 
sunthesis, PET imaging , Histology and cytokine analysis. This includes experiments 
and writing related to Figures 4.1, 4.4, 4.5, and 4.6. 
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Introduction 
CAR molecules are composed of synthetic binding moieties, typically an 
antibody-derived single chain fragment variable (svFv) or any native antigen-sensing 
element, fused to intracellular signaling domains composed of the TCR zeta chain and 
costimulatory molecules such as CD28 and/or 4-1BB[1, 2]. The advantages of CAR 
mediated targeting include: 1) the provision of activation, proliferation, and survival 
signals in-cis via a single binding event, compared to the natural, non-integrated TCR 
and costimulatory signaling; 2) the ability to bypass the downregulation of MHC by 
tumor cells through MHC-independent antigen recognition; and 3) a reduced 
activation threshold as well as recognition of tumor cells with low antigen density 
enabled by the high affinity interaction between CAR and antigen [3, 4]. As such, T 
cells modified with scFv-based CARs to recognize the pan B-cell antigen CD19 have 
demonstrated unprecedented remission rates in relapsed and refractory B cell leukemia 
and lymphomas[5-8]. However, CD19 CAR T cell therapies have also caused 
profound treatment-related toxicities, such as cytokine release syndrome, 
encephalopathy, B-cell aplasia, graft versus host disease, and coagulopathy [9]. In 
comparison, the advancement of CAR T cell therapy in solid tumors has been limited 
due to the scarcity of tumor antigens that are deemed safe for targeting. Thus far, 
clinical outcomes in solid malignancies have been poor in comparison to those in 
hematological settings [10, 11], and methods to improve efficacy are being actively 
investigated. 
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The ideal CAR target antigen would be a native, surface-exposed tumor 
neoantigen that is highly expressed and is undetectable in healthy tissues. However, 
due to the implicit rarity of such antigens, many commonly targeted solid tumor 
antigens, such as human epidermal growth factor receptor 2 (ErbB2), epidermal 
growth factor receptor (EGFR), mucine 1 (MUC1), prostate-specific membrane 
antigen (PSMA), and diganglioside (GD2)[10], are also expressed by non-tumor 
tissues, albeit at lower levels. CAR molecules with high affinity to such antigens can 
lead to collateral targeting of healthy tissues resulting in on-target, off-tumor toxicity, 
a major limiting factor to the progress of CAR T cell therapy to date. In the case of 
CD19-specific CAR T cells, elimination of healthy B cells is a manageable morbidity 
and therefore has not been a critical safety issue. However, recent reports on severe 
adverse toxicities and fatalities associated with CAR T cells in solid tumor 
settings[12-14] illustrate the importance of ligand-receptor pair selection and the role 
of affinity in determining the therapeutic index.  
The affinity of a TCR for its cognate pMHC typically ranges between 1-100 
µM, thus endowing T cells with tolerance towards cells with subthreshold levels of 
pMHC expression [15-17]. Similarly, T cells possessing micromolar affinity (1 µM) 
CARs are capable of lysing cells overexpressing target antigens while sparing those 
with much lower densities [18]. The affinity and avidity of a CAR for its target 
antigen also influences cytokine release, the rate of tumor killing, and T cell 
persistence [3, 18-20]. Studies using engineered TCRs with pMHC affinities 
significantly above their natural range caused T cells to exhibit rapid exhaustion and 
poor persistence in vivo[21-23]. Together, these studies emphasize the need to 
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reconsider the criteria used to determine optimal CAR affinities to achieve enhanced 
therapeutic indices.  
 
In this study, we redirected affinity variant CAR T cells toward intercellular 
adhesion molecule (ICAM)-1, a molecule that is upregulated in several carcinomas 
and the associated stroma[24] as well as  in inflammatory conditions[25]. Aside from 
diseased tissues, ICAM-1 is basally expressed in several cell types including 
endothelial cells, immune cells, and some epithelial cells [25]. The antigen-binding 
domain of the CAR used in this study is constructed from the native ligand for ICAM-
1, the inserted (I) domain of lymphocyte function-associated antigen (LFA)-1, which 
exhibits a solution affinity of approximately 1 mM[26]. Previously, the I domain was 
engineered using directed evolution to isolate variants exhibiting affinities to ICAM-1 
that span six orders of magnitude (KD ~1 nM to 1 mM)[27]. As human LFA-1 I 
domain exhibits the capability of cross reacting with both murine and human ICAM-1 
with comparable affinities[28], we were able to preclinically address potency against 
human tumors overexpressing ICAM-1 and simultaneously monitor potential on-
target, off-tumor systemic toxicity against normal mouse tissues expressing murine 
ICAM-1. We found that I domain CARs exhibiting affinities in the micromolar range 
(~10 µM) exhibited a significantly higher therapeutic index, while increasing the 
affinity further (1-100 nM) caused unbiased reactivity against normal cells with basal 
ICAM-1 expression and led to less efficient tumor regression. Simultaneous 
expression of a reporter gene, human somatostatin receptor 2 (SSTR2), on affinity 
variant CAR T cells utilized for longitudinal position emission tomography and 
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computed tomography (PET/CT) imaging [29] enabled spatiotemporal mapping and 
further evaluation of adoptively transferred T cells in vivo.  
 
Experimental Procedures 
Cell lines and primary human lymphocytes 
Human dermal microvascular endothelial cells (HMEC-1) were obtained from 
the Center for Disease Control and were cultured in MCDB 131 medium (Invitrogen) 
supplemented with 10% (v/v) fetal bovine serum (FBS, Atlanta Biologicals), 10 mM 
L-alanyl-L-glutamine dipeptide (Gibco), 100 units/ml Penicillin-Streptomycin (Pen-
strep), 1 µg/ml hydrocortisome (MP Biomedicals), and 10 ng/ml recombinant human 
epidermal growth factors (Invitrogen). Mouse brain microvascular endothelial cells 
(bEnd.3, ATCC) were maintained in Advanced Dulbecco’s Modified Eagle Medium 
(ADMEM, Invitrogen) supplemented with 4 mM L-glutamine, 100 units/ml Pen-strep, 
and 10% FBS. HeLa cells (ATCC) were cultured in ADMEM containing 10% FBS, 2 
mM L-glutamine, and 100 units/ml Pen-strep. 8505C cells (DSMZ) were cultured in 
RPMI-1640 medium (Invitrogen) containing 10% FBS, 2 mM L-glutamine, and 100 
units/ml Pen-strep. HMEC-1, bEnd.3, HeLa, and 8505c cells were transduced with 
lentivirus encoding Firefly Luciferase-F2A-GFP (Biosettia) and sorted based on 
fluorescence.  
Human peripheral blood was obtained from healthy volunteer donors by 
venipuncture. Peripheral blood mononuclear cells were isolated using Ficoll-Paque 
PLUS (GE Healthcare) and cultured in Optimizer CTS T-cell Expansion SFM 
(Thermo) supplemented with 5% human AB serum (Sigma), 2 mM L-alanyl-L-
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glutamine dipeptide, and 30 IU/ml human IL-2 (Cell Sciences) (T cell culture 
medium). Non-adherent cells were removed after 24h and enriched for T cells with 
Dynabeads CD3/CD28 T cell expander (Thermo) at a 2:1 bead to T cell ratio. 
Dynabead-bound T cells were subsequently cultured in IL-2 containing media at a 
density of 1 x 106 cells/ml. All cells were incubated at 37°C in a 5% CO2 humidified 
incubator. 
 
Construction of I domain CAR vector  
Genetic sequences encoding LFA-1 I domains of varying affinities to ICAM-1 
were derived from a previous study[27]. I domain variants were fused at the C-
terminus directly to the CD8 hinge, CD28 transmembrane domain, and the 
intracellular portions of the 3rd generation CAR architecture incorporating the 
cytoplasmic domains of CD28, CD137, and CD3!. The complete CAR inserts were 
then subcloned into a pLenti backbone [29]. A reporter gene for CAR T cell imaging, 
SSTR2, was linked to I domain at the N-terminus using a ‘ribosome skipping’ porcine 
teschovirus-1 2A (P2A) sequence to ensure comparable production of CAR and 
SSTR2 from the same mRNA. 
 
Lentivirus production and transduction of T cells  
Lentivirus was produced by transiently transfecting HEK 293T cells using 
calcium phosphate. Briefly, 10 !g of transfer gene, 7.5 !g of pCMV-dR8.2 (Addgene) 
and 5 !g of pCMV-VSVG (Addgene) were mixed and incubated with 2 M CaCl2 
followed by 2x HBSS. Resulting solutions were added dropwise to 10 cm2 cell culture 
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dishes seeded with 3.2 x 106 HEK 293T cells in 10 ml DMEM 24h previously. 
Transfection media was replaced after 6 h.  Media containing lentivirus was harvested 
at 48 and 72 h post transfection, filtered through 0.45 !m filters, and concentrated by 
ultracentrifugation at 75,000x g for 2 h at 4 °C. Lentivirus was then resuspended in 
serum containing media and frozen at -80 °C. Human T cells were transduced 24 – 72 
h post activation with anti-CD3/CD28 Dynabeads either by spinfection (1,000 g for 1 
h at 32 °C) or by overnight incubation with lentivirus. T cells were transduced once 
more 24 h after the first transduction. During and following transductions, media 
containing IL-2 was replaced with media containing human IL-7 (10 ng/ml) and IL-15 
(5 ng/ml) (Peprotech). Jurkat T cells were transduced by a single overnight incubation 
with lentivirus. 
 
In vitro target cell killing assay 
2 x 105 target cells (HMEC-1, bEnd.3, HeLa, and 8505c) stably transduced to 
express GFP and firefly luciferase were co-cultured with either non-transduced or I 
domain CAR T cells at varying effector to target ratios (E:T). In certain conditions, the 
ICAM-1 gene was disrupted in 8505C cells using CRISPR/Cas9 (Santa Cruz, #sc-
400098; denoted as 8505C/-ICAM-1) or, alternatively, 8505C cells were exposed to 1 
µg/ml lipopolysaccharide (LPS; Escherichia coli O26:B6, Sigma) for 12 h to induce 
overexpression of ICAM-1 (denoted as 8505C/LPS). Co-cultures were carried out in T 
cell culture medium containing 150 !g/ml D-Luciferin (Gold Biotechnology) and no 
cytokine supplementation.  Luminescence was measured using a plate reader (TECAN 
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infinite M1000 PRO) with readings in each E:T condition normalized to the non-
transduced T cell:target co-culture controls.  
 
8505C mouse model, whole-body tumor imaging, and serum cytokine analysis 
7.5 x 105 8505C cells were injected into NSG mice via tail vein. 1-3 x 106 T 
cells were injected via tail vein 8-10 days after tumor cell injection. Injection timing 
was chosen based on prior studies with R6.5 CAR T cells which demonstrated tumor 
elimination using similar CAR dosages at up to 10-days post xenograft[29]. 
Luminescence imaging of tumor xenografts in live mice was performed using a whole 
body optical imager (In-Vivo Extreme, Bruker). Mice were anesthetized with 2% 
isoflurane in 2 L/min O2. Tumor burden was quantified through integration of 
luminescence over chest cavity and the entire mouse body. For serum cytokine 
analysis, 50-100 µl of blood was collected via tail-vein into Eppendorf tubes on ice. 
Plasma was immediately isolated after removing cell pellet by centrifugation at 2,000 
g for 10 min at 4 °C, and stored at -80 °C. Human cytokines (GM-CSF, IL-2, IL-6, 
IFN-", TNF-#, CXCL10) were measured in duplicate using Bio-Plex MAGPIX (Bio 
Rad) according to the manufacturer’s instructions.  
  
Ex vivo cellular analysis  
Tumor xenografts were resected from mice at appropriate time points. 
Resected tumors were diced and flushed through 80 !m cell strainers to yield single 
cell suspensions. Red blood cells were lysed by incubation with 1x RBC lysis buffer 
(eBiosciences). Remaining cells were washed, re-suspended in 1x HBSS containing 
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2% normal goat serum, and blocked with mouse IgG at 2 !g/ml for 10 min. This was 
followed by staining with 1 !g/ml Propidium Iodide (Invitrogen) in combination with 
2 !g/ml mouse anti-human CD3-Alexa Fluor 647 (Biolegend) or 2 !g/ml rabbit anti-
c-myc-Alexa Fluor 647 (Biolegend). Resulting cells were acquired on a Gallios flow 
cytometer (Beckman Coulter). Initial flow cytometry gates were determined based on 
live cell gating (Propidium Iodide negative).  
 
ICAM-1 and CAR expression quantification 
ICAM-1 expression on various cell lines was determined using a mouse anti-
human R6.5 monoclonal antibody (10 !g/ml) obtained from hybridoma (ATCC). I 
domain CAR expression on T cells was detected using 2 !g/ml rabbit anti-c-myc-
Alexa Fluor 647 (Biolegend). I domain Jurkat T cell variants were incubated with 10 
!g/ml recombinant human ICAM-1 fused to human Fc" (R&D Systems). Cells were 
then washed and resuspended in 1 µg/ml rabbit anti-human PE (Santa Cruz 
Biotechnology) prior to flow cytometry analysis.  
 
In vitro measurement of IFN-! 
Target cells were washed and suspended at 1 # 106 cells/ml in T cell culture 
medium without cytokines. 100 µl of each target cell was added in triplicate to a 96-
well round bottom plate (Corning). T cells resuspended at 5 # 106 cells/ml in T cell 
culture medium were combined with target cells in appropriate wells. Plates were 
incubated at 37°C for 24 – 48 h. After incubation, supernatants were collected for 
ELISA to detect IFN-" (Biolegend). 
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CD25 and CD69 staining 
Jurkat cells modified with I domain CARs were co-cultured with target cells at 
an effector to target ratio of 1:1 (1 # 105 effectors: 1 # 105 targets) in a 96-well plate. 
The plate was incubated at 37 °C for 6 h. After incubation, cells were washed prior to 
labelling with 2 µg/ml anti-human CD25-allophycocyanin (APC; Biolegend) for 30 
min on ice. After incubation, samples were washed and analyzed by flow cytometry. 
As an alternative to ICAM-1 expressing cells, we also used microbeads coated with 
known amounts of ICAM-1. 1 x 106 sulfate latex microbeads (8 mm, ThermoFisher 
Scientific) were resuspended in 100 mL of PBS containing indicated amounts of 
human or murine recombinant ICAM-1-Fc" (R&D Systems) conjugated with Cy5.5 
(Sulfo-Cyanine5.5 NHS ester, Lumiprobe) overnight at room temperature with gentle 
mixing. Protein-labeled particles were pelleted and resuspended in fresh PBS 
containing 0.1 M glycine pH 7.4 for 1 h, while supernatant was used to measure bead 
adsorption efficiency by fluorescence (TECAN infinite M1000 PRO). After saturation 
of bead surface with glycine, beads were pelleted and resuspended in PBS containing 
5 mM MgCl2. Jurkat cells modified with each I domain CAR variant were incubated 
with ICAM-1-bound latex beads at 1:3 (cell:bead) ratio overnight at 37°C. Cells were 
then collected, labeled with 2 µg/ml anti-human CD69-APC (Biolegend) for analysis 
by flow cytometry.  
 
 
 
 157 
V-bottom adhesion assay 
V-bottom 96-well plates (Corning) were coated with either murine or human ICAM-1-
Fc" (10 µg/ml in PBS, pH 7.4) or 2% BSA at 4°C overnight. The plates were then 
blocked with 2% BSA for 1h at 37°C. I domain CAR T clones were first stained with 
CellTracker Orange according to manufacturer’s protocol and then added to ICAM-1-
coated wells in 50 µl of PBS containing 5 mM MgCl2 and 1% BSA. Plates were 
immediately centrifuged at 200 g for 15 min at room temperature. Nonadherent cells 
that accumulated at the bottom of the V-bottom plates were quantified by a 
fluorescence plate reader (TECAN infinite M1000 PRO). Cell binding to ICAM-1 was 
calculated from the fluorescence intensity values of experimental measurements (FCAR 
and FNT) and normalized to the fluorescence from the wells coated with BSA alone 
(FBSA): 100 x ((FBSA-FCAR)/FBSA)/((FBSA-FNT)/FBSA). 
 
Labeling of 18F-NOTA-octreotide (NOTAOCT) 
NOTAOCT (1,4,7-Triazacyclononane-1,4,7-triacetic acid-octreotide[30], GMP 
grade) was obtained as a 1 mg lyophilized powder (cat #9762, ABX Pharmaceuticals). 
The NOTAOCT vial content was diluted with 18 MW water to 200 µl (5 mg/ml 
solution) and stored at 4 ºC as a stock solution. For chelation of NOTA with Fluorine-
18[31], 5 µl of NOTAOCT was added to 10 µl of 0.1 M sodium acetate, pH 4, 6 µl of 
2 mM AlCl3, and 100 µl containing ~30 mCi 18F. The solution was immediately 
placed in a Thermomixer (Eppendorf) at 100 ºC and incubated for 15 minutes 
followed by cooling to room temperature and dilution in 15 ml ddH2O. A Sep-Pak 
light C18 column was regenerated in 3 ml 100% ethanol and washed twice in 5 ml 
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ddH2O with an observed flow rate of 10 drops per minute. NOTAOCT was then 
loaded to the Sep-Pak column, which was later washed in 15 ml 18 MW water to 
eliminate any remaining free 18F. Trapped NOTAOCT was eluted from the column 
using 300 µl of ethanol and diluted to 1.5 ml with PBS for injection, providing the 
final product in ~15% ethanol isotonic, injectable solution. The eluent was passed 
through 0.2 µm filter. The purity of the final product was checked by reverse phase 
HPLC. 
 
PET/CT imaging 
Registered CT images were acquired using a micro-PET/CT scanner (Inveon, 
Siemens) at 1-2 h post NOTAOCT injection. Projection data was acquired in a cone-
beam geometry with approximately 1 s steps at 1 degree angular increments. At least 
10 million coincidence events were acquired for PET per study using a 250 to 750 keV 
energy window and a 6 ns timing window. A reference tube containing 100 !l of a 10 
%ID/cm3 equivalent dose for quantification of NOTATOC uptake in vivo. To compute 
NOTAOCT uptake within mouse lungs, ellipsoids were drawn separately on the left 
and right sides of lungs to enclose the majority of their footprint. The %ID/cm3 values, 
computed relative to the counts obtained in the reference tube, were approximated to a 
standard uptake value (SUV [32]) by dividing %ID/cm3 by four, assuming injection 
efficiency of 100% and 25 g of body weight. Visualization and analyses of PET/CT 
images were performed using AMIDE software (http://amide.sourceforge.net). 
 
Histology  
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After euthanasia, mouse lungs were perfused via trachea with 4% 
paraformaldehyde, and each of five lobes were separated post fixation and embedded 
in paraffin. Tissues were cut to produce 5 !m sections (Microtome, Leica). Paraffin 
embedded sections were stained with hematoxylin and eosin (H&E) or hematoxylin 
only for CD3 and GFP immunostaining (performed by HistoWiz, Inc.). Histological 
analysis was performed by an experienced pathologist. 
 
Statistical analysis  
One-way ANOVA, Dunnett’s multiple comparisons test, and unpaired 
Student’s t-test were performed using Prism (GraphPad) on data indicated. 
 
Study Approval  
The protocol for blood draw from healthy volunteers was approved by the 
Institutional Review Board of Weill Cornell Medicine (Permit Number: 1302013613). 
All animal experiments were performed in strict accordance with the 
recommendations contained within the National Institute of Health’s Guide for the 
Care and Use of Laboratory Animals. Animal handling protocols were approved by 
the Institutional Laboratory Animal Use and Care Committee of Weill Cornell 
Medicine (Permit Number: 2012-0063). 
 
Results. 
ICAM-1 specific CAR T cells with 106-fold, step-wise variation in affinity.  
 160 
 161 
Figure 4.1 Construction of ICAM-1 specific CARs with step-wise, 106-fold 
variations in affinity. (a) Schematic of LFA-1 in complex with ICAM-1. # and $ 
chains, and modular domains of LFA-1 integrin are labeled. Metal ions necessary for 
LFA-1 and ICAM-1 interaction are shown in circles. (b) Structural model of LFA-1 I 
domain and the N-terminal domain of ICAM-1 (D1) are drawn in ribbon diagram. N 
and C-termini, and mutational hot spots are indicated. (c) SPR sensogram of I domain 
variants binding to immobilized human ICAM-1, except F265S/F292G*, which was 
flowed over murine ICAM-1 (adapted from Fig 2 of Jin et. al.[33], and Fig 1 of Wong 
et. al[34]). (d) A schematic of the lentivirus vector encoding I domain CAR. LTR = 
long terminal repeat; SD = splice donor; SA = splice acceptor; %+ = packaging signal; 
SS = signal sequence; TM = transmembrane; Cyt = cytosolic domain. (e) Anti-Myc 
antibody binding to Jurkat T cells transduced with Myc-tagged CARs (TM, F292G, 
F292A, and WT I domain). NT = non-transduced. (f) Recombinant ICAM-1-Fc 
binding to CARs expressed in HEK 293T cells. (g) V-bottom adhesion assay 
measuring relative binding affinities between I domain CARs expressed in Jurkat T 
cells and soluble human (top) and murine (bottom) ICAM-1 (CD54) coated surfaces. 
n=3; p < 0.01 for * vs. NT by Dunnett’s multiple comparisons test. 
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CAR constructs specific to ICAM-1 were built using the I domain derived from LFA-
1 (Figure 4.1a,b). Various activating point mutations in the I domain have previously 
been isolated, which were localized outside of the binding interface that includes a 
region known as the metal-ion dependent adhesion site (MIDAS) (Figure 4.1b). The  
step-wise elevation of affinity to ICAM-1 is proposed to be induced by lowering the 
energy barrier of the transition from inactive (closed) to active (open) conformations. 
For example, substitution of Phe-292 located in the C-terminal $7-helix with Ala 
(F292A) and Gly (F292G) led to affinities (KD) of ~20 !M and 0.1 !M, respectively 
(Table 1). The combination of F292G with another comparably activating mutation in 
Phe-265 (F265S/F292G) led to an affinity of 6 nM, approximately 200,000-fold 
higher than the wild-type (WT) I domain (KD = 1.5 mM) (Figure 4.1c). To lock the C-
terminal $7-helix of F265S/F292G in the open position (Figure 4.1a), Gly-311 was 
replaced with Cys (G311C) in the F265S/F292G mutant (F265S/F292G/G311C, 
dubbed triple mutant or TM) to form a disulfide bond with the naturally unpaired Cys-
125 (Table 1). Therefore, the monovalent affinities of individual I domain variants for 
ICAM-1 span approximately six orders of magnitude (KD ~1 nM to 1 mM), as 
measured by surface plasmon resonance (SPR) or estimated by flow cytometry (Figure 
4.1c; Table 1). Human I domain binds murine ICAM-1 with comparable affinity to 
human ICAM-1 (2 nM vs. 6 nM respectively; Figure 4.1c). Cross-reactivity with its 
murine homologue enables examination of on-target, off-tumor toxicity of I domain 
CAR T cells concurrently with on-target, on-tumor efficacy in preclinical mouse 
models with human tumor xenografts. In comparison, the R6.5 scFv (derived from the  
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Table 1. Measured affinity of LFA-1 I domain to 
ICAM-1 
Name Sequence Affinity 
Wild-type (WT) G128-G311 1.5 mM* 
F292A G128-G311  20 µM* 
F292G G128-G311 119 nM* 
F265S G128-G311 145 nM* 
F265S/F292G (DM) G128-G311 6 nM* 
F265S/F292G/G311C (TM) E124-S313 ~1 nM* 
R6.5 scFv 10 nM** 
*SPR measurements; **Estimated from titrated R6.5 
antibody binding to HeLa cells[35].  
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mouse hybridoma clone, R6.5[36]) has a Kd of 10 nM for human ICAM-1 (Table 1) 
but does not cross-react with murine ICAM-1.  
To test whether the mutant I domain affinities correlate with CAR affinities, 
HEK 293T and Jurkat T cells were transduced with lentivirus encoding 3rd generation 
CARs containing TM, F292G, F292A, or WT I domain, and assayed for ICAM-1 
binding. A myc tag was appended to the N-terminus of each I domain variant to aid 
measurement of CAR expression (Figure 4.1d,e). To avoid background ICAM-1 
binding to endogenous LFA-1 in Jurkat T cells, CAR affinity for ICAM-1 was 
estimated using the I domain CAR-transduced HEK 293T cells. The level of 
recombinant human ICAM-1 binding to I domain CAR-expressing HEK 293T cells 
correlated with solution affinity measurements, with TM exhibiting the strongest 
binding, followed by F292G and F292A, and no detectable binding to WT compared 
to non-transduced (NT) T cells (Figure 4.1f). Differential CAR affinities for ICAM-1 
and cross-reactivity with murine ICAM-1 were also examined by measuring cell 
adhesion to V-bottom plates coated with recombinant human or murine ICAM-1 
(Figure 4.1g). Jurkat cells transduced with TM and F292G CARs demonstrated a 
higher level of binding to both human and murine ICAM-1 compared to non-
transduced cells. However, despite increased binding of recombinant ICAM-1 to 
F292A CAR-expressing HEK 293T cells compared to their WT I domain-expressing 
counterparts (Figure 4.1f), F292A CAR-Jurkat cells lacked any additional binding to 
plate-bound ICAM-1 compared to NT or WT I domain-expressing cells (Figure 4.1g). 
In the case of F265S I domain, which demonstrated soluble ICAM-1-binding 
comparable to F292G (145 vs. 119 nM, Table 1), F265S CAR T cells failed to 
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demonstrate any additional binding to plate-bound human ICAM-1 while elevated 
binding was more apparent to murine ICAM-1. As anticipated, T cells transduced to 
express R6.5 CAR, which is specific to human ICAM-1 only, exhibited elevated 
binding to human but not to murine ICAM-1 (Figure 4.1g).  
 
Influence of CAR affinity and target antigen density on CAR T cell activation in vitro.  
 Jurkat T cells expressing I domain CARs were used to examine the extent to 
which CAR T cell activation was influenced by CAR affinity and ICAM-1 antigen 
density in target cells. Jurkat T cells were incubated with various target cell lines with 
different ICAM-1 expression levels (Figure 4.2a). ICAM-1 surface densities of target 
cell lines were estimated by first assaying the levels of anti-ICAM-1 antibody binding 
to them and comparing these signals to those obtained using latex beads pre-coated 
with known amounts of the same antibody (Figure 4.2a; top panel). The panel of target 
cells include: HMEC-1 and bEnd.3, representing, respectively, healthy human and 
mouse cells with physiological levels of ICAM-1 (~104 molecules per cell); anaplastic 
thyroid carcinoma (8505C) expressing an intermediate level (~105 per cell); and 
cervical cancer (HeLa) cell lines expressing a high level of ICAM-1 (~106 per cell). 
For additional comparisons, we included 8505C with CRISPR/Cas9-mediated ICAM-
1 gene inactivation (8505C/-ICAM-1) and 8505C treated with LPS to upregulate 
ICAM-1 expression (8505C/LPS). Activation of CAR T cells upon interaction with 
target cells was examined by measuring CD25 (IL-2 receptor #) and CD69 expression 
(Figure 4.2b,c). Elevated levels of CD25 were observed in WT I domain CAR T cells 
following incubation with LPS-stimulated 8505C but not with other cell lines  
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Figure 4.2 Affinity and antigen-density dependent activation of Jurkat CAR T 
cells in vitro. (a) Top, histograms depicting 8 µm latex beads coupled with known 
amounts of R6.5 antibody conjugated with cy5.5 (103-107 antibodies per bead). The 
level of shift after incubation with R6.5 (black) from non-labeled (grey) was used to 
estimate ICAM-1 density in each indicated target cell line. 8505C/-ICAM-1; 8505C 
cells with ICAM-1 gene inactivation by CRISPR/Cas9. 8505C/LPS, 8505C cells were 
incubated with LPS to induce overexpression of ICAM-1. (b) CD25 expression in 
Jurkat CAR T cells (WT, F292A, F292G, and TM) after co-incubation with different 
target cell lines for 24 h (n = 3-4). p < 0.01 for * vs. 8505C/-ICAM-1 by Dunnett’s 
multiple comparisons test. (c) Induction of CD69 after incubation with latex beads 
coated with 106 recombinant human ICAM-1-Fc molecules. Histograms correspond to 
CD69 expression in Jurkat cells without (thin, dotted line) and with (think) bead 
incubation. (d) ICAM-1 expression in Jurkat T cells compared to HeLa cells. Grey and 
black histograms correspond to unlabeled cells and R6.5 antibody-labeled cells, 
respectively.
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expressing lower levels of ICAM-1 (Figure 4.2b). In contrast, increased CD25 
expression was seen when high affinity TM CAR T cells were incubated with high 
ICAM-1 expressing cells as well as with HMEC-1 and bEnd.3 cells expressing basal 
levels of ICAM-1. A low-level of CD25 expression was detected on TM CAR T cells 
following incubation with target cells lacking ICAM-1 expression (8505C/-ICAM-1), 
likely due to homotypic cellular contacts mediated by molecular interactions between 
TM CAR and basal expression of ICAM-1 on Jurkat cells (~104 molecules/cell; Figure 
4.2e). T cells expressing F292G behaved similar to TM, except that CD25 expression 
was close to background levels following co-incubation with 8505C/-ICAM-1. The 
micromolar affinity F292A T cells demonstrated selective activation displaying 
elevated CD25 expression only upon incubation with 8505C and 8505C/LPS cells 
(Figure 4.2b). This indicates that a threshold target antigen density of  >105 ICAM-1 
molecules per cell was required for F292A CAR T cell activation. In contrast to the 
ICAM-1 density-dependent activation of CD25, increased CD69 expression was 
observed even in the absence of target cells, with expression levels aligning closely 
with CAR affinity to ICAM-1, which was not further enhanced by incubation with 
ICAM-1 coated latex beads (Figure 4.2c). Compared to CD25, CD69 induction 
appeared to require a lower level threshold of antigen density for activation, which 
was provided by homotypic interaction between CAR T cells.  
 
Influence of CAR affinity and target antigen density on CAR T cell cytotoxicity in 
vitro.  
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After validating affinity and antigen-dependent activation of CAR-modified 
Jurkat T cells, we sought to examine the influence of CAR affinity and antigen density 
on primary T cell activation and cytotoxicity in vitro. Primary T cells were transduced 
with TM, F292A, F292G, and WT I domain CARs, and added to various target cells 
to determine their cytotoxic efficacy in vitro. Overall, there was a positive correlation 
between the rate of target cell lysis and ICAM-1 expression (HeLa > 8505C/LPS > 
8505C > HMEC-1 > bEND.3) across all I domain variant CAR T cells (Figure 4.3a). 
The rate of killing was also faster when T cells expressed CARs possessing higher 
affinity for ICAM-1 (TM > F292G > F292A > WT). To quantitatively compare the 
efficacy of killing by affinity variant CAR T cells, a variable slope sigmoidal curve 
(%live = 100/[1+10(t-&_50%)* Slope]) was used to find the best fit values describing the 
time required to achieve 50% killing (&_50%) and the Hill slope (Figure 4.3b). The 
time to 50% target killing was longer with either lower affinity CAR T cells or lower 
antigen density for the same CAR T cells. The Hill slope, corresponding to the rate of 
target killing by CAR T cells, was higher with increases in affinity (lower Kd) for the 
same target cells. The Hill slope was also greater with increases in antigen density for 
the same CAR T cells. CAR T cell killing of target cells was specific as evidenced by 
the lack of observed killing of ICAM-1 negative 8505C cells by all of I domain variant 
CARs except TM. Low yet gradual killing of 8505C/-ICAM-1 by TM T cells was 
likely due to cytotoxic activation caused by homotypic cellular contacts mediated by 
TM interaction with ICAM-1 in T cells. ICAM-1 expression in primary T cells can be 
induced after T cell activation such as by incubation with CD3/CD28 beads (~105 
molecules/cell; Figure 4.3c). In comparison, WT CAR T cells possessing millimolar 
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affinity (Kd = 1.5 mM) could specifically lyse HeLa cells only, indicating a threshold 
antigen density of approximately 106 molecules per cell for ~1 mM Kd CAR T cells. 
Importantly, F292A and WT I domain CAR T cells (Kd > 10 µM) were unreactive to 
human and murine healthy control cells, HMEC-1 and b.END3 (~104 per cell; Figure 
4.3a). Likewise, IFN-" release by CAR T cells aligned closely with the rate of target 
cell death, where increasing levels were found in co-cultures containing higher affinity 
CAR T cells and/or higher levels of target antigen expression (Figure 4.3d). One 
exception to target antigen density-dependent IFN-" release was TM and F292G, 
which showed significant amounts of IFN-" release (>1 ng/ml) in the absence of target 
molecules (8505C/-ICAM-1). This is again likely due to the homotypic interactions 
between T cells, which is also supported by the observation of the difficulty with 
expanding TM CAR T cells, particularly when the level of CAR expression was high. 
Release of IFN-" by micromolar affinity CAR T cells (F292A) was in proportion to 
the ICAM-1 density in target cells, demonstrated by a lack of release upon incubation 
with 8505C/-ICAM-1, and progressively increasing with incubation with HMEC-1, 
8505C, 8505C/LPS, and HeLa in this order (Figure 4.3d). Consistent with WT I 
domain’s cytotoxicity toward HeLa cells, IFN-" release upon incubation with HeLa 
was comparable to the levels secreted by other higher affinity CAR T cells.  
 
In vivo efficacy of affinity-tuned I domain CAR T cells.  
We examined how affinity-dependent CAR T cell cytotoxicity patterns in vitro 
would translate to tumor xenograft models in vivo. In solid tumors, CAR T cell  
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Figure 4.3 Affinity and antigen-density dependent activation of primary CAR T 
cells in vitro. (a) Effector to target (E:T) assay for measuring target killing by primary 
T cells transduced with different I domain CARs. Each target was separately incubated 
with TM, F292G, F292A or WT CAR T cells at 5:1 E:T ratio. Percent viability was 
normalized to luminescence from target cells incubated with NT T cells (n=3, ± = 
standard deviation (SD)). A variable slope sigmoidal curve equation was used to fit 
data. p < 0.01 for * vs. NT by Dunnett’s multiple comparisons test. (b) The best fit 
values of 50% killing and Hill slope of the sigmoidal equation were plotted against the 
affinities of I domain CARs. The best fit values with r-square values higher than 0.85 
were plotted. (c) ICAM-1 expression in primary T cells in comparison to HeLa cells. 
Grey and black histograms correspond to unlabeled cells and R6.5 antibody-labeled 
cells, respectively. (d) IFN-" release was measured by ELISA for each CAR T variant 
after co-incubation with different target cells for 24 h (n=3). p < 0.01 for * vs. 
8505C/-ICAM-1 by Dunnett’s multiple comparisons test. 
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efficacy is influenced by their ability to traffic to tumor sites, penetrate, serially lyse 
tumor cells, and undergo expansion and contraction in accordance with tumor burden. 
Here, mice were xenografted by systemic i.v. injections of 0.75x106 8505C-
FLuc+GFP+ cells followed by treatment with ~1-3x106 I domain CAR T cells (WT, 
F292A, F265S, F292G, and TM), SSTR2-R6.5 CAR[29], NT T cells, and no T cells at 
8-10 days post-xenograft (5-20% CAR expression). Tumor burden was evaluated by 
whole-body luminescence imaging of firefly luciferase activity. Primary tumors 
localized to the lungs and liver with distant metastatic foci evident throughout the 
body (Figure 4.4a). Cohorts receiving either no T cells or NT T cells succumbed to 
tumor burden within 3-4 weeks of tumor inoculation. Mice treated with TM CAR T 
cells displayed rapid initial reductions in tumor burden; however, at approximately 7 
days post T cell injection, mice began to show symptoms of systemic toxicity 
indicated by lethargy and weight loss, resulting in death by day 15 post treatment 
(Figure 4.4a,b). F292G CAR T cells were capable of tumor elimination with 
inconsistent toxicity development, which appeared to be partially dependent on tumor 
burden at the time of CAR T cell treatment. For example, either delayed infusions of 
F292G CAR T cells (day 10) or higher tumor burden at the time of treatment led to 
more frequent deaths. T cells expressing F265S CARs (Table 1), eliminated tumors 
without observable toxicity. This suggests that an I domain CAR affinity of ~100 nM 
Kd defines an approximate threshold affinity above which treatment leads to reduced 
discrimination between high and low antigen densities and an increased likelihood of 
on-target off-tumor toxicity. Consistent with limited or lack of killing of 8505C by 
WT CAR T cells in vitro, tumor progression in vivo was unimpeded by the treatment,  
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Figure 4.4 Micromolar affinity CAR T cells provide superior tumor eradication, 
suppression of tumor relapse, and survival benefit. (a) Whole-body luminescence 
imaging was used to estimate tumor burden in mice infused with different CAR T cell 
variants 8 days post-tumor implantation. No T = mice received no T cells. (b) Mice 
were treated with CAR T cells 10 days post tumor implantation. NT = non-transduced 
T cells. (c) Luminescence measurements of mice treated with different CAR T cells. 
Individual lines indicate luminescence values from each mouse. P values of two-tailed 
student’s t-test versus NT (n = 3) are not-significant for No T (n = 8), p<0.001 for 
F292A (n = 8) and F292G (n = 5), and p<0.05 for TM (n = 5). (d) Survival curves of 
mice receiving different treatments. Log-rank (Mantel-Cox) test P values versus NT 
are not-significant for No T and TM, and p = 0.008 for F292G, p = 0.025 for R6.5, and 
p = 0.0016 for F292A. 
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similar to NT T cells (Figure 4.4b). In contrast, F292A CAR T cells, which exhibited a 
much slower in vitro rate of 8505C killing compared to its higher affinity counterparts, 
achieved rapid reductions in tumor burden with no apparent toxicity irrespective of 
treatment timing (Figure 4.4a-c). Moreover, F292A CAR T in vivo efficacy was 
superior to the scFv-based R6.5 CAR despite >1,000-fold lower affinity to ICAM-1 
(10 nM vs. 20 !M), as evidenced by a faster rate of tumor clearance and durable 
suppression of tumor relapse (Figure 4.4a). Overall, the anti-tumor efficacy of I 
domain CAR T cells led to statistically significant increases in cohort survival 
compared with no T or NT T cell treated mice (Figure 4.4d). However, CAR T cell-
treated mice even with no to little tumor burden began to show signs of toxicity (e.g., 
weight loss, loss of fur) that eventually led to frequent death ~10 weeks after T cell 
injections. This was suspected to be related to graft-versus-host disease[37] and not 
on-target, off-tumor toxicity as similar toxicities were observed in mice treated with 
R6.5 CAR T cells that exclusively target human ICAM-1.  
 
Cellular analysis of CAR T cell efficacy and toxicity.  
Cellular analysis of tumor and T cells by flow cytometry revealed the cause for 
systemic toxicity induced by high affinity CAR T cells, such as TM. Similar to the 
previously observed biphasic expansion and contraction response of human ICAM-1-
specific, R6.5 CAR T cells[29], TM CAR T cells also exhibited gradual expansion 
concurrent with reductions in tumor burden. However, in contrast to R6.5 CAR, TM 
CAR continued to expand even after tumor elimination, eventually accounting for 
~50% of live cells in the lungs at the time of death or sacrifice (Figure 4.5a). This  
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Figure 4.5 Analysis of systemic toxicity by flow cytometry and histology. (a) Flow 
cytometry analysis of cells harvested from the lungs of non treated (No T) or treated 
(TM CAR) mice. GFP and CD3 were used as markers of 8505C tumor and T cells, 
respectively. Mice treated with TM CAR T cells were sacrificed at different time 
points to represent the association between tumor burden and TM CAR T cells. (b) 
Lung tissues harvested from untreated mice and mice treated with TM and F292A 
CAR T cells were processed for H&E, GFP and CD3 staining. The scale bar in each 
image is 2 mm. Tissue sacrifice time points are indicated on the left. For example, 
X20T10 represents 20 days post tumor xenograft and 10 days post T cell infusion. (c) 
Murine ICAM-1 expression in lung cells harvested from tumor-bearing mice after 
treatment with TM CAR T cells. 
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expansion of TM CAR T cells in the absence of or with very low tumor burden was 
also confirmed by histology (Figure 4.5b). Compared to the heavy tumor burden in 
lungs of untreated mice, the lungs from mice treated with TM CAR T cells exhibited 
sparsely distributed tumor cells while demonstrating heavy infiltration with CD3 
positive T cells. In comparison, the lungs of mice treated with F292A CAR T cells 
were almost entirely tumor-free with only sparsely distributed T cells present, 
indicative of the T cell contraction observed previously with R6.5 CAR T cells after 
tumor elimination in the same model[29]. The near uniform systemic toxicity 
observed in mice treated with TM CAR T cells appeared to depend on the initial 
presence of tumor as there was no apparent systemic toxicity observed in non-tumor 
bearing mice that received TM CAR T cells (4/4 mice surviving more than 2 months 
after T cell infusion). We speculate that TM and at times, F292G CAR T cells reacted 
with murine ICAM-1 that was upregulated in response to exposure to inflammatory 
cytokines secreted by CAR T cells or lysed tumor cells during interaction with human 
ICAM-1-expressing tumors. Indeed, similar to the induction of ICAM-1 in the lungs 
by LPS in our previous study [38], ~50% of live lung cells from TM CAR T-treated 
mice stained positive for murine ICAM-1, compared to much lower expression and 
percentage of ICAM-1 stained cells from non-tumor bearing or tumor-xenografted 
mice without T cell treatment (Figure 4.6 a&b in Kang et al.,[38]; Figure 4.5c). 
 
Real-time imaging of CAR T cell kinetics, efficacy, toxicity, and correlation with 
cytokine profiles.  
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To spatiotemporally monitor T cell distribution in real-time by PET/CT, we 
introduced an imaging reporter gene, SSTR2 into the I domain CAR vector using a 
ribosome skipping P2A sequence to ensure equal expression of CAR and the reporter 
on the surface of T cells (Figure 4.6a). Expression of SSTR2 enables binding and 
intracellular accumulation of an infused, positron-emitting, SSTR2-specfic radiotracer, 
18F-NOTA-Octreotide[30]. Emitted signals can then be detected with high resolution 
with no tissue penetration issues by a micro PET scanner. Expression of SSTR2 and 
Myc tagged I domain was confirmed by antibody staining, although higher level of 
binding was found with SSTR2 antibody (Figure 4.6b). Mice were xenografted with 
8505C tumors as before, and were treated with NT, F292A, or F292G CAR T cells. 
Whole-body luminescence imaging was performed to estimate tumor burden while 
PET/CT imaging was performed on the same day to track CAR T cell distribution 
(Figure 4.6c). At each time point, blood was collected to measure human cytokines for 
correlation with T cell dynamics. PET/CT images in mice displayed expected 
background levels in gall bladder, kidneys and bladder caused by radiotracer excretion 
(Figure 4.6c; far-right). In the NT treated control cohort, a small but gradual increase 
in non-specific tracer uptake was observed, which was due to increasing tumor burden 
and the associated increase in blood pooling (Figure 4.6c,d). In contrast, specific tracer 
uptake was observed in mice treated with SSTR2-F292A CAR T cells, demonstrating 
the expansion and contraction phases in the lungs, with peak CAR T cell signal 
occurring approximately 4 days following peak tumor burden and gradually 
decreasing to background levels (Figure 4.6c,d). This biphasic T cell expansion and 
contraction phenomenon was reminiscent of our previous study using SSTR2-R6.5  
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Figure 4.6 Longitudinal, concurrent measurements of tumor burden, T cell 
distribution, and cytokine release. (a) Schematic of SSTR2-I domain vector. (b) 
Flow cytometry measurements of SSTR2 reporter gene and Myc-tag expression 
representing CAR on the surface of primary human T cells. Thin and thick histograms 
represent T cells with and without antibody labeling, respectively. (c) Longitudinal 
measurements of NOTAOCT uptake by PET/CT (top half of each panel), and tumor 
burden by whole body luminescence imaging (bottom half of each panel). Images are 
representative of four mice in each cohort. Whole body PET/CT images, taken on the 
day of maximum tracer uptake, are shown on the far right. Imaging time points are 
indicated below the bottom panel. For example, X15T7 represents 15 days post tumor 
xenograft and 7 days post T cell infusion. (d) Quantification of luminescence and 
tracer uptake in the lungs of mice treated as indicated. (e) Cytokine levels measured 
from blood drawn at various time points from the same mice in ‘c’ and ‘d’ are plotted 
(mean ± SD, duplicate measurements). 
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CAR T cells in the same mouse tumor model[29]. Cytokine analysis of serum 
obtained from treated mice demonstrated a surge in IFN-", IL-6, and CXCL10 
concentrations prior to peak T cell expansion, which also returned to background 
levels post tumor elimination and following contraction of T cell density in the lungs 
to background levels (Figure 4.6e). F292G CAR T-treated mice showed similar yet 
lower T cell expansion in the lungs, with a peak T cell density being nearly concurrent 
with the maximum tumor burden. The serum cytokine profile was similar to that 
observed in F292A CAR T-treated mice. Again, in some instances treatment with 
F292G CAR T led to host mortality, likely due to on-target, off-tumor toxicity. This 
was clearly evidenced by a gradual increase in F292G CAR T cell presence in lungs 
and other organs, as detected by PET/CT imaging, leading to a tracer uptake of ~6% 
ID/cm3 even after tumor clearance. Based on our previous study, we estimate that this 
level of uptake corresponds to a T cell density in lungs that is significantly above 10% 
(which gave ~3 ID/cm3 in 10% SSTR2 positive Jurkat mosaic tumors). The level of 
tracer uptake, far higher than T cell peak from interaction with tumor, was reminiscent 
of the case with TM CAR T cells, where T cells accounted for >50% of total cells in 
lungs post tumor eradication (Figure 4.5a).  
 
Discussion 
The paucity of native, surface-expressed, and tumor-specific antigens presents 
a significant hurdle to developing CAR T cell therapy against solid cancers[39, 40]. 
Conventional CARs are constructed using a single-chain antibody format, and are 
selectively engineered to possess sub- to low nanomolar affinities for target antigens. 
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However, increased CAR T cell sensitivity may be an advantage only when targeting 
true tumor antigens or those with the highest levels of restriction[17, 39]. Otherwise, 
increased sensitivity comes at the price of reduced selectivity with lysis of target-
expressing cells in a manner largely insensitive to antigen density[18]. By functionally 
investigating CAR affinities spanning step-wise across a 106-fold range, concurrently 
with target cells with varying levels of antigen expression, we systematically 
examined the influence of CAR affinity and antigen density on T cell efficacy in vitro 
and in vivo. T cell activation status in vitro, as measured by CD25, cytokine release, 
and cytotoxicity, was to a remarkable degree dependent on affinity and target antigen 
density, resulting in more potent T cell activation and target killing with increases in 
CAR affinity and antigen density. The activation threshold of nanomolar affinity CAR 
T cells (TM, F292G) was less dependent on antigen density compared to the 
micromolar affinity CAR T cells (F292A), reacting to antigen density as low as 104 
molecules/cell. In contrast, F292A CAR T cells rapidly lost the ability to lyse cells 
expressing target antigens below 105 molecules/cell. Millimolar affinity CAR T cells 
(WT) were largely unreactive to target cells with low to moderate levels of antigen, 
requiring a threshold antigen density of 106 molecules/cell for detectable activation, 
cytokine release, and target lysis to occur. The quantitative harmony between CAR 
affinity and anti-tumor potency in vitro was discordant with quantitative in vivo 
observations whereby micromolar affinity CAR T cells were superior to higher 
affinity CAR T cells as measured by the rate of expansion at the tumor site, the rate of 
tumor eradication, frequency of tumor relapse, and levels of on-target, off-tumor 
toxicity.  
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The ability of I domain CAR T cells to cross-react with murine ICAM-1 
allowed for a rigorous and simultaneous assessment of CAR T cell efficacy against 
human tumor cells and on-target, off-tumor toxicity against murine ICAM-1 on 
healthy tissues. Onset of toxicity appeared to be dependent on CAR affinity and 
tumor-burden, as demonstrated by the uniform fatalities in mice treated with the 
highest affinity (TM) CAR T cells, the increased rate of toxicity observed in F292G 
CAR-treated mice with larger tumor burden, and the absence of detectable toxicity 
after treatment with micromolar affinity F292A CAR T cells. The relationship 
between tumor-burden and CAR-mediated toxicity is likely a consequence of ICAM-1 
biology. ICAM-1 is an inducible adhesion molecule that is sensitive to inflammatory 
stimuli and the tumor-related inflammatory milieu[41-44]. We suspect that cytokine-
induced ICAM-1 overexpression is a reason for the onset of toxicity mediated by the 
high affinity CAR T cells, demonstrated by the lack of apparent toxicity following TM 
CAR T treatment in non-tumor bearing animals. This observation suggests that either 
ICAM-1 density is below the threshold antigen density for TM (104 molecules/cell) or 
the cells expressing ICAM-1 above this threshold are not exposed to TM CAR T cells. 
Leukocyte adhesion and diapedesis requires LFA-1 to be in an activated, open 
configuration along with concurrent upregulation of ICAM-1 on endothelial cells[45]. 
This augments the hypothesis that ICAM-1 upregulation on healthy tissues is also 
necessary for activation of even nanomolar affinity I domain CAR T cells. Rapid 
expansion of CAR T cells in response to growing tumor burden may drive local 
concentrations of inflammatory cytokines to breach the antigen threshold to cause both 
F292G and TM CAR T cells to become fatal to the host despite the approximately 
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100-fold difference in affinity. Despite induction of similar peripheral concentrations 
of inflammatory cytokines (IFN-", IL-6, and CXCL10) in mice treated with F292G or 
F292A CAR T cells, local or systemic toxicity by F292A CAR T was not observed. 
Given the estimated threshold antigen density requirement of ~105/cell for F292A 
mediated-cytotoxicity to occur, we speculated that inflammation-induced murine 
ICAM-1 may still be below this threshold. Systemic toxicity and fatality were also 
absent in animals treated with F265S CAR T cells. The F265S CAR demonstrated 
weaker binding to plate-bound ICAM-1 in vitro compared to F292G CAR despite 
their comparable solution affinity to ICAM-1.  
To investigate the mechanics of affinity-variant CARs in vivo, we employed 
longitudinal and concurrent measurements of cytokine release, T cell distribution, and 
tumor killing. In our model, high concentrations of IFN-", IL-6, and CXCL10 were 
measured as early as 7 days post-infusion of T cells, indicating that infused T cells 
were engaging their target and proliferating. In agreement with our previous study 
using R6.5 CAR T cells targeting human ICAM-1 only[29], there was a time delay 
between  peak tumor burden and peak I domain CAR T cell expansion as measured by 
PET/CT. The swift reduction in tumor burden and CAR T cell numbers at the tumor 
site, along with the resolution of inflammation as measured by cytokines, is indicative 
of therapeutic efficacy in a manner similar to classical infection scenarios[46, 47]. 
This biphasic response is absent in situations where CAR T cells fail to properly 
control tumor growth[29]. The onset of cytokine release detected prior to observable T 
cell expansion by PET/CT using the SSTR2 radiotracer suggests that any 
improvement on imaging sensitivity (currently 1% SSTR2+ T cell density within 
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tumors) can shorten this imaging latency period and aid in determining if heightened T 
cell activity is at on- or off-target sites. Peak serum IL-2 levels were determined to be 
relatively low (<50 pg/ml) in comparison to IFN-", IL-6, and CXCL10 levels. As 
severe cytokine release syndrome was determined as the cause of death in some 
patients enrolled in CD19-targeting CAR T cell trials, our cytokine kinetics data 
suggests that blood analysis immediately after T cell infusion will be critical to 
estimate T cell activity. Once a cytokine surge is observed, patients receiving tumor-
targeted T cells expressing SSTR2 can be subjected to PET/CT to examine the T cell 
distribution profile and determine whether they are expanding at the tumor site, 
indicating T cell killing of tumor, or, if they are expanding away from the tumor, 
indicating the onset of off-tumor toxicities. In our study, the continued expansion of 
the nanomolar affinity F292G CAR T cells despite elimination of tumors was likely 
caused by activation of CAR T cells by inflammation-induced ICAM-1. Such 
instances of off-tumor T cell expansion in patients could be easily diagnosed and 
localized by imaging techniques such as PET/CT, which we anticipate will be 
increasingly utilized in future adoptive T cell trials to provide detailed trafficking 
information and thus aid general therapy development including dosing protocols and 
intervention strategies to avoid harmful or even fatal toxicities by administered 
cells[48, 49].  
The functional goal when creating affinity tuned CAR T cells in prior studies 
has been to minimize off-tumor toxicity against basally expressed antigens in normal 
tissues[18, 50]. However, we believe that CARs possessing affinities in the 
micromolar range may be superior to those in the nanomolar range for additional 
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reasons. Engagement of target antigen by nanomolar affinity CAR T cells (e.g., TM, 
F292G, and R6.5 CAR) likely results in an unnaturally slow off rate, deviating from 
transient and dynamic nature of interactions natively found between TCRs and 
pMHCs[51]. High affinity and avidity interactions by CAR can reduce T cells’ 
propensity for serial killing, potentially causing exhaustion or increased susceptibility 
to activation-induced cell death[52]. The fact that the majority of CARs developed to-
date rely upon nanomolar-affinity scFvs raises the possibility that these CAR T cells 
may not have achieved their maximum potential therapeutic index. This speculation 
also draws on prior observations on the influence of high affinity TCR and pMHC 
interactions on T cell fate [15, 16, 21, 23, 53]. Future CAR engineering strategies 
should evaluate a broader affinity range to examine the influence on T cell behavior 
and functionality in vivo more rigorously. This particularly applies to CARs targeting 
solid tumor antigens, which are likely to require evolved strategies to counter the more 
challenging environment.  
In summary, our study demonstrates that CAR T cells with target-affinities 
mimicking that of native TCR for pMHC can eschew targeting of healthy tissue with 
basal antigen expression while simultaneously exhibiting increased potency and long-
term efficacy against tumor tissue with high target expression. The micromolar 
affinity F292A CAR enabled T cells to neglect tissues expressing less than 105 
molecules/cell, a threshold which anaplastic thyroid tumors surpass yet healthy tissues 
that we examined do not. Various protein engineering approaches including directed 
evolution, alanine substitution within antibody complementary determining regions, or 
humanization of mouse antibodies[27, 50, 54, 55] to isolate lower affinity variants can 
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be used to modulate the affinity of scFv-based CARs or TCRs. Systematic studies 
examining the influence of scFv-based CAR (e.g., CD19 CAR) affinity on CAR T cell 
efficacy and toxicity will be necessary to further examine the hypothesis that T cells 
expressing traditional nanomolar affinity CARs are operating sub-optimally and may 
be more prone to exhaustion and excessive cytokine release, ultimately facilitating off-
tumor toxicity or 
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CHAPTER 5 
 
TAKING ADVANTAGE OF SSTR2 BIOLOGY FOR SPATIOTEMPORAL 
CONTROL OF CAR T CELLS AND UTILIZING THIS REPORTER WITH OTHER 
CAR T THERAPYS AND THERAPY COMBINATIONS 
 
Summary 
So far we have been successful in our ability to target ICAM1 positive tumors and 
utilizing SSTR2 as a PET reporter to track CAR T cell bio-distribution and dynamics.  
Here, we share data that opens the possibility of utilizing SSTR2 beyond a simple PET 
reporter. Here, we also share additional preliminary data imaging SSTR2 in combination 
with other ACT’s, such as CD19 targeting CAR T.  
 
Using SSTR2 to control CAR T cell activation 
SSTR2 expression in T cells is absent or very low, while high levels of expression 
have been found in some neuroendocrine tumors [1, 2]. In terms of SSTR2 expression on 
the surface of tumors (specifically neuroendocrine and pituitary tumors), the signaling 
mediated via SSTR2 imparts anti-proliferative action through phosphotyrosine 
phosphatases which modulate MAPK and PI3K/Akt pathways [3]. SSTR2 is a G-protein 
coupled receptor with 7-transmemberane domains, and is categorized as G!-GPCR. 
SSTR2 belongs specifically to G!i, as its induction inhibits adenylyl cyclase and cAMP 
production [4]. SSTR2 has also been shown to activate phospholipase C [5]. All of these 
signaling cascades in tumor cells seem to induce anti-proliferative qualities to the cells. 
However in the context of T cell biology, it has long been understood that it is absolutely 
essential for the depletion/inhibition of cAMP in order for TCR mediated T cell 
activation to occur[2, 6-8]. Therefore, it was logical to perceive that inducing SSTR2 
signaling cascade would lead to the depletion of cAMP and encourage/simulate TCR 
 195 
mediated T cell activation. These same signaling cascades, when applied to T cell 
biology, not only can activate T cells but could possibly also induce chemotaxis. 
 To answer this possibility, we tested these signaling cascades in human primary 
T cells with and without SSTR2 transduction. First, we confirmed the signaling cascade 
in primary T cells follows the same molecular events as those described in tumors cells in 
the past: Ca2+ induction via phospholipase C, induction of phosphoAKT via MAPK and 
PI3K/Akt pathways, and even cAMP inhibition. All of these molecular events were 
confirmed via the use of Lanreotide (SSTR2 agonist) only on SSTR2-transduced T cells, 
with no effect on non-transduced T cells. We looked at and confirmed activation markers, 
such as CD69, being induced via SSTR2+Lanreotide incubation. In addition, we also 
verified the induction of activation/proliferative cytokine (IL2) secretion, upon 
Lanreotide incubation. This gave us the indication that SSTR2 induced activation to some 
degree mimics TCR mediated T cell activation.  
 
Experimental procedure 
CD69 activation check.  
To measure intracellular calcium release, the CMyc-F292A-CAR-P2A-SSTR2 (mAS) 
transduced and NT Primary T cells were left un-treated or treated with 1!M Lanreotide 
or 1!M Ionomycin for 2hours. These cells were then labeled with 2 !g/ml anti-human 
CD69-APC (Biolegend) for analysis by flow cytometry (Gallios cytometer, Beckman 
Coulter). 
 
Ca2+ signaling check.  
To measure intracellular calcium release, the CMyc-F292A-CAR-P2A-SSTR2 (mAS) 
transduced and NT Primary T cells were stained with 2 !g/mL Fluo-4 AM (Molecular 
Probes) at 37 °C for 30 min followed by incubation in fresh media for an additional 10 
min. To test Ca2+ excitement via Flow cytometry (Gallios cytometer, Beckman Coulter), 
 196 
cells were gated for Live cells using CalceinBlue-AM. Cells were read without 
stimulation. After significant events were captured, the reading was paused and 
Lanreotide was spiked-in at the final concentration at 1!M. After significant events were 
captured, the reading was paused and Ionomycin was spiked-in at the final concentration 
at 1!M, before the final event was captured. For measurements on a microscope (EVOS, 
Thermo Fisher), the same Fluo-4 AM labeled cells were plated on an 8-chamber slide 
(NUNC, Inc) and protected from light. A time lapse image is initiated and within 10-15 
seconds 1!M final Lanreotide was spiked-in, and about 60-80 seconds later 1!M final 
Ionomycin was spiked-in. Collected time-lapse images were analyzed using ImageJ mean 
intensity quantification. 
 
cAMP and IL2 ELISA.  
To measure the cAMP level, human primary T-Cells were first incubated with 10!M 
forskolin (Invitrogen) at 37 °C for 30 min and then stimulated by incubating with 1!M 
SDF1alpha or 1 !M  Lanreotide for 5 min. The cells were washed with PBS and 
immediately lysed in cell lysis buffer. cAMP level in the lysates was determined using a 
cAMP Elisa Kit (cAMP complete ELISA Kit, Enzo Life Science, Inc.).  To test IL2 
secretion, SSTR2 transduced and Non-Transduced T cells were incubated in media with 
and without 1!M Lanreotide. After 24Hr incubation, the media was collected and the 
level of IL2 secretion was quantified using ELISA (Biolegend, USA). 
 
Phosphor-AKT Western Blot.   
Non-Transduced human primary T cells and T cells transduced to express SSTR2 were 
treated at different concentrations of Lanreotide. Alternatively, these same cells were 
either treated with 1!M SDF1alpha or 1!M Lanreotide, and sampled over a time course 
(10min, 30min, 1hr, 3hr, 6hr). Total cell lysates were prepared and Western blot analysis 
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was performed using rabbit polyclonal antibodies specific for phospho-Akt (Ser473) and 
GAPDH (Cell Signaling).  
 
SSTR2 + CD3 cell expansion test.  
To test the possibility of using Lanreotide as a means of T cell activation as well as 
maintenance of proliferation and differentiation, human primary T cells transduced with 
CMyc-F292A-CAR-P2A-SSTR2 (mAS) were washed and re-suspended in cytokine free 
media. These cells were plated at 0.5x 106 cell/ml and separated into 5 conditions (no 
addition, IL2 at 30UI/ml, CD3 conjugated DynaBeads,  1!M Lanreotide, and CD3 
conjugated DynaBeads + 1!M Lanreotide.) 1/10 of the culture was tested for viability via 
Calcein-AM Flow Cytometry, 4 days post incubation. 
 
Results: SSTR2 mediated activation of CAR T cells is achievable with FDA approved 
drugs 
We see clear signs of SSTR2 transduced Primary T cells being activated, while being 
incubated with FDA approved SSTR2 agonist (Lanreotide).  CD69 is an early inducible 
cell surface glycoprotein acquired during lymphoid activation and is involved in 
lymphocyte proliferation. We see clear signs that CD69 is unregulated when incubated 
with Lanreotide only with SSTR2 transduced primary T cells (Figure 5.1A), presumably 
due to inhibition of cAMP production (Figure 5.2 B). There is basal level of activation of 
the CAR T transduced T cells, as naive t cells have minor expression of ICAM-1.This 
CAR T is against ICAM-1, imparting minor level of basal activation. At the same time 
the same level of CD69 up-regulation is seen in both non-transduced and SSTR2-
transduced Primary T cells when incubated with Ionomycin, an experiment control to 
verify the function in both cell types. 
We also verified that SSTR2-transduced cells mediate Ca2+ release. Using Fluo-4 
AM to label intracellular Ca2+, florescence imaging and flowcytometry showed an 
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increase in calcium signaling in the transduced cells upon Lanreotide addition (Figure 5.1 
B&D). Calcium ion increase leads to NFAT activation, required for T cell activation, IL-
2 production and T cell survival[9]. 
The Akt/protein kinase B plays a central role in T-cell proliferation, function, and 
survival. pAKT expression in activated human T cells increased proliferation and 
cytokine production, a likely result of their sustained expression of nuclear factor-"B 
(NF-"B), and provided resistance to apoptosis by up regulating anti-apoptotic 
molecules. Here we see that even at a very low concentration of Lanreotide (10nM) we 
are able to induce phosphoAKT in SSTR2-transduced Primary T cells (Figure 5.1C). We 
evaluated the duration of this induction, which lasts between 3-6 hours when incubated 
with 1µM Lanreotide in SSTR2-Transduced cell, with no signs of induction in non-
transduced cells (Figure 5.2A). We then verified the secretion of IL2 by these cells when 
incubated with Lanreotide (Figure 5.2 B), an indication that SSTR2 induced activation to 
some degree mimics TCR mediated T cell activation induction of activation/proliferative 
cytokine (IL2) secretion. To this point we can keep SSTR2-Transduced cells alive 
without replenishing additional proliferative cytokines (Figure 5.2D). 
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Figure 5.1 Verifying SSTR2 can be used to activate Primary T cells.  
 
A. Illustrated on top: Schematic of lentiviral construct used to transduce Primary T 
cells.  Left panel: dot-blot of flowcytometry check for expression of both CMyc-
Fused ICAM1-CAR (anti-CMyc-FITC), and SSTR2(Anti-SSTR2-APC), cells were 
gated for live cell population only via CalceinBlue AM(FL9). Center panel: non-
transduced , Right panel CMyc-F292A-CAR-P2A-SSTR2 (mAS) -Transduced 
Human Primary T cells untreated or incubated 1µM Lanreotide or 1µM Ionomycin at 
37 °C for 2 hr and stained for CD69 expression 
B. Top: Graphic Illustration of SSTR2 associated Ga signaling cascade, belongs to Gai, 
inhibiting adenyl cyclase and cAMP production. [10] 
C. Bottom: Analyzed using ImageJ mean intensity quantification. Fluo-4 AM labeled 
cells imaged over time. After imaging initiated, within 10-15 seconds 1µM final 
Lanreotide is spiked-in, and about 60-80 seconds later 1µM final Ionomycin is 
spiked-in. Graph illustrates change in Flour-4 fluorescence intensity over the time 
coarse, measuring intracellular calcium release. Orange line is SSTR2-transduced 
cells, Blue line are non-transduced cells. 
D. Western Blot for phospho-Akt (Ser473). CMyc-F292A-CAR-P2A-SSTR2 (mAS) 
transduced un-treated or treated at different concentrations of Lanreotide (0.01!M to 
100!M) or SDF1a (1!M). Bar graph showing average fold increase in blot, 
normalized to untreated cells. 
E. Flow cytometry to measure intracellular calcium release, the CMyc-F292A-CAR-
P2A-SSTR2 (mAS) transduced and NT Primary T cells were stained with Fluo-4 
AM Cells were read without stimulation (Red), 1!M Lanreotide (Green), 1!M 
Ionomycin (Blue), Right imaging panel are representative images from Figure 5.1 B. 
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Figure 5.2 Verifying SSTR2 signaling cascades in Primary T cells   
 
A. Western Blot for phospho-Akt (Ser473). CMyc-F292A-CAR-P2A-SSTR2 (mAS) 
transduced (right) vs. non-transduced T cells. Un-treated or treated with 1!M 
Lanreotide (over a time coarse 10min, 30min, 1hr, 3hr, 6Hr) or SDF1a (1!M). Bar 
graph showing average fold increase in blot, normalized to untreated cells. 
B. ELISA quantitation of IL2 secretion from Primary T cells. CMyc-F292A-CAR-P2A-
SSTR2 (mAS) transduced (right) vs. non-transduced T cells (left), when incubated 
with or without Lanreotide (1µM) for 24Hr . 
C. ELISA of cAMP induction/depletion from Primary T cells. CMyc-F292A-CAR-
P2A-SSTR2 (mAS) transduced (orange) vs. non-transduced T cells.(blue). All cells 
pretreated with Forskolin for 30min, then washed, and either treated with Lanreotide 
(1µM) or SDF1alpha (1µM) for 10min before cell lysis. Graph illustrates fold 
decrease of cAMP. 
D. Flow cytometry to see the amount of CMyc-F292A-CAR-P2A-SSTR2 (mAS) 
transduced Primary T cells. Dot-blot of FS/SS, after gating for Live cells via 
CalceinAM. 
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Adapting SSTR2 mediated imaging on Other CAR T therapies (CD19-CAR) 
     CD19-specific CAR T cell immunotherapy has shown significant antitumor activity in 
the treatment of high-risk relapsed and refractory leukemia and lymphoma, and has 
revolutionized the treatment landscape for patients with advanced lymphoid 
malignancies. However, manipulating the immune system is also associated with unique 
and potentially life-threatening toxicities. Two of these therapies (Kymriah™ and 
Yescarta™) were recently approved by the FDA[11]. Kymriah™ (tisagenlecleucel) is for 
the treatment of pediatric patients and young adults with refractory or relapse (R/R) B 
cell precursor acute lymphoblastic leukemia (ALL). Yescarta™ (axicabtagene ciloleucel) 
is for the treatment of adult patients with R/R large B cell lymphoma. They are 
both genetically modified autologous T cells expressing a CD19-specific CAR, lysing 
CD19-positive targets (normal and malignant B lineage cells). A noted difference is 
shown in the vectors used for Kymriah™ (lentiviral vector) and Yescarta™ (#-retroviral 
vector). Their dramatic efficacy in the short term has been highlighted by many media 
reports. By contrast, their glaring safety gaps behind the miracles remain much less 
addressed.  To help answer these concerns and keep a watchful eye on these cells in-vivo, 
we did a preliminary study to evaluate SSTR2 as a PET-reporter to image CD19 CAR. 
Though this study has not mimicked what others have published, it does show that 
SSTR2 as a PET reporter monitor CD19-CAR in-vivo. 
 
Experimental procedure 
Construction of SSTR2-CD19 CAR vector.  
Genetic sequences encoding single chain fragment variable (scfv) against anti-CD19 
(mAb clone FMC63) were derived from a previous study[12, 13]. CD19-scfv were fused 
at the C-terminus directly to the CD8 hinge, CD28 trans-membrane domain, and the 
intracellular portions of the 3rd generation CAR architecture incorporating the 
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cytoplasmic domains of CD28, CD137, and CD3$. In addition a CMyc tag was fused to 
the N-terminus of the CD19-scfv, to enable cell surface expression verification. The 
complete CAR insert was then subcloned into a pLenti backbone. A reporter gene for 
CAR T cell imaging, SSTR2, was linked to CD19-CAR at the N-terminus using a 
‘ribosome skipping’ porcine teschovirus-1 2 A (P2A) sequence to ensure comparable 
production of CAR and SSTR2 from the same mRNA.  
Lentivirus production and transduction of T cells.  
Lentivirus was produced by transiently transfecting HEK 293 T cells using calcium 
phosphate. Briefly, 10 µg of transfer gene, 7.5 µg of pCMV-dR8.2 (Addgene) and 5 µg of 
pCMV-VSVG (Addgene) were mixed and incubated with 2 M CaCl2 followed by 2x 
HBSS. Resulting solutions were added drop-wise to 10 cm2 cell culture dishes seeded 
with 3.2 % 106 HEK 293 T cells in 10 ml DMEM 24hr previously. Transfection media 
was replaced after 6 h. Media containing lentivirus was harvested at 48 and 72 h post 
transfection, Filtered through 0.45 µm filters, and concentrated by ultracentrifugation at 
75,000x g for 2 h at 4 °C. Lentivirus was then re-suspended in serum containing media 
and frozen at &80 °C. Human T cells were transduced 24–72 h post activation with anti-
CD3/CD28 Dynabeads either by spinfection (1,000 g for 1 h at 32 °C) or by overnight 
incubation with lentivirus. T cells were transduced once more 24 hr after the 
transduction. During and following transductions, media containing IL-2 was replaced 
with media containing human IL-7 (10 ng/ml) and IL-15 (5 ng/ml) (Peprotech). 
Burkitt Lymphoma mouse model, whole-body tumor imaging.  
All animal studies were approved by Weill Cornell Medicine's Institutional Animal Care 
and Use Committee. 8 to 10-week old female and male NOD-scidIL2Rgnull (NSG) mice 
(Jackson Laboratory) were used for xenograft experiments with Raji cells. GFP and fLuc-
expressing Raji (0.75x106cells per mouse) were intravenously injected to establish the 
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xenograft. Longitudinal measurements of Raji tumor burdens were taken using a whole-
body optical imager (In-Vivo Xtreme 4MP, Bruker) 15 minutes after intra-peritoneal 
injection of 100 mL of 150 mg/mL D-luciferin (GoldBio). Total tumor burden was 
measured by generating full body region of interests (ROI) and integrating total flux of 
luminescence using Bruker Analysis software. GFP-expressing livers, spleen, heart, and 
lungs were extracted from mice and imaged with a whole-body optical imager (In-vivo F-
Pro, Bruker). Mice were then treated with 5x106 CAR T+ cells, or matched dose of Non-
transduced (NT) T cell control. T cells were injected via Tail-vein 7 days post Tumor 
injection. To image the CAR T distribution PET/ CT is performed targeting SSTR2 PET 
reporter. 
Labeling of 18F-NOTA-octreotide (NOTAOCT).  
NOTAOCT (1,4,7-Triazacyclononane-1,4,7-triacetic acid-octreotide, GMP grade) was 
obtained as a 1 mg lyophilized powder (cat #9762, ABX Pharmaceuticals). NOTAOCT 
vial content was diluted with 18 MOHM-cm water to 200 µl (5 mg/ml solution) and 
stored at 4 °C as a stock solution. For chelation of NOTA with Fluorine-18, 5 µl of 
NOTAOCT was added to 10 µl of 0.1 M sodium acetate, pH 4, 6 µl of 2 mM AlCl3, and 
100 µl containing ~30 mCi18F. The solution was immediately placed in a thermomixer 
(Eppendorf ) at 100 °C and incubated for 15 minutes followed by cooling to room 
temperature and dilution in 15 ml ddH2O. A Sep-Pak light C18 column was regenerated 
in 3 ml 100% ethanol and washed twice in 5 ml ddH2O with an observed flow rate of 10 
drops per minute. NOTAOCT was then loaded to the Sep-Pak column, which was later 
washed in 15 ml 18 MW water to eliminate any remaining free18F. Trapped NOTAOCT 
was eluted from the column using 300 µl of ethanol and diluted to 1.5 ml with PBS for 
injection, providing the final product in ~15% ethanol isotonic, injectable solution. The 
eluent was passed through 0.2 µm filter purity of the final product was checked by 
reverse phase HPLC. 
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PET/CT imaging.  
Registered CT images were acquired using a micro-PET/CT scanner (Inveon, Siemens) at 
1–2 h post NOTAOCT injection. Projection data was acquired in a cone-beam geometry 
with approximately 1 sec steps at 1 degree angular increments. At least 10 million 
coincidence events were acquired for PET per study using a 250 to 750 keV energy 
window and a 6 ns timing window. References tube containing 100 µl of a 10%ID/cm3 
equivalent dose for quantification of NOTATOC uptake in-vivo. To compute NOTAOCT 
uptake within mouse lungs, ellipsoids were drawn separately on the left and right sides of 
lungs to enclose the majority of their footprint. e %ID/cm3 values, computed relative to 
the counts obtained in the reference tube, were approximated to a standard uptake value 
(SUV) by dividing %ID/cm3 by four, assuming injection efficiency of 100% and 25 g of 
body weight. Visualization and analyses of PET/CT images were performed using 
AMIDE software (http:// amide.sourceforge.net).  
Histology.  
After euthanasia, mouse tissue was harvested and fixed with 4% paraformaldehyde. Post 
fixation and embedded in paraffin. Tissues were cut to produce 5 µm sections 
(Microtome, Leica). Sections were stained with hematoxylin and eosin (H&E) or 
hematoxylin only for CD3 immunostaining (performed by HistoWiz, Inc.).  
Study Approval.  
The protocol for blood draw along with acquisition of informed consent from healthy 
volunteers was approved by the Institutional Review Board (IRB) of Weill Cornell 
Medicine (Permit Number: 1302013613). Studies involving human blood were carried 
out in strict accordance with Weill Cornell’s IRB guidelines and regulation. All animal 
experiments were performed in strict accordance with the recommendations contained 
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within the National Institute of Health’s Guide for the Care and Use of Laboratory 
Animals. Animal handling protocols were approved by the Institutional Laboratory 
Animal Use and Care Committee of Weill Cornell Medicine (Permit Number: 2012–
0063).  
Results: Real-time imaging of CD19-CAR T cell kinetics, efficacy, and toxicity.  
To spatiotemporally monitor T cell distribution in real-time by PET/CT, we 
introduced an imaging reporter gene, SSTR2, into CD19 CAR (3rd generation) vector 
using a ribosome skipping P2A sequence to ensure equal expression of CAR and the 
reporter on the surface of T cells (Figure 5.3A). Expression of SSTR2 enables binding 
and intracellular accumulation of an infused, positron-emitting, SSTR2-specfic 
radiotracer, 18F-NOTA-Octreotide (NOTAOCT) Emitted signals can then be detected 
with high resolution without limits on tissue penetration by a micro PET scanner. 
Expression of SSTR2 and CMyc-tagged I domain was confirmed by antibody staining 
(Figure 5.3A), although a higher level of binding was found with the SSTR2 antibody, 
likely due to lower background noise. Mice were xenografted with Raji tumors that were 
transduced with GFP-Firefly Luciferase. As before, the mice were then treated with NT, 
or CD19-CAR T cells 7 days post tumor xenograft. Whole-body luminescence imaging 
(Figure 5.3B) was performed to estimate tumor burden while PET/CT imaging was 
performed on the same day to track CAR T cell distribution (Figure 5.4C). PET/CT 
images in mice displayed expected background uptake levels of NOTAOCT in 
gallbladder, kidneys, and bladder caused by radiotracer excretion (Figure 5.3 C)[14]. In 
the NT treated control cohort, a small but gradual increase in non-specific tracer uptake 
was observed, which was due to increasing tumor bur- den and the associated increase in 
blood pooling (Figure 5.3 C). In contrast, specific tracer uptake was observed in mice 
treated with SSTR2-CD19-CAR T cells, demonstrating the expansion wherever the Raji 
tumor cells seem to be present via luminescence (Figure 5.3B) head, lungs, liver and 
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spine. Radiotracer shows some background uptake by the liver, resulting in bright signals 
in the gall bladder, which clears through gut. It is also cleared through kidneys and 
bladder. While there is no biphasic expansion and contraction observed like our previous 
study[13]. 
It is clear that the early attempts of this study did not follow the scenario that 
others have published [15-18]. It requires optimization in carrying out the ideal dose for 
both tumor and T cell. Furthermore it is important to evaluate multiple generations of this 
construct, in-order for us to properly evaluate this therapy. However, it is clear that the 
SSTR2-PET in conjunction with this CAR T would work. As it is obvious the co-
localization was clear in PET/CT (Figure 5.3C) and even evident in histology (Figure 
5.3D). Xenograft shows growth in the brain (subarachnoid, ventricles), spine, lymph 
nodes, liver, and bones. Tumor-specific localization and expansion of SSTR2-CD19CAR 
T-Cells are confirmed by PET/CT using a radiotracer 18F-NOTA-Octreotide, CAR T cell 
expansion in seen in the head, lungs, liver, and spine. Video recording show great impact 
with this therapy. These Raji cells seems to travel the subarachnoid and ventricles spaces 
surrounding the nervous system, produced great toxicity, where mice were showing 
severe hind limb paralysis. After a few days of CD19-CAR, these paralytic incidences 
vanished in the CAR treated mice. Additionally, we clearly see via histology the 
localization of T cell, along with Raji cells logged in between the cerebrum and 
cerebellum in mice were the T cell expansion was not fast enough to completely clear the 
Raji tumors (Figure 5.3D). A broader study for evaluating multiple generations of CD19-
CAR is currently underway. In addition to analyzing if there are any dynamics of 
expansion and contraction, when it comes to non-solid tumors. 
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Figure 5.3 Longitudinal, concurrent measurements of tumor burden, T cell 
distribution for CD19-CAR 
A. Schematic of the lentivirus vector encoding SSTR2-CD19CAR. LTR = long terminal 
repeat; SD = splice donor; SA = splice acceptor; '+ = packaging signal; SS = signal 
sequence; TM = transmembrane; Cyt = cytosolic domain. Anti-Myc antibody binding 
and Anti-SSTR2 binding to T cells transduced with SSTR2-CD19CAR=green 
histogram. Red histogram= non-transduced T cells.  
B. Whole-body luminescence imaging was used to estimate tumor burden in mice 
infused with T cells 7 days post-tumor implantation. NT = non-transduced T cells. No 
T = mice received no T cells. X# indicating days of Xenografts, T# indicating days of 
CAR T/NT cell administration. 
C. Raji (Burkitt’s lymphoma) xenografts shows growth in the brain (subarachnoid, 
ventricles), spine, lymph nodes, liver, and bones. Tumor-specific localization and 
expansion of SSTR2-CD19 CAR T Cells are confirmed by PET/CT using a 
radiotracer 18F-NOTA-Octreotide, CAR T cell expansion in seen in the head(d-g), 
lungs (f-g), liver (d-g), and spine (g). Radiotracer shows some background uptake by 
the liver, resulting in bright signals in the gall bladder, which clears through the gut. It 
is also cleared through kidneys and bladder. Right panel, matching luminescence 
images of mouse (f) and (g); Ventral image on top, Lateral Right on bottom. 
D. Liver and Brain tissues harvested from mice treated with SSTR2-CD19 CAR T cells. 
Sections were processed for H&E and CD3 staining. scale bar in each image is 1 mm. 
Arrow indicates tumor  
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CHAPTER 6 
 
CONCLUSION AND FUTURE DIRECTION 
Conclusion: 
So far, we have achieved a few goals within the field of Adoptive Cell Therapy 
(ACT): 
• We successfully developed an intercellular adhesion molecule-1 (ICAM-1) 
targeting CAR T for the treatment of aggressive thyroid cancer in a solid tumor 
model. This CAR mediated profound tumor killing that resulted in long-term 
remission and significantly improved the survival outcome compared to that of 
untreated mice. Additionally, similar results were shown even with patient 
derived tumors. 
• We adapted Somatostatin receptor 2 (SSTR2), as a T cell PET reporter, used with 
ATC to quantitatively and longitudinally visualize the whole-body T cell 
distribution and antitumor dynamics by using a clinically approved radiotracer 
for PET imaging. T cells were detectable at low densities with high sensitivity 
and specificity.  
• We adapting SSTR2-based PET to ICAM-1- Targeting CAR-T cells to show the 
treatment dynamics in-vivo with anaplastic thyroid tumors. This method hinted 
whether or not the CAR T is actually taking effect in-vivo by showing a real-
time PET imaging to reveal biphasic T cell expansion and contraction at tumor 
sites.  
• Chapter 4 illustrated how utilizing the same PET reporter helped to establish safety 
criteria for CAR T. In fact, it also evaluates the ideal affinity of the antigen 
recognition moiety to use when developing a CAR T therapy, which can 
significantly boost efficacy and safety. 
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Using SSTR2-PET, along with additional ACTs 
One of the most obvious goals of this work would be to apply the use of 
SSTR2 as a PET reporter to any and all adoptive cell therapies that are currently in 
use. So far, we have been using ICAM-1 targeting CAR as our launching pad, but 
recently we have also evaluated CD19-CAR. However, since I made lentiviral 
constructs for various CAR T models, such as Her2, Mesothelin, and J591(PSMA 
targeting). I would like to see if this reporter would work in a TCR or even a TIL 
model. It would be of interest to see if the spatial localization dynamics of these 
therapies are any different from that of CAR T therapies. Ideally, this would provide 
some insight into the expansion kinetics of these TILs in-vivo and help push this broad 
therapy for more successful outcomes. 
 
Utilizing SSTR2 as a “kill-Switch” in-vivo 
One of the most useful tools we need for CAR T therapy is to eradicate the 
therapeutic in-case there are adverse effects. There are suicide genes currently under 
evaluation for this purpose, but their path to FDA approval is uncertain. Interestingly 
enough, the FDA recently approved Lutathera® (lutetium-177 (177Lu)-Dotatate) for 
the treatment of gastro-enteropancreatic neuroendocrine tumors (GEP-NETs), and 
pancreatic neuroendocrine tumors (PNETs), that express Somatstatin receptors.[1] 
177Lu is a low-energy !"-emitter (0.497 MeVmax) with a relatively short tissue 
penetration range[2]. These physical properties suggest 177Lu to be an appropriate 
choice for treating small tumor lesions and micrometastases while limiting normal 
tissue damage. Since this is already FDA approved, it would be reasonable to try 
infusing this drug for CAR T cells eradication/killed in-vivo. Also, we can try yo look 
for a kamikaze effect, where the killing/targeting of CAR T cells leads to the killing of 
the surrounding tumor, due to CAR T localization.  
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Utilizing SSTR2 beyond a PET tracer in-vivo 
 We saw clear signs of SSTR2-transduced Primary T cell activation, when it is 
under incubation with FDA-approved SSTR2 agonist (Lanreotide). This activation 
could be NFAT-mediated, via calcium ion increase, leading to IL-2 production and T 
cell survival[3]. Since we see such clear signs of pAKT expression upon Lanreotide 
incubation, the activation might just be nuclear factor-#B (NF-#B) mediated. After 
deciphering the exact activation pathway that this signaling mediates, I would like to 
apply this in-vivo, to see if a first generation CAR in combination with SSTR2 
activation would mimic the expansion/functional/proliferative dynamics of a 3rd 
generation. 
In addition, I want to explore fusing co-stimulatory domains of CAR directly on to 
SSTR2, to observe if the functions of these domains can be split between the CAR and 
SSTR2, where the full cytotoxic function of the CAR-T would only be achieved with 
presence of Lanreotide. This concept, which is very similar to “Tandem-CAR”, would 
add a layer of safety to the therapy. 
 
SSTR2 as a molecular switch 
We have clearly seen that SSTR2 activation can lead to the secretion of IL2 
and induce CD69. Discovering if this activation is NFAT mediated will allow me to  
easily generate a cell therapy to induce the secretion of molecules. Using SSTR2 as a 
molecular switch, would all utilizing CRISPR/Cas9 to introduce molecules of interest 
to be transcribed downstream from IL2 or CD69. Utilizing a ribosome-skipping (P2A) 
motif can result in transcribing other cytokines along with IL2 or CD69.  
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